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ABSTRACT 
Over the last few decades some mechanisms of diseases, especially those which are associated  
with recently described dysregulation of the adipose tissue due to certain medications/drugs, 
have been discovered, shedding light on the pathophysiology of obesity-associated metabolic 
alterations. Investigation of the functions of distinct cytokines, overall redox status, 
transcriptional regulation and protein expression of crucial adipogeneic markers may provide 
new comprehension of the pathophysiology of obesity, diabetes and cardiovascular diseases, as 
well as specific targets for future therapeutic approaches. This study was particularly designed 
with the knowledge that certain medications and drugs such as paracetamol, caffeine, 
rilpivirine, estradiol and β-naphthoflavone (BNF) may contribute significantly to the process of 
adipogenesis, broadly termed drug-induced metabolic alterations. Furthermore, the present 
study investigated the combined effects of some of these drugs for comparison. 
The results from the treatment of adipose cells with caffeine, paracetamol and β-
naphthoflavone either alone or in combination have shown anti-adipogenic effects of caffeine, 
paracetamol and β-naphthoflavone through inhibition of adipogenesis and enhancement of the 
lipolytic process. A combination of β-naphthoflavone with caffeine and paracetamol was further 
shown to attenuate triglyceride accumulation. 
 This study also investigated the inflammatory status of 3T3-L1 human pre-adipocytes when 
treated with different concentrations of either rilpivirine or estradiol alone and in combination 
with β-naphthoflavone (BNF). The results show that either rilpivirine or estradiol individually or 
during their combination can evoke significant increases in glycerol release and a concomitant 
significant decrease of adiponectin from adipocytes in a dose dependent manner. The effects of 
combined treatments were much larger than individual concentration for each drug. Both drugs 
had little or no effect on leptin levels, except for a small decrease with 10 µM rilpivirine alone or 
when combined with estradiol. In addition, both drugs evoked small increases in the release of 
resistin and interleukin-8 with significant values at higher doses compared to untreated 
adipocytes.When adipocytes were pretreated with BNF, either rilpivirine or, estradiol or when 
combined evoked a much larger release in glycerol and a much larger decrease in adiponectin 
compared to the absence of BNF. 
3 
 
The study further investigated the lipodystrophic effects of rilpivirine on adipose cells and its 
nutritional management using quercetin. The results have shown that rilpivirine exerts 
lipoatrophic effects on adipose cells by impairing triglyceride accumulation, increasing 
inflammation, repressing anti-oxidant enzymes and inhibiting the expression of genes 
controlling adipogenesis (PPARg, C/EBPα, SREBP-1c, fatty acid synthase and aP2). A combination 
of rilpivirine and quercetin shows that quercetin was able to decrease inflammation and restore 
the levels of anti-oxidant enzymes but failed to overcome the lipoatrophic effects of rilpivirine.  
The present study also elucidated the role of 17β-estradiol on human subcutaneous cells in vitro 
either individually or in combination with quercetin. The results revealed that both estradiol and 
quercetin can promote leanness in part by reducing adipocyte size through reduced uptake of 
fatty acids and reduced lipogenesis. Experimental data show a decrease in the expression of 
adipogenesis target genes suggesting anti-adipogenic as well as anti-lipogenic action of estradiol 
and quercetin in adipose cells.  
In conclusion, the results from this study revealed complex interactions between metabolic and 
inflammatory pathways during the process of adipogenesis. However, the data further suggests 
that HIV and obese patients who are under increased risk should seek advice from their 
physicians to offer differentiated and optimized therapeutic approaches. 
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1. INTRODUCTION AND BACKGROUND 
1.1 Obesity: Epidemiology and Patho-physiology  
The World Health Organization (WHO) defines obesity as “an abnormal or excessive fat 
accumulation in adipose tissue, to the extent that health is impaired”. The currently accepted 
classification of obesity for epidemiological purposes defines overweight at body mass index 
(BMI) levels greater than 25 kg/m2 and obesity beginning at BMI of 30 kg/m2 (WHO, 2000). It is 
an exaggeration of normal adiposity and is a central player in the patho-physiology of diabetes 
mellitus (DM), insulin resistance (IR), dyslipidemia, hypertension, atherosclerosis, coronary heart 
diseases, stroke, liver disease, sleep apnea, osteoarthritis, and gynecological complications and 
cancer, specifically breast and colon (Obesity and Initiative, 1998. Due to its dramatic increase in 
prevalence rates over the last few decades, obesity is becoming a pressing international concern 
for health care officials worldwide. WHO outlines the severity of the problem in the following 
global key estimates: In 2014, more than 1.9 billion adults aged 18 years and older were 
overweight. Of these, over 600 million adults were obese. Overall, about 13% of the world’s 
adult population (11% of men and 15% of women) were obese in 2014, while 39% of adults aged 
18 years and over (38% of men and 40% of women) were overweight. The worldwide 
prevalence of obesity has more than doubled between 1980 and 2014. An estimated 41 million 
children under the age of 5 years were overweight or obese in the year 2014 and this is an 
extreme worry concern for the subjects and Governments of the world (WHO, 2016).  
Obesity is a multi-factorial disorder resulting from a combination of several lifestyles, 
environmental and genetic factors. Reduction in physical activity, metabolic rate and 
thermogenesis eventually decrease energy expenditure leading to increased energy storage and 
obesity. Some of the causes of obesity include availability of palatable fast food, sedentary 
lifestyle, certain medications as well as genetic factors. Figure 1.1 illustrates some of the factors 
that contribute to obesity. 
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Figure 1.1: Flow diagram showing the energy balance and etiology of obesity (Taken from 
Gurevich-Panigrahi et al., 2009). 
Obesity is characterized by excess fat in the body, contributing considerably to harmful 
metabolic consequences. Moreover, obesity represents significant medical and socio-economic 
burden in the world today. According to a recent report, the global cost of treating obesity has 
risen to a dangerous $2 trillion USAD (McKinsey Global Institute, 2014).  
It is a consequence of adverse increase in adipose tissue mass resulting from increased fat cell 
size (hypertrophy) or number (hyperplasia) (de Ferranti et al., 2008; Spalding et al., 2008). These 
two events, together, orchestrate a series of co-morbidities leading to the development of 
obesity. Targeting adipocyte biology and identifying potential factors that can regulate these 
processes may be of significant importance in the prevention and treatment of obesity. 
1.2 Drug-induced metabolic alterations 
Both weight gain and loss are common, but often overlooked side-effects of many widely used 
drugs. In susceptible individuals, the weight gain may result in clinically significant obesity and 
associated co-morbidities. Many prescription medications are prominently cited for producing 
persistent and problematic body weight alterations in treated patients and have a serious 
impact on medication compliance to an otherwise beneficial treatment. For some (e.g. certain 
serotonin re-uptake inhibitors, oral contraceptives), the evidence of an effect on body weight is 
23 
 
less consistent (Keith et al., 2006) while others are consistently associated with weight gain, and 
are considered obesogenic (Pijl et al., 1996; Lean, 2003). This effect can arise as a consequence 
of differing mechanisms, such as increased appetite (corticosteroids) or reduced metabolic rate 
(beta-adrenoceptor blockers). In one previous research study, a total of 9% of adults attributed 
to weight gain due to intake of drugs they were prescribed (Leslie et al., 2014). Table 1.1 shows 
few classes of medications that cause obesity.  
Standard Anti-retroviral therapy (ART) consists of the combination of anti-retroviral (ARV) drugs 
to maximally suppress the Human Immuno Deficiency Virus (HIV) to stop the progression of HIV 
disease. Although highly active, anti-retroviral drugs slow down the HIV disease progression and 
help to prevent HIV-related deaths, their prolonged use can lead to several undesirable side 
effects. One such common adverse effect of anti-retroviral therapy is lipo-dystrophy in which 
the body’s fat stores are re-distributed. This can involve lipo-atrophy, which refers to loss of fat 
in the face, buttocks, and limbs, and/or lipo-hypotrophy, in which there is accumulation of fat in 
the breasts, back or stomach region. These may be accompanied by dyslipidemia, IR (Insulin 
resistance), impaired glucose tolerance test (IGTT), hypertension, endothelial cell dysfunction 
(ECD), and altered cytokine and adipokine production (Galescu et al., 2013). Estrogens are 
important regulators of adiposity and may contribute significantly to the process of 
adipogenesis. 
Table 1.1: Table showing major classes of drugs which can cause weight gain (Taken from  
Breum et al., 2001). 
Anti-psychotics All subgroups 
Anti-depressants Tricyclic anti-depressants, lithium, MAO inhibitors 
Anti-convulsants Valproate, carbamazepine 
Anti-migrane and Anti-histaminergic 
drugs 
Cyproheptadine, flunaizine, pizotifen 
Anti-diabetic drugs Sulfonylurea agents, all insulin preparations, 
glitazones 
Glucocorticoids Pharmacological doses 
Beta-blockers Non-specific, e.g. propranolol 
Sex hormones Estrogen (high dose), megestrol acetate, tamoxifen 
Other  Anti-neoplastic agents 
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This review now focuses on the role of few such drugs as contributors and/or inhibitors of 
obesity.  
 
1.2.1 Caffeine 
Caffeine (1, 3, 7-trimethylxanthine) is a plant alkaloid found in coffee, tea, chocolate, cola, and 
soft drinks. It is one of the most  commonly consumed ingredient around the world, especially in 
Europe and North America (Putnam et al., 2006). Interestingly, caffeine has  been proposed for 
weight loss and maintenance for a long time, and is a non-selective antagonist for adenosine 
receptors (Jacobson, 2009). A number of studies have shown that caffeine reduces body weight  
and adipose tissue weight in animal models (Yun et al., 2008; Hursel et al ., 2010). Caffeine has 
been reported to have thermogenic effects and can stimulate fat oxidation in vitro, in part 
through sympathetic activation of the central nervous system (Dulloo et al., 1992). In humans, 
caffeine has been shown to stimulate thermogenesis and fat oxidation (Dulloo et al., 1989; 
Astrup et al., 1990; Bracco et al., 1995). It affects the thermogenesis process by inhibiting the 
enzyme phosphodiesterase. This enzyme degrades intracellular cyclic amino mono phosphate 
(Cornelis et al., 2007). Usually it hydrolyses cyclic adenosine monophosphate (cAMP) to AMP, 
but after consumption of caffeine, cAMP concentration rises resulting in increased activity of 
sympathetic nervous system (SNS). This in turn activates the inactive hormone-sensitive lipase 
enzyme, which promotes lipolysis (Acheson et al., 2004). Besides the inhibition of 
phosphodiesterase, caffeine is also known to affect thermogenesis through the stimulation of 
substrate cycles such as the Cori-cycle and the Free Fatty Acid-triglyceride cycle (Astrup et al., 
1990). In the Cori cycle, lactate moves from the muscles to the liver, where it is converted into 
pyruvate. This pyruvate is then converted to glucose by the enzyme lactate dehydrogenase 
and circulated back to the muscles through the blood. It has reported that free fatty acid 
turnover and lipid oxidation are increased after the consumption of caffeine (Astrup et al., 
1990). The study also reported that caffeine antagonizes the inhibitory effects of adenosine 
on lipolysis by adenylyl cyclase. Previously conducted  studies have shown that caffeine 
suppresses intracellular lipid accumulation in 3T3-L1 mature adipocytes (Nakabayashi et al., 
2009) and inhibits insulin-stimulated glucose uptake but increases lipolytic effects in adipose 
cells (Akiba et al., 2004). It is further reported that caffeine significantly stimulates lipolysis in 
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mature adipocytes (Acheson et al., 2004). Figure 1.2 shows the proposed mechanism of caffeine 
as inhibitor of adipogenesis in obesity. However, the effects of caffeine on adipogenesis and the 
process of preadipocyte differentiation into adipocytes have not been determined yet. 
 
Figure 1.2: Proposed mechanism of caffeine as inhibitor of adipogenesis in obesity (Taken from 
lelyana, 2017).  
1.2.2 Paracetamol 
Paracetamol/Acetaminophen is one of the most popular and commonly used analgesic and 
antipyretic drugs around the world. It is available without a prescription, both in mono- and 
multi-component preparations. It is a drug of choice in patients that cannot be treated with non-
steroidal anti-inflammatory drugs (NSAID), such as people with bronchial asthma, peptic ulcer 
disease, hemophilia, salicylate-sensitized people, children under 12 years of age, pregnant or 
breastfeeding women (Leung, 2012). The mechanism of action is complex and includes the 
effects of both the peripheral (COX inhibition), and central (COX, serotonergic descending 
neuronal pathway, L-arginine/NO pathway, cannabinoid system) and redox mechanism (Sharma 
et al., 2014; Benista et al., 2014). It has been assumed that paracetamol probably acts through 
the cyclooxygenase (COX) pathway (See figure 1.3). This is the pathway through which the non-
steroidal anti-inflammatory drugs (NSAIDs) act. The NSAIDs inhibit production of prostaglandins 
(pro-inflammatory chemicals; PGE2, PGI2, PGF2α) and exert consequent effect. They also 
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influence thromboxane (TXA2). TXA2 is a vasoconstrictor, potent hypertensive agent, and 
facilitator of platelet aggregation.   
 
  
 
Figure 1.3: Schematic diagram of arachidonic acid metabolism (Taken from  Zealand, 2008). 
 
The role of prostaglandins (PGs) and subsequent hormones and enzymes synthesized is essential 
in adipocyte differentiation. PGs are lipid mediators that undergo synthesis through the action 
of different enzymes. Archadionic acid is first released by phospholipases (PLA2s) and undergoes 
conversion to PGH2 by one of the two COX isozymes (COX-1 or COX-2). The PGH2 that is 
produced is metabolized into different PGs that are involved in adipocyte differentiation which 
causes the activation of PPARγ (Ghoshal et al., 2011; Ueno et al., 2011). Therefore, bearing this 
expression mechanism in mind- the inhibition of COX-2 would prevent or decrease the 
conversion of archadionic acid to PGH2 which will have the ultimate effect of reducing and/or 
inhibiting adipocyte differentiation. COX-2 activation has also been found to be significantly 
involved in the development of an inflammatory response in adipose tissue (Hsieh et al., 2010) 
and has been linked to contribute  in brown adipocyte differentiation in mice (Ghoshal et al., 
2011). 
Despite this proposed mechanism, no conclusive research has yet provided a definitive answer 
to the role of COX-2 inhibition or over-expression in adipocyte expression. Studies conducted on 
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3T3-L1 cell lines showed that different adipocyte specific markers which included PPARγ and 
adiponectin were found to be decreased after the use of COX inhibitors (Mazid et al., 2006). 
COX-2 deficient murine models which were supplied with a high fat diet showed lower body 
mass than their wild type counterparts along with higher metabolic activity, lower PPARγ, lower 
inflammatory markers and significantly higher levels of adiponectin (Ghoshal et al., 2011). These 
variables coincide with other results linking them to increased lipolysis and lower body fat and 
basal metabolic index (BMI), thus suggesting that the use of a COX-2 inhibitor (such as 
paracetamol) can provide a protective treatment opportunity against obesity and can be 
employed as a future anti-obesity medication.  
1.2.3 β-naphthoflavone (BNF) 
Humans are indeed exposed to an increasing number of environmental xenobiotics. Organic 
pollutants such as 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD), β-naphthoflavone (BNF), and 
polychlorinated biphenyl (PCB) are well-known environmental toxins that might affect our 
endocrine system. Such pollutants are broadly termed as endocrine disruptors. Figure 1.4 
illustrates the sources of many common endocrine disruptors in the environment. 
 
Figure 1.4:  Common sources of endocrine disruptors in the environment (Taken from Grindler 
et al., 2005). 
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Some of these toxins escape from the body metabolic system and tend to accumulate in the 
white adipose tissue (WAT). Although mechanisms of this accumulation are still poorly 
understood, they may modulate the WAT metabolism and function. This could affect the 
physiological role of WAT, leading, for instance, to the development of obesity related disorders. 
The mechanisms through which such chemicals modulate the differentiation, metabolism, and 
secretory function of adipocytes are numerous (Müllerová et al., 2007). The link between 
exposure to endocrine disruptor xenobiotics and obesity has already been proposed (Elobeid et 
al., 2008) and some phthalates, which are highly prevalent lipophilic pollutants, have been 
shown to promote adipocyte differentiation, therefore supporting this hypothesis (Feige et al., 
2007). Several epidemiological studies have also linked dioxin exposition to increased risk of 
diabetes or modified glucose metabolism (Uemura et al., 2008).  Although the liver is the main 
organ involved in metabolizing drugs, the expression and induction of drug-metabolizing 
enzymes by xenobiotics is also often observed in extra hepatic tissues. It has been reported that 
rodent adipose tissue expresses functional Aryl hydrocarbon receptor (AhR) and NF-E2-related 
factor 2 (Yoshinari et al., 2004, 2006). AhR is a cytosolic ligand-activated transcription factor that 
participates in a variety of metabolic processes, including detoxification and adipogenesis. It 
would therefore be significant to employ in vitro models to investigate and ascertain the bio- 
activation potential of such environmental contaminants acting as endocrine disruptors. 
1.2.4 Rilpivirine 
Rilpivirine (Trade name: Edurant), is a prescription medicine approved by the U.S. Food and 
Drug Administration (FDA) for the treatment of HIV infection in adults and children 12 years of 
age and older who have never taken HIV medicines before and who have a viral load (number of 
HIV RNA copies /mL of blood) of 100,000 copies/mL or less at the start of treatment. It belongs 
to a class (group) of HIV drugs called non-nucleoside reverse transcriptase inhibitors (NNRTIs).  
Re-distribution and or accumulation of body fat, including central obesity, dorso-cervical fat 
enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and 
"cushingoid appearance" have been observed in patients receiving antiretroviral therapy. The 
mechanism(s) and long-term consequences of these events are currently unknown. A causal 
relationship has not been established. Since rilpivirine is a newly developed medicine, its role in 
body fat redistribution is still in its infancy stages of investigation. Not much clinical data are 
available showing its effect on the adipose tissue distribution and function. Clinical trials with 
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patients taking rilpivirine, in association with distinct drug backbones and in comparison with 
one of the most commonly prescribed anti-retroviral drug, efavirenz, concluded that both of 
these drugs had similar antiviral efficacy (Cohen et al., 2011; Molina et al., 2011). However, 
treatment with rilpivirine caused a much lower increase in blood triglycerides, total cholesterol, 
low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol 
compared to efavirenz treatment (Cohen et al., 2011; Molina et al., 2011; Wilkin et al., 2012). 
Another report indicated that there was no change in limb fat in patients taking either rilpivirine 
or efavirenz in a clinical trial setting (Tebas et al., 2014). Although the results from these clinical 
trials are contradictory to each other, the approval document of rilpivirine issued in 2011 by the 
U.S. Food and Drug Administration (FDA) included fat re-distribution among its warnings and 
precautions. Figure 1.5 shows the factors that might contribute to lipodystrophic effects of 
these drugs. 
 
Figure 1.5: Pathways involved in the development, differentiation, and death of adipocytes. 
Red arrows indicate the factors that might contribute to the lipo-dystrophic effects of anti-
retroviral drugs (Modified from Agarwal et al., 2006). 
1.2.5 17β-Estradiol 
Estradiol (also known as E2 or 17β-estradiol) is a naturally occurring hormone that circulates 
endogenously within the human body. It is the most potent form of mammalian estrogenic 
steroids and acts as the major female sex hormone. As such, estradiol plays an essential role in 
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the regulation of the menstrual cycle, in the development of puberty and secondary female sex 
characteristics, as well as in ageing and several hormonally-mediated disease states. Estrogen 
mediates its effects across the body through potent agonistic effect of the Estrogen Receptor 
(ER), which is located in various tissues including in the breasts, uterus, ovaries, skin, prostate, 
bone, fat, and brain. Estradiol binds to both subtypes of the Estrogen Receptors namely 
estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ). Estradiol also acts as a potent 
agonist of G Protein-coupled Estrogen Receptor (GPER), which has recently been recognized as a 
major mediator of estradiol's rapid cellular effects (Prossnitz et al., 2014). Figure 1.6 shows the 
chemical structure of 17β-estradiol. 
 
Figure 1.6: Chemical structure of Estradiol (Taken from National centre for biotechnology 
information, 2016). 
Synthetic estrogens are used as part of some oral contraceptives, in estrogen replacement 
therapy for postmenopausal women, and in hormone replacement therapy for women (Christin-
Maitre, 2017). The steroid 17β-estradiol is the most potent and prevalent endogenous estrogen, 
although several metabolites of estradiol also have estrogenic hormonal activity (Evans et al., 
2015). It is important in the regulation of the estrous and menstrual female reproductive cycles 
and for the development and maintenance of female reproductive tissues (Ryan, 1982). 
Estradiol acts primarily as an agonist of the estrogen receptor (ER) which is a nuclear steroid 
hormone receptor. There are two subtypes of the ER, ER alpha (ERα) and beta (ERβ), and 
estradiol potently binds to and activates both receptors. The result of ER activation is a 
modulation of gene transcription and expression in ER-expressing cells, which is the 
predominant mechanism by which estradiol mediates its biological effects in the body. Estradiol 
also acts as an agonist of membrane estrogen receptors, such as G protein-coupled estrogen 
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receptor 1 (GPER), a recently discovered non-nuclear receptor for estradiol, via which it can 
mediate a variety of rapid, non-genomic effects (Nilsson et al., 2011; Prossnitz et al., 2014).  
Several studies have provided evidence of a hormonal regulation of pre-adipocyte proliferation 
(Hausman et al., 2001; Thorn et al., 2007). Estrogens promote subcutaneous fat and regulate 
adipose tissue distribution through its receptors, ERα and ERβ (Matelski., 1985; Kuiper et al., 
1996). However, only ERα has been reported to have any major influence on energy 
homeostasis (Heine et al., 2000) and is necessary for genomic actions of estradiol on body 
weight regulation (Musatov et al., 2007). 17β-estradiol has been shown to have stimulatory 
effects on proliferation of female rat pre-adipocytes (Dieudonne et al., 2000) and in human pre-
adipocytes (Anderson et al., 2001).  
1.3 Role of adipose tissue in the development of obesity 
1.3.1 Adipogenesis 
Adipose tissue is an areolar connective tissue that regulates and maintains body temperature, 
attaches the skin, and shields internal organs. It is further sub-divided into two types namely 
brown adipose tissue (BAT) and white adipose tissue (WAT). Figure 1.7 shows the distribution of 
white and brown fat in the human body.  
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Figure 1.7:  Distribution of white and brown fat in the human body (Modified from Gesta et al., 
2007).  
While WAT serves as the reservoir of energy, where triglycerides are stored in large lipid 
droplets, BAT mainly serves in the regulation of body temperature and energy expenditure 
(Girard et al., 2008). It is now a well-accepted fact that mesenchymal stem cells (MSCs) act as 
precursor cells to proliferate and undergo differentiation to become mature adipocytes. The 
process of differentiation of the fibroblast like pre-adipocytes into mature lipid-laden, insulin-
responsive adipocytes is known as adipogenesis (Lefterova et al., 2009). 
1.3.2 The Adipocyte life cycle 
The adipocyte life cycle starts with differentiation of adipocytes from either committed 
embryonic stem cells or mesenchymal stem cells. This includes a growth phase followed by 
growth arrest, clonal expansion, and a complex sequence of changes in gene expression leading 
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to storage of lipid and finally death (Gregoire, 2001). Figure 1.8 shows the phases in life cycle of 
an adipocyte. 
 
Figure 1.8: Flow diagram showing the life cycle of an adipocyte. Note the different phases 
involved in the differentiation of mesenchymal stem cells into mature adipocytes (Taken from 
(Abdel-sattar et al.,  2014). 
Once triggered to mature, pre-adipocytes proliferate and undergo growth arrest followed by a 
round of cell division known as clonal expansion. These cells then commit to differentiate into 
mature adipocytes. This process is accompanied by a dramatic increase in expression of 
adipocyte-specific genes. Several adipokines, hormones, enzymes, nutritional and 
environmental factors influence adipocyte life cycle contributing to overall adipose tissue 
growth and development. 
1.4 Inflammatory markers of obesity 
Over the recent years, an understanding of the adipocytes as mere fat storage cells has changed 
dramatically. They are now known to participate in several metabolic regulations by secreting a 
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large number of protein mediators that are termed adipocytokines /adipokines. Research 
studies are now concentrating on the concept that obesity could be a source of inflammatory 
factors, which enhance insulin resistance and create a chronic low-grade systematic 
inflammation (Kang et al., 2016).  Some of the well-studied adipokines that influence adipocyte 
growth through both central and peripheral mechanisms include adiponectin, plasminogen 
activator inhibitor-1, tumour necrosis factor-alpha (TNF-α), leptin, resistin, interleukin-6 and 
macrophage chemoattractant protein-1. These are implicated for their role in different 
mechanisms like regulation of energy balance, insulin action glucose metabolism, inflammation 
and immunity (Rondinone, 2006). Figure 1.9 shows the contribution of some of the important 
adipokines in the development of obesity and its related complications. 
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Figure 1.9: Diagram showing the contribution of adipokines to obesity and metabolic 
syndrome abnormalities (Taken from Falcão-Pires et al., 2012). 
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1.4.1 Leptin 
Leptin is a 16-kDa polypeptide containing 167 amino acids. Moreover, it was originally 
discovered as the missing protein in the genetically obese ob/ ob mouse (Halaas et al., 1995) 
and was later widely recognized for its ability to regulate adipose tissue mass by influencing 
food intake and energy expenditure (Brennan et al., 2006). Leptin concentration in plasma is 
proportional to total body adiposity and direct nutritional state (Frederich et al., 1996). It is 
present in human serum in ranges of 1-15 ng/ml in non-obese individuals, and levels more than 
30 ng/ml in individuals with BMI ≥30 kg/m2 (Caro et al., 1996). 
The role of leptin in counteracting obesity is mediated through its receptors, which are 
members of the cytokine receptor class I super-family and are expressed in both the central 
nervous system and periphery (Elmquist et al., 1999). These receptors orchestrate complex 
metabolic changes in a number of organs and tissues, altering nutrient flux to favor lipid 
mobilization over lipid storage (Baile et al., 2000). Leptin receptors are highly expressed in 
hypothalamic neurons involved in regulation of food intake and they are probably the most 
physiologically relevant target for leptin especially since brain specific deletion of leptin receptor 
is sufficient to cause severe obesity (Cohen et al., 2001).  
Previously documented evidences on the effects of leptin on energy homeostasis are available 
and previous studies have suggested that leptin can also decrease adiposity by triggering 
apoptosis and lipolysis in adipocytes (Della-Fera et al., 2008). Adipose tissue from rats that were 
given cerebral ventricular injections of leptin demonstrated features of apoptosis, including 
inter-nucleosomal fragmentation of genomic DNA, elevated levels of DNA strand breaks, 
reduction in total DNA content, and cellular volume (Qian et al., 1998). The mechanisms of 
leptin-induced adipose tissue apoptosis are not fully understood. Most of the effects of leptin on 
adipocyte apoptosis and lipolysis are believed to be centrally-mediated by stimulation of the 
sympathetic nervous system. The possibility that leptin can act directly on adipocytes to induce 
apoptosis has not been thoroughly investigated so far. Although it has been reported that leptin 
did not directly stimulate apoptosis in 3T3-L1 adipocytes in vitro (Ambati et al., 2007), it 
significantly reduced lipid accumulation and GPDH (Glycerol-3 phosphate dehydrogenase) 
activity in maturing 3T3-L1 pre-adipocytes, indicating that leptin may not act directly to induce 
adipocyte apoptosis, but can act directly to inhibit maturation of pre-adipocytes. Figure 1.10 
shows the three general ways in which alterations of the leptin regulatory loop could lead to 
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obesity. a). Failure to produce leptin, as occurs in ob/ob mice. b). Inappropriately low levels of 
leptin secretion for a given fat mass. In the latter case, the fat mass would expand until 'normal' 
leptin levels are reached, resulting in obesity. c). Finally,obesity could result from either relative 
or absolute insenstivity to leptin at its site of action. Such resistance would be associated with 
increased circulating leptin, analogous to the increased insulin levels seen with insulin-resistant 
diabetes. In general, high plasma leptin levels are evident in obese mice and rodents. 
Differences in leptin production and leptin senstivity could be the result of genetic, 
environmental and psychological factors. 
 
 
 
 
Figure 1.10: Flow diagram showing general ways in which dysregulation in leptin production 
may lead to obesity (Taken from Friedman et al., 1998).  
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ARVs, such as nevirapine and efavirez, have been reported to reduce leptin expression to a 
significant level in human adipocytes (Díaz-Delfín et al., 2011; 2012). Another ARV, ritonavir, also 
decreased leptin levels in mice (Vyas et al., 2010). An investigational study on serum leptin 
concentrations in women taking oral contraceptives containing the same gestagen and different 
low-doses of ethinyl estradiol, did not exert any influence on serum leptin or BMI, and therefore 
did not induce any significant influence on body energy metabolism (Rechberger et al., 1999). 
1.4.2 Adiponectin  
Adiponectin, having been discovered by several groups, has been attributed numerous different 
names including ACRP30 (adipocyte complement-related protein of 30 kDa) or adipoQ in mouse 
and GBP28 (gelatin-binding protein 28) or APM1 (adipose most abundant gene transcript 1) in 
humans (Kadowaki  et al., 2005). It is specifically expressed in differentiated adipocytes, and its 
expression is higher in subcutaneous than visceral adipose tissue (Fain et al., 2004). Plasma 
levels of adiponectin, which constitute 0.01 % of circulating proteins, are between 5 to 30 mg/L 
in lean control subjects (Lihn et al., 2004). Moreover, a negative correlation between plasma 
concentration of adiponectin and BMI in men and women (r = -0.71; P < 0.0001; and r = -0.51, 
P<0.0001, respectively) has been reported in the literature (Arita, 2012).  Data from both animal 
and human studies indicate that adiponectin has insulin-enhancing as well as anti-inflammatory 
actions (Kadowaki et al., 2006). Figure 1.11 shows some of the anti-inflammatory effects of 
adiponectin.  Adiponectin levels are markedly reduced in obese and diabetic mice, and injection 
of the adiponectin globular domain to these animals ameliorates insulin resistance, an effect 
that can be ascribed to an enhancement of fatty acid–β oxidation in skeletal muscle and a 
decrease of hepatic gluconeogenesis mediated by AMP-activated protein kinase (Berg et al., 
2001; Maeda et al., 2001; Yamauchi et al., 2002; Combs et al., 2004). Furthermore, adiponectin 
knockout mice showed increased susceptibility to diet-induced insulin resistance as well as 
injury-induced arterial stenosis and neointimal formation (Kubota et al., 2006; Matsuda and 
Shimomura, 2013). Consistent with the results from animal models, several cross-sectional 
studies have shown an association between low serum adiponectin levels and insulin resistance, 
type 2 diabetes (T2DM) and cardiovascular diseases (CVDs) in humans (Hotta et al., 2001; 
Spranger et al., 2003; Yang et al., 2005).  
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Figure 1.11: Diagram showing the proposed salutary effects of adiponectin (Taken from 
Menzaghi et al., 2007). 
A study on Pima Indian population showed that individuals with low concentrations of plasma 
adiponectin have reduced insulin sensitivity, and they tend to develop T2DM (Lindsay et al., 
2002). Elevated plasma adiponectin levels were found in low BMI diabetic and non-diabetic 
subjects.  
 Adiponectin exerts its biological effects by binding to ubiquitously expressed receptors AdipoR1 
and adipoR2, as well as Y-cadherin. The synthesis and secretion of adiponectin are regulated by 
endoplasmic reticulum molecules including calcium (Ca2+), and once in circulation, its stability is 
maintained by post –transcriptional modifications (Caselli, 2014). 
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Besides the metabolic effects, adiponectin executes anti-inflammatory effects through inhibition 
of NF-κB signaling and reduced secretion of several inflammatory cytokines released from 
monocytes, macrophages and dendritic cells (Scherer, 2006). 
In vitro studies in 3T3-L1 and Simpson Golabi Behmel Syndrome (SGBS) adipocytes treated with 
ARVs have shown inconsistent results. For example, ritanovir, in particular, has been shown to 
reduce adiponectin mRNA expression and its secretion by up to 50% as compared to control 
(Grigem et al., 2005; Lagathu et al., 2007; Adler-Wailes et al., 2012; Kim et al., 2012). Moreover, 
it has been suggested to occur as a result of increased oxidative stress (Lagathu et al., 2007) and 
also by a negative feedback mechanism involving inflammatory cytokines (Luo et al., 2009). 
However, in other studies ARVs either increase adiponectin expression (Díaz-Delfín et al., 2011), 
or have no effect (Jones et al., 2008). The use of stavudine was associated with low adiponectin 
level in plasma and increased insulin resistance compared with abacavir (Podzamczer et al., 
2007). 
Currently, little is known about the association of adiponectin and female sex steroids. A cross-
sectional study with 32 healthy women showed that total adiponectin, high molecular weight 
multimer, and medium molecular weight hexamer were inversely related to estradiol and 
progesterone. However, a low molecular weight trimer was not associated with female sex 
hormone. The study also indicated that the effect of estradiol and progesterone on insulin 
function might be mediated indirectly by their interactions with adiponectin (Leung et al., 2009). 
1.4.3 Resistin 
Resistin is a 12.5 kDa cysteine-rich protein secreted in rodents by adipocytes and in humans by 
macrophages (Steppan et al., 2001; Park and Ahima, 2013) in response to chronic inflammation, 
a characteristic feature of obesity and T2DM. Among the adipokines, a characteristic expression 
profile for resistin was obtained during the differentiation and maturation of 3T3L-1 cells and 
primary pre-adipocytes obtained from Zucker obese rats (Ikeda et al., 2013).  
Plasma resistin levels have been shown to be significantly greater in HIV-infected individuals 
without lipo-dystrophy (LD) compared with those with lipo-dystrophy and uninfected individuals 
(4.21 vs. 3.64 vs. 2.74 ng/ml, respectively), and in patients with isolated linolenic acid compared 
with those with a mixed form of LD (4.64 vs. 3.27 ng/ml) (Escoté et al., 2011). These findings 
have been supported by another group (Arama et al., 2014). A single nucleotide polymorphism 
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in the resistin gene was reported to increase the risk of metabolic complications associated with 
ARVs (Ranade et al., 2008). The degree of involvement and the specific role of resistin in the 
metabolism of ARVs still remain to be elucidated. 
17β-estradiol has been reported to stimulate resistin gene expression in 3T3-L1 adipocytes via 
the estrogen receptor extracellularly to regulate kinase enzymes, and CCAAT/enhancer binding 
protein- pathways (Chen et al., 2006). Despite the importance of resistin, relatively little is 
known about the control of production of resistin by sexual hormones and still much more 
needs to be studied.  
1.4.4 Interleukin-8 (IL-8) 
Interleukin-8 is a chemokine produced by macrophages and other cell types such as epithelial 
cells, airway smooth muscle cells and endothelial cells (Hedges et al., 2000). One of the well-
known and important complications of obesity is atherosclerosis. Since it is recognized that 
atherosclerosis might have inflammation as an important part of its pathology, IL-8 has been 
suggested to contribute to atherogenesis through several actions. Previously reported 
observations have demonstrated proximity to the initial pre-atherosclerotic lesion as well as in 
the advanced atherosclerotic plaque. Oxidized low-density lipoprotein, which is well described 
in the atherosclerotic process, can stimulate the release of IL-8 from macrophages in the 
atherosclerotic lesion (Liu et al., 1997). Because the adipose tissue can produce and release 
various cytokines and IL-8, it is possible to extrapolate a link to the atherosclerotic process. It 
may be of great interest to investigate the ability of human adipose tissue and isolated 
adipocytes to express and release IL-8. Increased expression of IL-8 was observed in HIV infected 
people (Lihn et al., 2003). 
1.5 Oxidative Stress and Antioxidant defense 
In addition to exacerbated inflammatory outcomes, accompanied by infiltration of immune cells 
in adipocytes, obesity is also characterized by increased oxidative stress. Release of 
inflammatory adipocytokines and oxidative stress machinery are not only inter-related, but their 
impairment can lead to pathogenesis of obesity and its associated risk factors. Oxidative stress 
refers to any disturbance in the balance of antioxidants and pro-oxidants in favour of the later 
due to different factors such as ageing, drug action and toxicity, inflammation and/or addiction 
(Sies et al., 1985). It is an imbalance between antioxidants [e.g., superoxide dismutase (SOD) and 
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glutathione peroxidase (GPX)] and reactive oxygen species [e.g., superoxide (O2−), hydrogen 
peroxide (H2O2), and hydroxyl radical (OH−)] (Sies, 1997). Oxidative stress causes healthy cells of 
the body to lose their function and structure by attacking them. Damage to DNA, proteins, and 
other macromolecules due to oxidation has been implicated in the pathogenesis of a wide 
variety of diseases (Halliwell et al., 1994). Both cell culture and animal studies have 
demonstrated that oxidative stress can cause an increase in pre-adipocyte proliferation, 
adipocyte differentiation, and the size of mature adipocytes (Furukawa et al., 2004; Lee et al., 
2009; Higuchi et al., 2013). Oxidative stress plays critical roles in the pathogenesis of various 
diseases (Brownlee, 2001). In the diabetic condition, oxidative stress impairs glucose uptake in 
muscle and fat (Rudich et al., 1998; Maddux et al., 2001) and decreases insulin secretion from 
pancreatic β cells (Matsuoka et al., 1997). Increased oxidative stress also underlies the 
pathophysiology of hypertension (Nakazono et al., 1991) and atherosclerosis (Ohara et al., 1993) 
by directly affecting vascular wall cells. Figure 1.12 shows a working model of how increased 
oxidative stress in potentially relates to various obesity-related diseases. 
 
Figure 1.12: Working model illustrating how increased oxidative stress in adipose tissue 
potentially relates to various obesity-related diseases. Abbreviations: NADPH, nicotinamide 
adenine dinucleotide phosphate; SOD, superoxide dismutase; GPX, glutathione peroxidase 
(Taken from Matsuda et al., 2013). 
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Oxidative stress is controlled by the endogenous antioxidant defense system, which includes 
antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, 
glutathione reductase; and non-enzymatic compounds such as ferritin, transferrin, bilirubin, 
ceruloplasmin and even albumin carrier low molecular weight, such as uric acid and lipoic acid 
(Poljšak et al., 2014).  Antioxidants are able to trap free radicals generated by cellular 
metabolism or exogenous sources through the donation of hydrogen atoms of these molecules, 
breaking the chain reaction, which prevents attack on lipids, amino acids in proteins, double 
bond of the polyunsaturated fatty acids, and DNA bases, avoiding formation of lesions and loss 
of cell integrity (Sies, 1993). Another role of antioxidants is the protection mechanism, which 
acts in the repair of damage caused by free radicals, a process related to the removal of the DNA 
molecule of damage and restoration of damaged cell membranes (Sies, 1991). 
1.5.1 Biomarkers of oxidative stress 
Species or molecules whether endogenous (internally synthesized) or exogenous (consumed), 
can play a major role in the antioxidant defense and this may be considered as biomarkers of 
oxidative stress. 
1.5.1.1 Catalase 
Catalase is an anti-oxidative enzyme which plays an important role against oxidative stress-
generated complications such as obesity, diabetes and cardiovascular diseases (Chelikani et al., 
2004). It acts as a major regulator of hydrogen peroxide metabolism. Hydrogen peroxide (H2O2) 
is a highly reactive small molecule formed as natural by-product of energy metabolism which in 
excessive concentration may cause significant damages to proteins, DNA, RNA, and lipids 
(Takemoto et al., 2009). Catalase catalytically converts H2O2 into water and oxygen and thus 
neutralizes it. Increased risk of obesity and diabetes has been documented in patients with 
catalase deficiency. In case of catalase deficiency, beta cell of pancreas that contain large 
amount of mitochondria, undergoes oxidative stress by producing excess reactive oxygen 
species (ROS) leading to dysfunction of  β-cells and ultimately obesity and diabetes (Jamieson et 
al., 1986). 
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1.5.1.2 Superoxide Dismutase (SOD) 
Superoxide dismutase (SOD) is the antioxidant enzyme that catalyses the dismutation of 
superoxide anion (O2 −) into hydrogen peroxide and molecular oxygen (Faraci et al., 2004; Wang 
et al., 2016). SOD provides first line of defense against ROS mediated cellular and histological 
damages by facilitating the conversion of superoxide radicals into hydrogen peroxide, and in the 
presence of other enzymes it is converted into oxygen and water (Tiwari et al., 2013). All 
mammalian tissues contain three forms of SOD: Cu-Zn-SOD, Mn-SOD, and extracellular EC-SOD, 
and each of them is a product of a distinct gene (Beyer et al., 1991).  
Superoxide reacts rapidly with nitric oxide (NO), reducing NO bioactivity and producing the 
oxidative peroxynitrite radical (Guzik et al., 2002). SOD, a major defender against superoxide, in 
the kidneys during the development of murine diabetic nephropathy and down-regulation of 
renal SOD (SOD 1 and SOD 3) may play a key role in the pathogenesis of diabetic nephropathy 
(Fujita et al., 2009). Over expression of SOD or the supplements of antioxidants including SOD 
mimetics, targeted to overcome oxidative stress, reduce ROS, and increase antioxidant enzymes, 
has been shown to prevent diabetes mellitus (Wang et al., 2011). 
1.5.1.3 Glutathione (GSH) 
Glutathione (GSH), a tripeptide, γ-L-glutamyl-L-cysteinyl glycine, is present in all mammalian 
tissues at 1–10 mM concentrations (highest concentration in liver) as the most abundant non-
protein thiol that defends against oxidative stress (Lu, 2013). GSH functions by maintaining SH 
groups of proteins in a reduced state, participate in amino acid transport, detoxify foreign 
radicals, act as coenzyme in several enzymatic reactions, and also prevent tissue damage (Tsai et 
al., 2012). GSH is also considered as a biomarker of redox imbalance at cellular level (Rizvi et al., 
2011). Both obesity and diabetes have been reported to induce alterations in the activity of 
enzymes glutathione peroxidase and glutathione reductase. These enzymes metabolize peroxide 
to water and play a role in converting glutathione sulphide back into glutathione (Maritim et al., 
2003). Any alterations in the levels of these enzymes make the cells prone to oxidative stress 
and hence cellular injury. 
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1.5.1.4 Nitric Oxide (NO) 
Under normal physiological conditions, nitric oxide (NO) is a critical homeostatic regulator of the 
vessel wall and plays a role in the maintenance of vascular tone and reactivity (Verma et al., 
2002). NO acts as a physiological regulator of diverse functions in several tissues including 
cardiovascular, neuromuscular, neurological, genitourinary, gastrointestinal and renal. Inhibitors 
of nitric oxide synthase reduce NO production and prevent the decrease in insulin secretion 
caused by free fatty acids (Shimabukuro et al., 1997). It acts as an important anti-atherogenic 
agent and inhibits platelet activation and aggregation, leukocyte chemotaxis, and endothelial 
adhesion (Chakraborty et al., 2003). Under conditions of overweight and obesity, endothelium-
dependent vaso-dilation of NO is impaired (DeSouza et al., 2005).  
1.6 Transcriptional regulation of adipogenesis 
Differentiation of pre-adipocytes into adipocytes involves a comprehensive network including a 
number of transcription factors responsible for the expression of key proteins that induce 
mature adipocyte formation. This highly regulated transcriptional cascade begins with re-entry 
of growth arrested pre-adipocytes into the cell cycle where they undergo several rounds of 
mitosis. This initial phase is known as mitotic clonal expansion (MCE) and is accompanied by the 
transient expression of C/EBP-β and C/EBP-δ. These transcription factors subsequently stimulate 
transcription of PPAR, which in turn can activate C/EBP-α. PPAR-γ and C/EBP-α exist in a positive 
feedback loop to propagate differentiation and induction of late adipogenic genes including aP2 
and Fas in the terminal differentiation phase (Rosen et al., 2000). 
1.6.1 Peroxisome Proliferator-Activated Receptors (PPAR) 
Peroxisome Proliferator-Activated Receptors (PPARs) are a nuclear hormone receptor super 
family of ligand-activated transcription factors, which bind to the promoter of target genes 
leading to increased or decreased DNA transcription upon binding of ligands, and are involved in 
various biological processes such as energy metabolism, cell proliferation and inflammation 
(Kersten, 2002). PPAR plays a dominant role in adipogenic differentiation, glucose metabolism, 
inflammation and other physiological processes, and is also a receptor of an important class of 
anti-diabetic drugs (Kliewer et al., 1994; Tontonoz and Spiegelman, 2008). A series of gain-of-
function studies in which PPAR-γ was ectopically expressed in non-adipogenic mouse  fibroblasts 
showed that PPAR-γ alone can initiate the entire adipogenic program, giving rise to fat cells that 
46 
 
are capable of many of the functions of mature adipocytes (Tontonoz et al., 1994). 
 
1.6.2 CCAAT/Enhancer-Binding Proteins (CEBP)  
The CCAAT/enhancer binding proteins (C/EBPs) belong to a family of highly conserved basic 
leucine zipper transcription factors that play an important role in adipocyte differentiation. 
C/EBP-α is important in terminal differentiation of adipocytes, as absence of this factor leads to 
insulin resistance in in vitro experiments and hinders formation of WAT in vivo. In contrast, 
development of BAT is independent of C/EBP (El-jack et al., 1999; Linhart et al., 2001). 
C/EBP-β and C/EBP-δ have been postulated to be the first transcription factors induced during 
induction of adipogenesis, and therefore, play an important role in directing the differentiation 
process (Darlington et al., 1998). The importance of C/EBP-β and C/EBP-δ has been 
demonstrated in loss-of-function and gain-of-function studies where embryonic fibroblasts from 
mice lacking these two markers were unable to differentiate in response to hormonal induction. 
Consequently, these cells failed to express other important adipogenic markers such as C/EBP, 
PPAR or adipocyte binding protein 2 (aP2)/Fatty acid binding protein 4 (FABP4). These results 
suggest that in vitro, adipocyte differentiation proceeds according to the proposed 
transcriptional cascade in which C/EBPs and PPAR families of transcriptional factors are 
activated sequentially leading to formation of mature adipocytes (Tanaka et al., 1997). 
 
1.6.3 Sterol Regulatory Element-Binding Protein -1 (SREBP) 
The sterol regulatory element-binding protein-1 (SREBP-1), also referred to as the adipocyte 
determination and differentiation-dependent factor 1 (ADDDF-1), is a basic helix-loop-helix 
(bHLH) leucine transcription factor that is associated with adipocyte differentiation and 
cholesterol homeostasis (Yokoyama et al., 1993). SREBP-1 is expressed in different types of 
tissues but is predominantly expressed in brown adipose tissue (Tontonoz et al., 1993). As a 
member of bHLH transcription factor family, SREBP-1 has dual DNA binding specificity, in that it 
can bind to an E-box motif and a sterol regulatory element (SRE). Thus, when expressed in 
fibroblasts, SREBP-1 activates transcription through both the E-box motif and SRE, providing a 
novel mechanism to coordinate different lipid metabolism pathways (Yokoyama et al., 1993; 
Kim et al., 1995). SREBP-1 plays a role in adipocyte gene expression by regulating the expression 
of FAS and LPL, important genes involved in fatty acid metabolism (Kim, 1996). 
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1.6 Potential health benefits of bioactive compounds in combating obesity /Dietary 
interventions to combat drug induced inflammation and oxidative stress 
The popularity of dietary supplements for weight management has increased over the past 
years and a wide variety of these products are available over the counter. They represent an 
attractive adjuvant to traditional therapy because most of them have a low toxicity profile and 
are accessible to general population. It is therefore not surprising that these supplements 
account for more than $37 billion in sales in the USA (Bradley et al., 2015). A national survey 
published in 2008 found that 33.9% of adults who have made a weight loss attempt had used a 
dietary supplement to do so (Pillitteri et al., 2008). Despite widespread use, there are still 
limited data on the safety and efficacy of the products currently on the market. Identification 
has such dietary compounds has prompted researchers to explore the vast array of their 
beneficial effects. The American Dietetic Association (ADA) acknowledges the significance of 
consumption of bioactive compounds and therefore supports the marketing of functional foods, 
either conventional or modified, when there is substantial scientific evidence of benefit  (Hasler 
et al., 2009). 
1.6.1 Quercetin  
Quercetin a dietary flavonoid is abundantly present in different types of fruits and vegetables 
(Alinezhad et al., 2013). Onions, red apples, red wine, tea, cranberry, kale, hot peppers, 
coriander, fennel, raddish and broccoli are considered rich sources of quercetin (Aras et al., 
2014). Quercetin present in plant species is commonly found in glycoside forms (Rice-Evans, 
2001), with rutin being the most common (Manach et al., 1997). Other glycoside forms of 
quercetin commonly found in the human diet are 3-rutinoside (occurring in black tea), O-
glucoside (onions), quercetin galactosides (apples) and quercetin arabinosides (berries) 
(Hollman et al., 1997). 
The anti-inflammatory and anti-oxidative roles of quercetin to ameliorate obesity via different 
molecular pathways have been widely studied in animal models and cell lines over the past 
decade. Circumstantial evidences from different research groups in C57BL/6J mice have 
reported that a high-fat diet containing quercetin (0.05–0.25%) decreased body weight, liver fat 
accumulation, blood glucose, plasma and liver tri-acylglycerols, improved TBARS and glutathione 
levels in the liver. In addition, suppressed expression of important genes, including PPARγ, a 
transcription factor that regulates high-fat diet-induced fat accumulation in the liver was 
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observed previously (Jung et al., 2013). Other studies on Zucker obese rats showed that 
quercetin increased the plasma adiponectin concentration, reduced plasma nitrate and nitrite 
levels  and enhanced visceral adipose tissue endothelial (Rivera et al., 2008). Apart from animal 
models, cell lines have also been used extensively to understand how quercetin interferes with 
lipid metabolism to prevent obesity especially at molecular level.  
The protective effects of this compound have been linked to its anti-inflammatory and/or 
antioxidant properties. Anti-inflammatory effects of quercetin have been reported for both 
adipocytes and macrophages and these activities are mediated by NF-κB associated mechanisms 
(Overman et al., 2011). This study by Overman et al in 2011 reported that quercetin may lower 
inflammation in adipose tissue by reducing the infiltration of macrophages and preventing 
infiltrated macrophage-mediated inflammation and insulin resistance in human adipocytes and 
that these effects were associated with quercetin dependent suppression of NF-κB activation. 
Quercetin is known to decrease TNF-α-induced NF-κB transcriptional activity in primary human 
adipocytes and further attenuates the TNF-α-mediated suppression of PPAR-γ activity and PPAR-
γ target genes (Chuang et al., 2010). The anti-obesity action of quercetin is mediated by the 
AMPK and MAPK signaling pathways. It has been reported to attenuate adipogenesis and 
decrease expression of adipogenesis-related factors in 3T3-L1 pre-adipocytes by the up-
regulation of phosphorylated AMPK levels (Ahn et al., 2008).  
 
1.7 Significance and future implications of the study by basic scientists and clinicians  
The global outspread of obesity epidemic makes it crucial for Physicians to consider the weight 
effects of medications being prescribed and to balance the benefits of treatment with the 
potential for weight gain. Medication-induced weight gain is a significant problem for many 
treated patients and the weight promoting effects of such medications should be considered in 
drug choice. The Endocrine Society in 2015 has published clinical practice guidelines for 
pharmacological management of obesity, including data on medications that cause weight gain. 
It has further suggested alternatives that are weight–neutral or promote weight loss. Dietary 
supplements represent an attractive adjuvant to the meditational therapies promoting weight 
gain because of their low toxicity profiles and accessibility to the general population. The 
prospect of using natural products to treat obesity and diabetes is still not widely examined. 
Flavonoids offer a potential alternative treatment strategy for the development of effective and 
safe anti-obesity and anti-diabetes drugs. Emerging studies have described the promising role of 
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flavonoids in treating obesity and diabetes as well as their associated metabolic diseases. 
Positive results from a number of animal and human studies support the use of quercetin in 
fighting inflammatory disease. This study is a continued evaluation to uncover the exact 
mechanisms through which quercetin functions in order to satisfactorily address safety 
concerns. The present research will provide a mechanistic insight into the effects of quercetin as 
promising and potent antioxidant and anti-inflammatory agent against different molecular 
mechanisms involved in obesity pathogenesis. 
In conclusion, it is also hoped that this study will enhance knowledge and understanding as well 
as reigniting interest in the anti-inflammatory properties of natural flavonoids and encourage 
the public to explore vegetarian diets and natural medicines to combat drug-induced obesity. 
1.8 Scope of the Study 
1.8.1 Working Hypothesis 
Commonly used medicines either alone or in combination to treat patients may increase risk of 
metabolic syndromes. 
 1.8.2 Main aim 
The main aim of this study was to investigate and highlight commonly used medications 
including rilpivirine and quercetin that might increase the risk of the metabolic syndrome. The 
study also aimed to determine the modulatory role of quercetin to ameliorate rilpivirine and 
estradiol induced metabolic alterations. 
1.8.3 Specific Aims and Objectives 
The specific aims and objectives of this research are as follows: 
1. To culture and differentiate human pre-adipocytes into mature adipocytes. 
2. To determine the cytotoxicity of various at different time points and dose 
concentrations. 
3. To demonstrate the accumulation of triglycerides during the adipocyte differentiation 
process by quantitative measurement and staining of the adipose cells. 
4. To investigate the levels of inflammatory adipocytokines namely adiponectin, leptin, 
Interleukin-8 and resistin after adipocyte differentiation.  
5. To investigate the levels of oxidative stress markers namely glutathione (GSH), nitric 
50 
 
oxide (NO), superoxide dismutase (SOD) and catalase after adipocyte differentiation. 
6. To study the expression of C/EBP-α, PPAR-γ, SREBP-1, FAS, LPL and aP2 genes in the 
presence or absence of quercetin at mRNA level using RT-PCR. 
7. To measure protein levels of adipogenesis markers through quantitative measurement 
and immunostaining. 
8. To undertake a thorough literature search around the subject area, analyze the data and 
write up the PhD thesis.  
 
1.8.4 Justification of the Study 
It is noteworthy that the metabolic syndrome is a cluster of risk factors associated with an 
increased risk for CVDs and T2DM. The use of certain medications may increase the risk of the 
metabolic syndrome by either promoting weight gain or altering lipid or glucose metabolism. 
Health providers should recognize and understand the risk associated with certain medications 
and appropriately monitor for changes related to the metabolic syndrome. Careful attention to 
drug choices should be paid in patients who are overweight or have other risk factors for 
diabetes or CVDs. Several medications like paracetamol, caffeine, rilpivirine, estradiol can induce 
metabolic alterations by dysregulating adipocyte function, differentiation and disruption of 
inflammatory as well as oxidative profile at gene and protein levels. Dietary agents such as 
quercetin when used in supplementation to these drugs can mitigate adipocyte dysfunction by 
down-regulation of factors involved in the adipogenesis process and modulate the inflammatory 
and oxidative profile in adipose cells. 
As such, this study was designed to specifically investigate the effect of the two metabolic 
altering drugs, rilipivirine and estradiol, on lipid metabolism in human adipopse cells in the 
presence or absence of quercetin, an anti-inflammatory and anti-oxidant agent. It is justifiable 
to undertake the study in order to understand any adverse effects of rilpivirine and estradiol 
during the process of adipogenesis and more so, how quercetin can attenuate these side effects. 
The results, in turn, may provide knowledge and understanding on drug-induced adipogenesis 
and also for clinicians to make suitable choices of herbal supplements for therapeutic use. 
1.8.5 Approach or scope of the study 
This study consists of 7 chapters. Chapter 1 or the introduction chapter is related to the critical 
and comprehensive review of the subject area including the scope of the study. Chapter 2 
describes all the materials employed for the investigation of the study and the methodology and 
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experimental protocols used in solving the scientific problem. It also contains a short section on 
statistical data analysis. Chapter 3 is a developmental study relating to the effect of caffeine and 
paracetamol on adipose cells in the presence or absence of β-naphthoflavone. Chapter 4 
investigated the effect of rilpivirine and estradiol on adipogenesis in the presence or absence of 
β-naphthoflavone. Chapters 5 and 6 investigated the effect of rilpivirine and estradiol, 
respectively, either alone or in combination with quercetin, a natural flavanoid, at cellular and 
molecular levels during the process of adipogenesis. Finally, chapter 7 is related to a critical 
discussion of the findings in chapters 3-6. These different chapters are followed by future 
studies, limitations, references, appendices with supplementary data and publications. 
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Chapter 2 
 
 
 
 
Materials and Methods 
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2. MATERIALS AND METHODS 
2.1 Reagents, cell lines and Consumables 
Table 2.1 shows the reagents and consumables used in this study. 
Table 2.1:  List of reagents, consumables, media and kits employed in this study 
Sr.No. Items Manufacturers Catalogue 
numbers 
1. Adipose Derived Mesenchymal Stem 
Cells  
HiMedia Laboratories CL007 
2. Adipocyte Differentiation Medium HiMedia Laboratories AL521 
3.  Mesenchymal Stem Cell Expansion 
Medium 
HiMedia Laboratories AL512 
4. Human Subcutaneous Pre-adipocytes Lonza Walkersville, USA PT-5001 
5. Pre-Adipocyte Basal Medium Lonza Walkersville, USA PT-8202 
6. L-Glutamine Lonza Walkersville, USA PT-9001H 
7. Gentamicin sulfate amphotericin-B  Lonza Walkersville, USA PT-4504H 
8. Fetal Bovine serum Lonza Walkersville, USA PT-9000H 
9. Insulin Lonza Walkersville, USA PT-9003H 
10. Dexamethasone Lonza Walkersville, USA PT-9004H 
11. IBMX Lonza Walkersville, USA PT-9013H 
12. Indomethacin Lonza Walkersville, USA PT-9014H 
13. DMEM, High glucose HiMedia Laboratories AL007A 
14. Fetal Bovine serum HiMedia Laboratories RM112 
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15. Antibiotic-Antimycotic solution HiMedia Laboratories A002 
16. Dulbecco’s Phosphate Buffered Saline HiMedia Laboratories TL1006 
17. Trypsin/EDTA Solution HiMedia Laboratories TCL007 
18. Soybean Trypsin Inhibitor Solution HiMedia Laboratories TCL068 
19. CytoTox96 Non-Radioactive Cytotoxicity 
Assay Kit 
Promega G1780 
20. Lipolysis Assay Kit Abcam ab185433 
21. Adiponectin Human ELISA Kit Abcam ab99968 
22. Human Leptin ELISA Kit Sigma Aldrich RAB0333 
23. Human Interleukin-8 ELISA Kit Sigma Aldrich RAB0319 
24. Human Resistin ELISA Kit Sigma Aldrich RAB0419 
25. DMSO HiMedia Laboratories TC185 
26. Rilpivirine Sigma Aldrich PZ0180 
27. 17 β-Estradiol Sigma Aldrich E2257 
28. β-Naphthoflavone Sigma Aldrich N3633 
29. Trypsin Protease Hyclone SV3003701 
30. AdipoRed Assay Reagent Lonza Walkersville, USA PT-7009 
31. Phosphate buffered saline Hyclone H30256.01 
32. Human Leptin Duoset ELISA Kit R&D Biosystems DY398 
33. Human IL-8 /CXCL8 Duoset ELISA Kit R&D Biosystems DY208 
34. Human Resistin Duoset ELISA Kit R&D Biosystems DY1359 
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35. Human Adiponectin/ACRP30 duoset 
ELISA kit  
R&D Biosystems DY1065 
36. Dimethyl sulfoxide (DMSO) Sigma Aldrich M81802  
37. Rilpivirine Cayman chemicals  21559 
38. Quercetin Sigma Aldrich N3633 
39. Adipogenesis Marker Antibody Sampler 
Kit 
Cell Signalling 12589T 
40. Superoxide Dismutase Assay kit Cayman Chemicals 706002 
41. Glutathione Assay kit Sigma Aldrich CS0260 
42. Nitrate Colorimetric Assay Kit Cayman Chemicals 780001 
43. Catalase Assay kit Cayman Chemicals 707002 
44. Alexa Fluor 488 Stain  Thermo Fisher Scientific  A-11034 
45. Hoechst Dapi Stain Thermo Fisher Scientific 62249 
46. BCA Protein Assay kit Thermo Fisher Scientific 23225 
47. GenElute Mammalian total RNA 
MiniPrep kit 
Sigma Aldrich RTN10 
48. cDNA Reverese Transcription kit Applied Biosystems 4375575 
49. Triglyceride quantification kit Abcam Ab65336 
50. Oligonucleotides AccuvisBio  
 
Cell lines: 3T3-L1 adipose derived mesenchymal stem cells, Human subcutaneous preadipocytes 
Treatment drugs: Paracetamol, caffeine, β naphthoflavone, rilpivirine, estradiol, quercetin. 
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2.2 Investigational Study Design 
In order to confirm the hypothesis proposed in this thesis, human adipose cells were treated 
with various concentrations of drugs (caffeine, paracetamol, β naphthoflavone, rilpivirine, 
estradiol, quercetin) either alone or in combination. The study investigated the effect of these 
drugs at physiological concentrations on adipocyte function, gene expression and inflammation. 
The study also investigated gene polymorphisms of FABP4 and PPAR variants in diabetic patients 
in the United Arab Emirates (UAE) population. Investigational methods/techniques such as MTT, 
LDH, Staining, Inflammatory markers, Oxidative markers, immune-staining, PCR, RFLP, Lipid 
profiling etc. were employed. 
2.3 Biosafety Approval 
All ethical and safety consents were obtained by the Ethics Committee of the School of Forensic 
and Applied Sciences at the University of Central Lancashire, Preston, U.K (Unique reference 
Number: STEMH 445). 
2.4 a. Cell proliferation, seeding and differentiation (Used in Chapters 3 and 4) 
In this study, 3T3-L1 adipose derived mesenchymal stem cells (HiMedia) were used to model the 
individual as well as combinatory effects of rilpivirine and/or 17-β estradiol either with or 
without BNF in pre-adipocyte differentiation to mature adipocyte cells. The cell line was 
obtained from HiMedia Laboratories (CL007). These cells were at passage 2 after isolation from 
human lipo-aspirate collected after liposuction procedure. Upon arrival, morphology and 
confluency of the cells was checked under the microscope. The cells were then incubated for 3-4 
hours to allow floating cells to re-attach to the surface, in a humidified CO2 incubator with 5% 
CO2 and 37 ºC temperature. After incubation, the flask was replenished with appropriate 
amount of complete medium containing Dulbecco’s modified Eagle’s medium (DMEM) with 4.5 
g/liter D-glucose, 10% fetal calf serum (FBS) and penicillin /streptomycin (100 units/ml penicillin, 
50 µg /ml streptomycin). 
The medium was changed every 2-3 days and the cells were sub-cultured after they reached 70-
80% of confluency. For sub-culturing, the spent medium was aspirated gently without disturbing 
the monolayer and discarded. The cells were then washed with 2-3 ml of Dulbecco’s phosphate 
buffer saline (DPBS) to remove residual medium. 500 µL of pre- warm trypsin-EDTA 
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(Ethylenediamine tetra acetic acid) solution was added to detach the adherent cells from the 
walls of the flask. The flask was incubated for 30 minutes and then observed microscopically to 
ensure complete detachment of cells. The action of trypsin was neutralized by addition of 
complete medium and a homogeneous mixture of cells of obtained. The cells were counted 
using a haemocytometer and an appropriate number was used to seed fresh flasks at 
recommended seeding density (Approx. 0.125 x 106 cells/cm2 of the flask). 
After confluence, 3T3-L1 adipocyte differentiation into adipose cells was obtained in the 
presence of the same culture medium as used before supplemented with adipogenic 
differentiation medium (HiMedia). This medium contained supplement formulated with 
induction factors that induced adipogenic differentiation of human mesenchymal stem cells. 
Table 2.2 illustrated the different media used for maintenance, differentiation and treatment of 
3T3-L1 adipocytes in this study. 
Table 2.2: Table showing media formulations employed in the study. 
Medium Formulation 
Pre-adipocyte Expansion  90% Dulbecco’s Modified Eagle’s Medium (DMEM), and 10% 
Bovine Calf Serum  
Differentiation  90% DMEM, 10% Fetal Bovine Serum (FBS), 1.0 μM 
Dexamethasone, 0.5 mM Isobutyl methyl xanthine (IBMX), and 
1.0 μg/ml Insulin  
Adipocyte Maintenance  90% DMEM, 10% FBS, and 1.0 μg/ml Insulin  
 
For studies on the effects of drugs during adipocyte differentiation, treatment with either 17β- 
estradiol, rilpivirine or 17β- estradiol and rilpivirine in combination and either with or without β-
naphthoflavone (BNF) was initiated on day 0 and continued throughout the differentiation 
period of 10 days. Fresh drugs were added each time the medium was replaced. Stock solutions 
of 17β-estradiol and BNF were prepared in DMSO (DiMethyl Sulphoxide) while differentiation 
medium was used for preparing rilpivirine. They were then aliquoted and stored at -20 ºC prior 
to use.  
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2.4 b. Cell proliferation and seeding (Used in Chapters 5 and 6)  
 In the present study, human subcutaneous pre-adipocytes were used to model the effects of 
rilpivirine and 17β-estradiol in either the presence or absence of an anti-inflammatory flavanoid, 
quercetin. The cell line was obtained from Lonza (Cat. # PT5001). These cells were isolated from 
subcutaneous adipose tissue by enzymatic digestion and selective culturing techniques. 
2.4.1 Unpacking and Storage 
Upon arrival in the laboratory, the cryovials containing the cells were removed from the dry ice 
packing and immediately placed in liquid nitrogen. The cells were supplied with a BulletKitTM 
containing basal medium and a vial of SingleQuotsTM, which were stored at 4-8ºC and -20 ºC, 
respectively. Dulbecco's Phosphate Buffered Saline (DPBS) was stored at ambient temperature. 
Trypsin/EDTA solution was sterile filtered and stored at -20 ºC.  
2.4.2 Preparation of Media 
Pre-warmed (37 ºC), supplemented medium was used for the culturing of pre-adipocytes. 
Firstly, the external surface of the Pre-adipocyte Basal Medium-2 bottle was decontaminated 
with 70% v/v of ethanol. The Pre-adipocyte Growth Medium-2 was made by adding the entire 
contents of the fetal bovine serum (FBS), L-Glutamine, GA-1000 SingleQuotsTM to the bottle of 
Pre-adipocyte Basal Medium-2. The final concentrations of the supplements were 10%, 2 mM, 
30 µg/ml and 1 5 ng/ml, respectively. 
2.4.3 Thawing of cells and initiation of culture process 
Cryovial containing the cells was removed from liquid nitrogen storage and thawed rapidly in a 
37 °C water bath, for no more than 2 minutes. The external surface of the vial was 
decontaminated with 70% v/v ethanol or isopropanol. Thawed cell suspension was added to 50 
ml of pre-warmed Pre-adipocyte Growth Medium-2 and centrifuged at 300 x g for 10 minutes at 
room temperature. The cells were then washed leaving a minimum of 1 ml of wash at the 
bottom of the tube. A volume of either 2 or 3 ml of Pre-adipocyte Growth Medium-2 was added 
to this 1 ml of wash and the pellet was re-suspended. A total of 20 µl of the cell suspension was 
finally diluted with an equal amount of 0.4 % trypan blue and a cell count was done to 
determine % viability.  
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In order to expand the cells prior to use for assays, the pre-adipocytes were plated with 
approximately 9,000 cells cm2 in 0.2 ml medium cm2 growth area in tissue culture flasks. The 
flasks were placed in CO2 incubator (Forma™ Series II 3110 Water-Jacketed incubator from 
Thermo Fisher Scientific) maintained at 37 ºC and 5% CO2. Human primary pre-adipocytes 
appeared round when first plated and within four hours, greater than 90% of the cells began to 
flatten and elongate. Within 24-36 hours the cells were adherent, elongated and spindle 
shaped. As the pre-adipocytes began to divide, they rounded up. The cultures were fed every 3-
4 days after plating. 
2.4.4 Sub-culturing 
The spent media were aseptically removed and discarded from the flasks followed by washing of 
the attached cell layer with Dulbecco’s Phosphate Buffered Saline. The flask was rinsed 
thoroughly by rocking the flask back and forth several times. The wash solution was then 
aseptically removed and discarded. Sufficient volume of Trypsin-EDTA solution was then added 
to cover the cell layer (approx. 25 ml/cm2). Incubation was done at room temperature for 3 
minutes and the cells were then observed under the microscope. Once >90 % of the cells were 
rounded and detached, approximately 0.2 ml/cm2 of temperature equilibrated Pre-adipocyte 
Growth Medium-2 was added to each flask. Pipetting over the cell layer surface several times 
ensured dispersal of the solution. To remove the trypsin, the cells were centrifuged at 
approximately 300 x g for 10 minutes at room temperature. The obtained cell pellet was re- 
suspended in a minimal volume of temperature equilibrated growth medium and the total 
number of cells was counted using a haematocytometer. 
2.4.5 Maintenance and Differentiation 
In order to prepare adipocyte differentiation medium, entire contents of the SingleQuots™ 
containing insulin, dexamethasone, indomethacin and isobutyl-methylxanthine (IBMX) were 
added to 100 ml of preadipocyte growth medium-2 pre-warmed to 37°C. Pre-adipocytes were 
induced to differentiate by the addition of 0.1 ml of Adipocyte Differentiation Medium to each 
well for a period of 8 days. 
2.4.6 Adipocyte treatment 
In this study, the effect of drugs during adipocyte differentiation, treatment with 17β-estradiol, 
rilpivirine alone and then in combination with quercetin was initiated on day 0 and continued 
throughout the differentiation period of 8 days.  
60 
 
2.4.7 Preparation of treatment drugs 
Stock solutions of treatment drugs were prepared in DMSO/methanol. They were then 
aliquoted and stored at -20ºC prior to use. Working solutions of the treatment drugs were 
prepared in pre-adipocyte growth medium-2 by diluting them further as outlined in Table 2.3. 
Table 2.3: Table showing the concentrations of treatment drugs used in the study 
Treatment Drugs Stock concentrations Working concentrations 
Rilpivirine 25 mg/ml 0.1 µM, 1 µM,5 µM, 10 µM, 15 µM 
and 20 µM 
17-β Estradiol 1 mg/ml 0.0001 μM, 0.001 μM, 0.01 μM, 0.1 
μM and 1 μM  
Quercetin 50 mg/ml 50 μM  
Caffeine 1 mg/ml 0.1 mM 
Paracetamol 25 µg/ml 0.1 mM 
BNF 1 gm/ml 200 µM 
 
2.5 Lactate dehydrogenase Assay for the measurement of cell cytotoxicity 
 Potential cytotoxic effects of drugs on differentiating human pre-adipocytes was determined 
after exposure of drugs for 10 days using a CytoTox 96 kit (Promega), which measured the 
appearance of lactate dehydrogenase (LDH) in the cell culture medium. LDH is a stable cytocyclic 
enzyme normally released upon cell lysis. The released LDH in culture supernatants was 
measured with a 30-minute coupled enzymatic assay, which resulted in the conversion of a 
tetrazolium salt (iodonitro-tetrazolium violet; INT) into a red formazan product. The amount of 
color formed was proportional to the number of lysed cells. Cell viability was assessed on day 0, 
5 and 10. Following experimental treatment, supernatant samples were transferred to a 96 well 
plate and an equal volume of CytoTox 96® Reagent was added to each well and incubated for 30 
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minutes. Stop Solution was added, and the absorbance signal was measured at 490 nm using a 
plate reader.  
 2.6 Adipo Red Staining and Quantitative measurement of triglyceride accumulation 
Visualization and quantification of intracellular lipid droplets was done using AdipoRed™ 
Reagent following the manufacture's protocol. AdipoRed™ Stain was used to determine the 
effects of test compounds on the differentiation of adipocyte precursors as characterized by the 
accumulation of intracellular triglycerides. 
 For the assay, cells were seeded at 10,000 /cm2 of the surface area and cultured and 
differentiated as described above, using appropriate volumes of cell culture media. Immediately 
prior to the assay, each plate was rinsed with PBS followed by the addition of AdipoRed™, using 
the volumes as shown in Table 2.4. 
 Table 2.4: Table showing volumes of PBS and AdipoRed to be used for the assay 
 Rinse volume/well Final volume of 
PBS/well 
Volume of AdipoRed /well 
6-well plate 2 ml 5 ml 140 µl 
12-well plate 1 ml 2 ml 60 µl 
24-well plate 1 ml 1 ml 30 µl 
48-well plate 0.4 ml 0.4 ml 12 µl 
96-well plate 0.2 ml 0.2 ml 5 µl 
 
The plate was then incubated for 10 to 15 minutes and placed in the fluorimeter. The 
fluorescence was measured with excitation at 485 nm and emission at 572 nm.  
2.7 Quantification of free glycerol 
 The triglycerides within the cell were lipolysed into glycerol and free fatty acids. Commercially 
available Abcam’s Lipolysis Assay kit (ab185433) was used to measure glycerol released from 
3T3-L1 cells colorimetric method. This kit included glycerol assay buffer, glycerol probe, glycerol 
enzyme mix, glycerol standard, lipolysis assay and wash buffer and was stored at -20ºC away 
from light. The glycerol assay buffer, probe, lipolysis assay and wash buffer were warmed at 37 
ºC using a water bath prior to use. Glycerol enzyme mix was provided in a lyophilized form and 
was reconstituted with 20 µL of glycerol assay buffer. Standard curve was prepared by adding 10 
µL of 100 mM Glycerol standard to 990 µL of glycerol assay buffer to generate 1mm Glycerol 
62 
 
Standard. Thereafter, volume of 0, 2, 4, 6, 8 and 10 µL of 1 mM glycerol standard was added into 
series of wells in a 96 well plate to generate 0, 2, 4, 6, 8 and 10 nmol/well of glycerol standards. 
The volume of each well was adjusted to 50 µL with Glycerol assay buffer. Enough reaction mix 
consisting of 46 µL of glycerol assay buffer, 2 µL of glycerol enzyme mix and 2 µL of glycerol 
probe per well was prepared for the number of assays to be performed. A volume of 50 µL of 
this reaction mixture was added to each well of the 96-well plate containing the standards and 
the samples. The plate was then incubated at room temperature for 30 minutes protected from 
light. Absorbance was read at 570 nm in a micro-plate reader.  
For calculating glycerol concentrations in the cell samples, zero standard reading was subtracted 
from all readings and a standard curve was plotted. The corrected sample reading was then 
applied to the standard curve to get nmol of glycerol amount in the sample wells. 
2.8 Quantitative Measurement of Adipokines and Cytokines  
Commercially available Human Elisa kits from R&D Systems were used to quantitatively measure 
the adipocytokines (Adiponectin, leptin, resistin, Interleukin-8) released by adipocytes and 
accumulated in the cell culture medium at the end of 8 days of differentiation process following 
the manufacture’s protocol. Each of the kit components included human protein standard, 
human detection antibody, HRP conjugated streptavidin, ELISA colorimetric TMB substrate 
reagent and Stop solution. The kits were stored at -20 ºC upon receipt. All reagents were 
brought to room temperature and allowed to sit for a minimum of 15 minutes with gentle 
agitation after initial reconstitution. Working solutions of Streptavidin-HRP (1:200) and 
biotinylated mouse anti-human detection antibody were prepared by reconstitution of the 
supplied vials with Reagent diluent. Capture Antibody was reconstituted with 1.0 ml of PBS. 
Standards were prepared by reconstitution of each vial with either 0.5 ml of Reagent Diluent or 
1X PBS. A seven-point standard curve using 2-fold serial dilutions in Reagent Diluent was 
prepared as described by the Manufacturer.  
63 
 
Plate Preparation: In order to prepare the micro-plate for assay, capture antibody was diluted 
to the working concentration in PBS without carrier protein and a volume of 100 ml was 
immediately coated onto each well. The plate was then sealed and incubated overnight at room 
temperature. Each well was aspirated and washed with a 400 µl volume of wash buffer using an 
auto washer (HydroFlex™ micro-plate washer from Tecan). This process was repeated two times 
for a total of three washes. Complete removal of liquid at each step was ensured each time for 
good performance. After the last wash, any remaining Wash buffer was removed by aspirating 
or by inverting the plate and blotting it against clean paper towels. Wells were blocked by the 
addition of 300 μl reagent diluent to each well followed by incubation at room temperature for 
a minimum of 1 hour. Washing step was repeated as earlier and the plates were made ready for 
sample addition. 
Assay Procedure: A volume of 100 μl of either sample or standards in the reagent diluent, in 
duplicates, were added per well and incubated for 2 hrs at room temperature. Aspiration and 
washing steps were repeated as described earlier followed by addition of 100 μl of the 
Detection Antibody, diluted in Reagent Diluent, to each well. The plate was then covered with 
an adhesive strip and incubated 2 hours at room temperature. After this, a volume of 100 μl of 
the working dilution (1:200) of Streptavidin-HRP was added to each well and incubated for 20 
minutes at room temperature. Thereafter, aspirate / wash steps were repeated. A volume of 
100 μl of substrate solution was added to each well and the plate was incubated for 20 minutes 
at room temperature and any exposure to direct light was avoided. A volume of 50 μl of stop 
solution was added to each well and the plate was gently tapped to ensure thorough mixing. 
The optical density of each well was determined immediately, using a micro plate reader 
(Molecular Devices from Life technologiesTM equipped with Softmax pro7 Version 4.3 software) 
set to 450 nm. 
Calculation of results: For obtaining the results, average zero standard optical density was 
subtracted from mean absorbance of each set of duplicate standards, controls and samples. 
Standard curve was prepared by plotting the mean absorbance for each standard on the y-axis 
against the concentration on the x-axis and drawing a best fit curve through the points on the 
graph. Sample concentrations were calculated using the equation of the standard curve. 
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2.9 Quantitative measurement of oxidative stress markers 
Markers of oxidative stress (Superoxide dismutase, Glutathione, Nitric oxide and Catalase) were 
quantified using the cell lysates from the cultures using commercially available kits. 
2.9.1 Superoxide Dismutase (SOD) levels 
SOD levels were determined using the Superoxide Dismutase Assay kit (Cat. # 706002) 
purchased from Cayman chemicals, following the manufacturer’s protocol. The kit contained 
Assay buffer (10X), Sample buffer (10X), Radical detector, 1 vial of SOD Standard and Xanthine 
oxidase. Assay and Sample buffers were diluted to 1X using HPLC-grade distilled water. A 
volume of 50 μl of radical detector (tetrazolium salt solution) was diluted with 19.95 of diluted 
Assay buffer and covered with foil. To prepare the SOD standard, vial containing 100 μl of 
bovine erythrocyte SOD (Cu/Zn) was thawed on ice. A volume of 20 μl of this solution was 
diluted with 19.8 ml of 1X Sample buffer to obtain the SOD stock solution and standards were 
prepared serially in glass tubes ranging from A-G as outlined in table 2.5. 
Table 2.5:  Preparation of Superoxide Dismutase Standards 
Tubes SOD Stock (μl) Sample buffer (μl) Final SOD Activity (U/ml) 
A 0 1,000 0 
B 20 980 0.005 
C 40 960 0.010 
D 80 920 0.020 
E 120 880 0.030 
F 160 840 0.040 
G 200 800 0.050 
 
In order to perform the assay, SOD standard wells were prepared by adding 200 μl of the diluted 
radical detector and 10 μl of Standard (tubes A-G) per well. Sample wells were prepared by 
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adding 200 μl of the diluted Radical Detector and 10 μl of sample to the wells. Reaction was 
initiated by adding 20 μl of diluted Xanthine Oxidase to all the wells. The plate was then kept on 
a shaker for 30 minutes at room temperature and absorbance was read at 440-460 nm using a 
plate reader. Average absorbance for each standard and sample was calculated by subtracting 
the sample background absorbance from the sample. Linearized rate was obtained by dividing 
standard A’s absorbance by itself and then with absorbance values of all other standards and 
samples. This linearized SOD standard rate was plotted as a function of final SOD Activity. SOD 
activity was calculated by using the equation obtained from the linear regression of the standard 
curve and substituting the linearized rate for each sample (Figure 2.1). 
 
Figure 2.1 : Equation for the calculation of SOD activity. 
2.9.2 Glutathione Assay  
This assay was performed using the Glutathione Assay Kit from Sigma-Aldrich (Cat. #CS0260) 
following the manufacture’s protocol. For the assay, stock solution of 5, 5’-Dithiobis (2-
nitrobenzoic acid) [DTNB] was prepared by dissolving 8 mg of DTNB with 5.33 ml of DMSO to 
make a 1.5 mg/ml solution. NADPH stock solution was prepared by dissolving 25 mg of NADPH 
in 0.625 ml of water to give a 40 mg/ml solution. An amount of 2.5 gm of powdered 5-
sulfosalicylic acid (SSA) was completely dissolved in 50 ml of water to prepare a 5% stock 
solution. Glutathione (GSH) Standard Stock solution (10 mM) was prepared by dissolving the 
entire contents of glutathione reduced standard vial in 0.1 ml of water. For the working 
solutions, Assay buffer was diluted 5-fold to make 1X concentration. Glutathione Reductase 
Enzyme Solution was prepared by diluting it to a final volume of 250 μl with 1X assay buffer. 10 
μl of NADPH stock solution was added to 2.5 ml of 1 X Assay buffer to make its working solution. 
To make the working mixture 8ml of 1X Assay buffer, 228 μl of diluted enzyme solution and 228 
μl of DTNB Stock solution were mixed together. Glutathione standard solutions were prepared 
by diluting an aliquot of the Glutathione (GSH) Standard stock solution by 200-fold with 5% SSA 
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solution. Standards were prepared by adding 50 μM of glutathione solution in the first well and 
then subsequently diluting it serially as mentioned in table 2.6. 
Table 2.6: Table showing the preparation of glutathione standard solutions by serial dilution 
of the 50 μM glutathione solution 
Well Numbers 1 2 3 4 5 
GSH concentration 
(μM) 
50 25 12.5 6.25 3.125 
GSH solution (μl) 50 25(from 
well 1) 
25(from well 2) 25(from 
well 3) 
25(from well 4) 
5% SSA (μl) None 25 25 25 25 
Nmoles GSH in a 10 
μl sample 
0.5 0.25 0.125 0.0625 0.0312 
 
In order to prepare the samples for the assay, cell extracts were washed with PBS and at least 
1x108 cells were suspended per ml of PBS and transferred to a micro centrifuge tube. The cells 
were then centrifuged at 600 x g and supernatant was removed. The volume of the pellet was 
measured and 3 volumes of 5% SSA solution was added and vortexed. The suspension was then 
freeze-thawed twice using liquid nitrogen and a 37° C bath.  It was then left for 5 minutes at 2–8 
ºC. The extract was then centrifuged at 10,000 x g for 10 minutes. Volume of supernatant was 
measured, and the sample was kept at 2–8 ºC.  
For the assay procedure, plate reader was set to 412 nm with kinetic read at 1-minute intervals 
for 5 minutes. The reaction scheme was set up according to table 2.7. Each test was performed 
in duplicate. 
 
The first 2 wells contained only 10 µl of the 5 % 5-sulfosalicylic acid solution as a reagent blank. 
A total of 10 µl glutathione standard solutions and unknown samples in duplicate were added 
into separate wells of the plate. A volume of 150 µl of working mixture was added to each well 
using a multichannel pipette followed by 5 minutes of incubation at room temperature. After 
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incubation, 50 µl of diluted NADPH Solution was added to each well. Plate reader was used to 
measure the absorbance in each well. 
Table 2.7: Table showing Reaction Scheme for the GSH assay 
 Mix and Incubate 5 minutes Start 
Sample 
measured 
Sample Volume 5% SSA Working 
Mixture 
NADPH (0.16 
mg/ml) 
Reagent Blank - 10 µl 150 µl 50 µl 
Standard Curve 
(various 
dilutions) 
10 µl - 150 µl 50 µl 
Unknown sample x µl 10-x 150 µl 50 µl 
 
To compute the results, values from the glutathione standard solutions were used to determine 
the standard curve and calculate ∆A412 /min equivalent to 1 mole of reduced glutathione per 
well. 
Concentrations of nano-moles of GSH in the unknown samples were calculated using the 
following formula (Figure 2.2):  
 
Figure 2.2: Equation for the calculation of GSH activity. 
where:- 
∆A412 /min (sample) = slope generated by sample (after subtracting the values generated by the 
blank reaction). 
∆A412 /min (1 nmole) = slope calculated from the standard curve for 1 nmole of GSH 
Dilution = dilution factor of original sample 
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Volume = volume of the reaction in ml 
2.9.3 Nitric Oxide Assay 
Cayman's Nitrate/Nitrite colorimetric Assay kit (Cat. #780001) was used for the measurement of 
total nitric oxide following the manufacturer's protocol. The kit contained Nitrate/Nitrite Assay 
Buffer, Nitrate Reductase Enzyme Preparation, Nitrate Reductase Cofactor Preparation, Nitrate 
Standard, Griess Reagent R1, Griess Reagent R2 and 96 well micro-plate with cover sheet.  
The kit was stored at -20ºC upon receipt. Before the Assay procedure, working reagents were 
prepared by either dilution or reconstitution with a suitable reagent. Nitrate/Nitrite assay buffer 
was prepared by diluting the contents of the supplied vial to 100 ml of ultrapure water. 
Contents of nitrate reductase enzyme preparation and nitrate reductase cofactors Preparation 
were reconstituted with 1.2 ml of Assay buffer and kept on ice during use. Freezing and thawing 
of these solutions were limited to one time only. Vial containing lyophilized powder of nitrate 
standard was reconstituted with 1.0 ml of assay buffer and stored at 4ºC.Griess Reagents R1 and 
R2 were ready to use. 
Preparation of Nitrate Standard Curve:  Nitrate standard curve was prepared in order to 
quantify samples of nitric oxide concentrations. Stock standard (200 µM) was prepared by 
adding a volume of 0.9 ml of assay buffer to 0.1 ml of reconstituted nitrate standard. The 
standard curve for nitrate was prepared by addition of reagents to the plate wells as shown in 
Table 2.8. 
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Table 2.8: Table showing preparation of nitrate standard concentrations  
 
Wells Nitrate Standards 
(µl) 
Assay Buffer (µl) Final Nitrate 
Concentrations *(µM) 
A1, A2 0 80 0 
B1, B2 5 75 5 
C1, C2 10 70 10 
D1, D2 15 65 15 
E1, E2 20 60 20 
F1, F2 25 55 25 
G1, G2 30 50 30 
H1, H2 35 45 35 
 
* The concentration was calculated for the final 200 µl of assay volume after addition of the 
Griess Reagents. 
Assay Procedure: A volume of 200 µl of water or assay buffer (to be used as blank) and 80 µl of 
sample was added to the wells. After this, a total of 10 µl of the Enzyme Cofactor Mixture 
followed by 10 µl of the nitrate reductase mixture was added to each of the wells (standards 
and unknowns). The plate was covered and incubated for 2 hours at room temperature. After 
the incubation time, a volume of 50µl of Griess Reagent R1 followed by 50 µl of Griess Reagent 
R2 was added to each of the wells. The plate was left for 10 minutes at room temperature for 
the development of colour. Absorbance was read at 540 nm using a plate reader. 
Calculations: Mean absorbance values of the blank wells were subtracted from the absorbance 
values of all the other wells. Corrected absorbance values at 540 nm were plotted as a function 
of nitric oxide concentration. Sample nitric oxide concentrations were determined using the  
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following  formula (Figure 2.3):- 
 
Figure 2.3: Equation for the calculation of nitric oxide concentration. 
2.9.4 Catalase Activity 
The enzymatic activity of catalase was determined following Cayman's Catalase Kit (Cat. # 
707002) using the cell lysate. The kit was stored at 4ºC upon receipt. Before the assay, stock 
solutions of catalase assay buffer and catalase sample buffer were diluted to a 1 X concentration 
using HPLC grade water. Vial containing lyophilized powder of catalase positive control was 
reconstituted using 2 ml of diluted Sample buffer. Working solution of catalase hydrogen 
peroxide was prepared by diluting 40 µl of this solution with 9.96 ml of HPLC grade water. To 
prepare the samples, cells were collected by centrifugation at 1000-2000 g for 10 minutes at 4 
ºC. The resulting cell pellet was homogenized on ice in 1-2 ml of cold buffer (50 mM potassium 
phosphate, pH 7.0, 1 mM EDTA) followed by centrifugation at 10,000 g for 15 minutes at 4ºC. 
The supernatant was removed and stored on ice for the assay. For the preparation of 
formaldehyde standards, a volume of 10 µl of Catalase Formaldehyde Standard was diluted with 
9.99 ml of diluted sample buffer to obtain a 4.25 mM formaldehyde stock solution which was 
further serially diluted as described in table 2.9. 
For performing the assay, formaldehyde standard wells were prepared by adding a volume of 
100 µl of diluted assay buffer of standard (tubes A-G) per well in the designated wells on the 
plate. Positive control wells were prepared by adding 100 µl of diluted Assay buffer, 30 µl of 
methanol, and 20 µl of diluted Catalase (Control) to two wells. Sample wells were prepared by 
addition of 100 µl of diluted assay buffer, 30 µl of methanol, and 20 µl of sample to duplicate 
wells. Reaction was initiated by adding 20 µl of diluted hydrogen peroxide to all the wells. The 
plate was covered and incubated on a shaker for 20 minutes at room temperature. The reaction 
was terminated by adding 30 µl of potassium hydroxide followed by addition of 30 µl of catalase 
purpald (Chromogen) to each well. Incubation was done for 10 minutes at room temperature on 
the shaker. After this, a volume of 10 µl of catalase potassium periodate was added to each well 
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and incubation was done for 5 minutes at room temperature on a shaker. Finally, the 
absorbance was read at 540 nm using a plate reader.  Rate of the reaction was determined by 
subtracting the average absorbance of each standard and sample from the average absorbance 
of standard A. The corrected absorbance of standards was plotted as a function of final 
formaldehyde concentration (µM). Formaldehyde concentration of the samples was calculated 
using the equation obtained from the linear regression of the standard curve after substituting 
corrected absorbance values for each sample (Figure 2.4). 
 
Table 2.9: Table showing the preparation of formaldehyde standard solutions by serial 
dilution. 
Tubes Formaldehyde (µl) Sample Buffer (µl) Final Concentrations (µM 
formaldehyde) 
A 0 1,000 0 
B 10 990 5 
C 30 970 15 
D 60 940 30 
E 90 910 45 
F 120 880 60 
G 150 850 75 
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Figure 2.4: Equation for the calculation of formaldehyde. 
Calatase Activity of the samples was calculated using the following formula (Figure 2.5): 
 
 
Figure 2.5: Equation for the calculation of catalase activity. 
2.10 Immuno-fluorescence staining 
For immuno-fluorescence staining, cells were grown, treated, fixed and stained directly in 96 
well black-coloured plates with clear bottom. Following differentiation with treatment drugs, 
the media were aspirated, and the cells were fixed by covering them to a depth of 2-3 mm with 
4% formaldehyde diluted in 1X PBS for 15 minutes at room temperature. After fixation, the 
fixative was aspirated, and the cells were rinsed three times in 1X PBS for 5 minutes each. Cells 
were then blocked by incubating them in blocking buffer containing 5% normal goat serum and 
0.3% triton X-100 in 1X PBS for around 1 hour. Primary antibodies were prepared fresh in 
antibody dilution buffer containing 1% BSA and 0.3% triton-X in 1X PBS according to the 
dilutions mentioned in table 2.10. A volume of 50 µl of primary antibody was added to each 
well. The microplate was left to incubate overnight at 4ºC. Washing step was repeated as earlier 
and 50 µl of goat anti-rabbit fluorochrome-conjugated secondary antibody, Alexa Fluor 488 from 
Thermo Fisher Scientific (Cat. # A-11034), diluted to a concentration of 1:1000 in Antibody 
dilution buffer was added for 1-2 hour at room temperature in the dark. Wells were then 
carefully washed with 1X PBS to remove unbound probes and counter stained with a sufficient 
volume of Hoechst 33342 (Thermo scientific Cat. # 62249) working solution to completely cover 
the samples. An aluminum foil was placed over the micro plate to protect it from light and 
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incubated at room temperature for 5-10 minutes. Fluorescence images were acquired using an 
Olympus IX53 inverted microscope equipped with a CCD camera (Olympus, Tokyo, Japan) and 
computer assisted image analysis using CellSens imaging software. 
 
Table 2.10: Table showing primary antibody dilutions of different adipogenic markers used for 
immune-staining  
Primary Antibodies Dilutions 
Perilipin 1:200 
Cebpα 1:100 
Fabp4 1:200 
Ppar 1:100 
Fas 1:50 
Acetyl CoA carboxylase 1:200 
 
2.11 Protein Extraction and Quantification   
2.11.1 Extraction of total Protein 
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Human subcutaneous adipose cells were cultured in tissue culture dishes as described 
previously in sections 2.4.4 and 2.4.5. At approximately 80-90% of confluency, the cells were 
treated with different concentrations of drugs used in the study and differentiated into mature 
adipocytes for a period of 8 days. At the end of the treatment period the media were removed 
from the dishes, and the cells washed twice with PBS in order to ensure that all non-cell protein 
was removed from the plates. The cells were then transferred to 15 ml tubes and centrifuged at 
15,000 rpm for 10 minutes. The supernatant was removed and 150 ml of radio-immuno-
precipitation assay (RIPA) buffer was added to each tube in order to lyse the cells. The samples 
were then incubated on ice for 30 minutes and then centrifuged again for another 10 minutes at 
15,000 rpm and 4ºC temperatures. Finally, the supernatant containing the proteins was 
transferred to new eppendorf tubes and stored at -20 °C.                                                                                                                      
 
2.11.2 Quantification of total protein 
Total proteins in the samples were quantified using BCA (Bicinchoninic Acid) Protein Assay kit 
(Cat. # 23225) taken from Thermo Scientific following the Manufacturer's protocol. A set of 
diluted standards were prepared using 1 ml ampoule of 2 mg/ml of provided Bovine Serum 
Albumin (BSA) as shown in table 2.11. 
Table 2.11: Table showing preparation of BSA standards for protein quantification 
S.No BSA conc. 
(µg/ml) 
BSA Volume 
(µl) 
Diluent (1X PBS) volume (µl) Total Volume 
(µl) 
1. 2000 190 0 190 
2. 1500 52.5 of (1) 17.4 70 
3. 1000 80 of (1) 80 160 
4. 500 80 of (3) 80 160 
5. 250 80 of (4) 80 160 
6. 125 80 of (5) 80 160 
7. 25 20 of (6) 80 100 
8. 0 0 80 80 
 
BCA Working reagent was prepared by mixing 50 parts of BCA Reagent A with 1 part of BCA 
Reagent B. For the assay, a volume of 25 µl of replicate standards and the samples were 
pipetted into micro plate wells. This was followed by the addition of 200 µl of the prepared 
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working reagent to each well. The plate was mixed thoroughly using a plate shaker, covered and 
incubated at 37ºC for 30 minutes. It was then cooled to room temperature and absorbance was 
measured at 562 nm on a plate reader.   
2.12 Gene Expression Analysis 
 2.12.1 Total RNA Isolation  
Approximately 2 x106 adipose cells were cultured in T-75 tissue culture flasks in replicates as 
described previously. At approximately 80-90 % 0f confluency, the cells were treated with 
different concentrations of drugs used in the study and differentiated into mature adipocytes 
for a period of 8 days. RNA was isolated using GenElute Mammalian Total RNA Miniprep kit from 
Sigma-Aldrich (Cat. #RTN10) following the manufacturer's instructions. Attached adipose cells 
were trypsinised from the culture flasks and centrifuged to form a cell pellet. This was followed 
by lysis of the cells by adding a volume of 500 µl of Lysis solution/ 2-mercaptoethanol to each of 
the culture vessels. The cell lysate was then filtered to remove the cellular debris. A filtration 
column was assembled with a 2 ml collection tube and the lysed cells from the previous step 
were carefully pipetted onto the filtration column. Centrifugation was done at 15,000 rpm for 2 
minutes and the filtration column was discarded. An equal volume (500 µl) of 70 % ethanol was 
added to the filtered lysate and vortex-mixed thoroughly. A binding column was assembled with 
a 2 ml collection tube and 700 µl of the lysate/ethanol mixture was pipetted onto the binding 
column. Centrifugation was done at maximum speed of 14,000 rpm. Flow-through liquid was 
discarded while the collection tube was retained. A volume of 500 µl of the wash solution was 
into the column and centrifuged at maximum speed for 15 seconds. The binding column was 
then transferred to a fresh 2 ml collection tube and a volume of 50 µl of the elution buffer was 
pipetted into the column followed by centrifugation at maximum speed for 15 seconds. Elution 
step was repeated with a second 50 µl volume of the elution buffer, collecting both elutes in the 
same tube. It was then stored at -80  ºC until quantification.  
2.12.2 RNA Quantification  
Thermo Scientific™ NanoDrop 2000 was used to quantify and assess purity of RNA. Micro-
volume sample size (0.5-2.0 μL) was pipetted directly onto an optical measurement surface and 
RNA was quantified. Once the measurement was complete, the surface was simply wiped with a 
lint-free lab wipe. All samples were measured in duplicates. 
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2.12.3 cDNA conversion and Reverse transcriptase PCR 
Semi-quantitative RT-PCR method was used to assess gene expression. The cDNAs were 
synthesized using High Capacity cDNA Reverse Transcription Kit from Applied Biosystems as per 
the protocol provided by manufacturer. The kit contained 10X RT Buffer, 10X RT Random 
Primers, 25X dNTP Mix (100 mM), MultiScribe™ Reverse Transcriptase and RNase Inhibitor. The 
kit was stored at -20ºC upon receipt and thawed on ice before use. To synthesize single-
stranded cDNA from total RNA using the High Capacity cDNA Reverse Transcription Kits (Applied 
Biosystems), 2X Reverse Transcription Master Mix was added to 2 µg of the extracted RNA for 
each sample. Thereafter, 2X RT master mix (per 20 µL reaction)  was prepared by using the kit 
components before preparing the reaction plate according to table 2.12. 
Table 2.12: Table showing reaction volumes of kit components for the preparation of 2X RT 
Master mix 
Components Volume/Reaction(µl) 
10x RT Buffer 2.0 
25x dNTP Mix (100 mM) 0.8 
10x RT Random Primers 2.0 
MultiScribe™ Reverse Transcriptase 1.0 
RNase Inhibitor 1.0 
Nuclease-free H2O 3.2 
Total volume 10 
 
In order to prepare the cDNA RT reactions 10 µL of 2x RT master mix was pipetted into each 200 
µl PCR tube followed by 10 µL of RNA sample. The tubes were then vortex-mixed using mini-spin 
to ensure thorough mixing. Before loading into the thermal cycler, the tubes were briefly 
centrifuged to spin down the contents and to eliminate any air bubbles. In order to perform 
reverse transcription, thermal cycler was programmed according to the conditions in table 2.13. 
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Table 2.13: Thermal cycling conditions for RT-PCR  
 Step 1 Step2 Step 3 Step 4 
Temperature 25°C 37°C 85°C 4°C 
Time 10 min 120 min 5 min  ∞ 
 
The reaction volume was set to 20 µL and the reverse transcription run was started. The product 
purity was confirmed by a dissociation curve analysis. The mRNA levels of the target genes were 
normalized to the values of β-actin, and presented as qualitative changes relative to controls. 
Table 2.14 showed the list of primer sequences for adipogenic genes used in the study. 
Table 2.14: Table showing a list of primer sequences for adipogenic genes used in the study 
Genes  Primer sequences 
 Forward Reverse 
aP2 5'-TCA CCT GGA AGA CAG CTC CT-3' 5'-AAT CCC CAT TTA CGC TGA TG-3' 
C/EBPα 5'-GAA CAG CAA CGA GTA CCG GGT-3' 5'-GCC ATG GCC TTG ACC AAG GAG-3' 
FAS 5'-GCT TTG CTG CCG TGT CCT TCT-3' 5'-TCT AGC CCT CCC GTA CAC TCA-3' 
LPL 5'-AGT AGA CTG GTT GTA TCG GG-3' 5'-AGC GTC ATC AGG AGA AAG G-3' 
PPARγ 5'-CCA GAG CAT GGT GCC TTC GCT-3' 5'-CAG CAA CCA TTG GGT CAG CTC-3' 
SREBP-1c 5'-CGC TAC CGG TCT TGT ATC ATT G-3' 5'-TTG CTT TTG TGT GCA CTT CG-3' 
β-Actin 5'-AGG CTG TGC TGT CCC TGT AT-3' 5'-ACC CAA GAA GGA AGG CTG CA-3' 
 
2.13 Triglyceride Quantification 
Measured using Triglyceride Quantification Assay Kit from Abcam (ab65336) following the 
manufacturer’s protocol. The kit was stored immediately at -20 °C in dark upon receipt. The kit 
components included triglyceride assay buffer, triglyceride probe, lipase, triglyceride enzyme 
mix and 1 mM of triglyceride standard. Both triglyceride enzyme-mix and lipase were 
reconstituted in 220 µl volume of triglyceride assay buffer and kept on ice during the assay. A 
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0.2 mM triglyceride standard was prepared by diluting 100 µl of the 1 mM standard in 400 µl of 
assay buffer. Using this 0.02 mM standard, standard curve dilutions were prepared as described 
in table 2.16 below. 
Table 2.15: Serial dilution for preparation of standards for triglyceride assay 
Standard 
# 
TG Standard 
(µL) 
Assay buffer (µL) Final Volume 
Standard in well 
(µL) 
End amount of TG 
Standard in well 
(nmol/well) 
1 0 150 50 0 
2 30 120 50 2 
3 60 90 50 4 
4 901 60 50 6 
5 120 30 50 8 
6 150 0 50 10 
 
For the assay procedure, all materials and prepared reagents were gently agitated and 
equilibrated to room temperature prior to use. All standards, controls and samples were 
assayed in duplicate. For setting up the reaction wells, a total volume of 50 µl of standard 
dilutions and samples were used followed by addition of 2 µL of lipase. The wells were mixed 
thoroughly and incubated for 20 minutes at room temperature to convert triglyceride to 
glycerol and fatty acid. A total of 50 µl of triglyceride reaction mix (46 µL of triglyceride assay 
buffer + 2 µL of triglyceride probe + 2 µL of triglyceride enzyme mix) was added to each of the 
standard and sample wells. A master mix of the reaction mix was prepared to ensure 
consistency. Wells were mixed and incubated at room temperature for 60 minutes protected 
from light. Readings were taken on a microplate reader at an absorbance of OD 570 nm. For 
data analysis, corrected absorbances were calculated by subtracting mean value of blank 
(standard # 1) from all standards and samples. Corrected values for each standard were plotted 
as a function of the final concentration of triglyceride. Corrected sample OD was applied to the 
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standard curve to get triglyceride (B) amount in the sample wells. Concentration of triglyceride 
in nmol/µL (mM) in the test samples was calculated using the following equation: 
Triglyceride concentration = B/V*D 
Where: 
B= amount of triglyceride in the sample well calculated from standard curve in nmol. 
V= sample volume added in the sample wells (µL) 
D= sample dilution factor  
2.14 Statistical analysis of data 
Data were analyzed statistically using SPSS Version 25 software. The means of the data were 
presented either with the standard error mean (SEM) or the standard deviation (SD) where 
possible. The results were analyzed using one-way ANOVA to determine the significance of the 
mean between the groups. Values of p< 0.05 were considered significant. 
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Chapter 3: (A developmental Study) 
   
 
 
 
Effects of Caffeine, Paracetamol and β-Naphthoflavone on the 
Lipid Content and Differentiation of Human Adipose Derived 
Mesenchymal Stem Cells In Vitro. 
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3.1 Introduction 
Obesity is a disorder in which excessive accumulation of lipids in adipose tissue is characteristic. 
White Adipose Tissue (WAT) contains adipocyte precursors which under adipogenic conditions 
undergo adipogenesis to become mature adipocytes. Subsequent excessive proliferation of 
these adipocytes and their enlargement- hyperplasia and hypertrophy respectively, are 
characteristic features of obesity. Adipose tissue not only acts as fat storage, but also as an 
endocrinal organ and it secretes various important adipocytokines such as adiponectin (Desai et 
al., 2013; Meena et al., 2014). Obesity is also characterized by chronic low-grade inflammation 
due to over nutrition that stresses and overloads signaling networks as well as inflammatory 
cytokines which are released by WAT. In turn, this affects immune and metabolic systems 
leading to inflammation (Iyer et al., 2010).  
 It has also been linked with higher risks of cardiovascular diseases and muscular-skeletal 
disorders and its rise is now witnessed globally.  Approximately, 65% of the world’s population 
now resides in geographic areas where being overweight and obese causes more fatalities than 
being underweight. It has been suggested that individuals that suffer from obesity (BMI > 30) 
may be more prone to develop metabolic abnormalities. Due to the widespread effect of 
obesity, the search for compounds that can effectively be employed in the production of anti-
obesity drugs and treatments is now becoming more desirable.  
A lot of research has been conducted to study the effects of different chemicals and substances 
on adipogenesis, lipolysis and their subsequent effects on obesity and fat accumulation. One of 
the widely studied drugs is caffeine, being the most used pharmacologically active agent 
(Tofovic et al., 2002).  Caffeine is available in several over the counter cosmetics and a large 
variety of foods and drinks that are consumed by people every day contains caffeine. This makes 
the prospect of finding its therapeutic effects more desirable. When used in combination with 
other drugs (such as ephedrine) or other herbal supplements and concoctions, it has been 
shown to help in the treatment of obesity and promotion of weight loss. This is due to the 
metabolic effects that are exhibited by caffeine (Bracale et al., 2014).  Caffeine is a compound 
that acts as an antagonistic inhibitor of adenosine in the sympathetic nervous system. However, 
caffeine actually causes an increase in cell activity as opposed to adenosine binding which slows  
down its regulation (Bracale et al., 2014). Due to this, it prevents the breakdown of cyclic 
adenosine monophosphate (c-AMP). Higher concentrations of c-AMP causes an increase in 
protein kinase A (PKA) that subsequently increases the production of ATPase – an enzyme that is 
82 
 
involved in energy synthesis- and this, in turn, causes an overall increase in the body’s metabolic 
activity (Sassone-corsi, 2012). 
A key element of the adipogenic pathway related to c-AMP is the c-AMP-response element 
binding protein (CREB), whereby its activation has been shown to be necessary for the up-
regulation of several other adipogenic regulators. These include CCAAT/ enhancer-binding 
protein (C/EBP) whose isoform C/EBP β is an initiator of adipogenesis through the expression of 
C/EBP α and more importantly peroxisome proliferator activated receptor γ (PPARγ) 
transcription factors which work together to allow adipocyte differentiation (Fox et al., 2006; 
Darlington et al., 1999). 
PPARγ is involved heavily in lipid metabolism and is expressed in both white and brown adipose 
tissue. The deletion of PPARγ in mice sustained with a high fat diet revealed significant 
differences in the pattern and amount of lipid accumulation. They exhibited a loss of white 
adipose tissue mass, lower overall body fat percentage and an increase in adiponectin levels 
(Jones et al., 2005). This shows the importance of PPARγ in the adipogenic pathway and its 
effect on expression of adiponectin which is inversely proportional to fat mass and plays a role 
in inflammation and energy homeostasis.  
Adiponectin is an adipocytokine that causes an increase in fatty acid oxidation (Yamauchi et al., 
2002). Transgenic murine models designed to over-express adiponectin in adipose tissues were 
found to have a decrease in both adipose mass and adipocyte size due to a higher level of 
energy expenditure and glucose utilization caused by higher levels of expressed adiponectin 
(Bauche et al., 2007). The relationship between adiponectin levels and lipid accumulation has 
also been demonstrated in various murine obesity models as well as human obesity studies 
(Piñeiro et al., 2005; Bauche et al., 2007).  
These findings possibly provide a therapeutic possibility to battle obesity through the use of 
adiponectin enhancing agents – such as caffeine. Studies on mice models that were placed on a 
high fat diet and then treated with caffeine have demonstrated an increase in lipolysis of fat 
droplets (Han et al., 1999). Other studies have linked higher adiponectin serum levels and 
decreased lipoprotein cholesterol with increased intake of caffeine rich products such as coffee 
(Yamashita et al., 2012). The metabolic pathways and mechanics of caffeine in the human body 
are also important to be considered when attempting to understand its effects.  
In addition to the use of caffeine to sustain high c-AMP levels, the use of paracetamol 
(acetaminophen) due to its cyclooxygenase inhibiting mechanism can also affect adipocyte 
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differentiation by effectively attenuating the expression and activity of PPARγ. The mechanism 
of action for paracetamol is most likely to occur through the inhibition of prostaglandin (PG) 
synthesis via the inhibition of cyclooxygenase-2 enzymes (COX-2) (Anderson, 2008). The role of 
PGs and subsequent hormones and enzymes synthesized is essential in adipocyte 
differentiation. PGs are lipid mediators that undergo synthesis through the action of different 
enzymes. Archadionic acid is first released by phospholipases (PLA2s) and undergoes conversion 
to PGH2 by one of the two COX isozymes (COX-1 or COX-2). The PGH2 that is produced is 
metabolized into different PGs that are involved in adipocyte differentiation which causes the 
activation of PPARγ (Ghoshal et al., 2011; Ueno et al., 2011). Therefore, bearing this expression 
mechanism in mind- the inhibition of COX-2 would prevent or decrease the conversion of 
archadionic acid to PGH2 which will have the ultimate effect of reducing and/or inhibiting 
adipocyte differentiation. COX-2 activation has also been found to be significantly involved in 
the development of an inflammatory response in adipose tissue (Hsieh et al., 2010) and has 
been linked to contribute  in brown adipocyte differentiation in mice (Ghoshal et al., 2011). 
Despite this proposed mechanism, no conclusive research has yet provided a definitive answer 
to the role of COX-2 inhibition or over-expression in adipocyte expression. Studies conducted on 
3T3-L1 cell lines showed that different adipocyte specific markers which included PPARγ and 
adiponectin were found to be decreased after the use of COX inhibitors (Mazid et al., 2006). 
COX-2 deficient murine models which were supplied with a high fat diet showed lower body 
mass than their wild type counterparts along with higher metabolic activity, lower PPARγ, lower 
inflammatory markers and significantly higher levels of adiponectin (Ghoshal et al., 2011). These 
variables coincide with other results linking them to increased lipolysis and lower body fat and 
basal metabolic index (BMI), thus suggesting that the use of a COX-2 inhibitor (such as 
paracetamol) can possibly provide a protective treatment opportunity against obesity and can 
be employed as a future anti-obesity medication. However, a minor percentage of opposing 
research showed an activation of PPARγ in adipocyte cell lines when treated with non-steroidal 
anti-inflammatory (NSAID) drugs such as indomethacin (Lehmann et al., 1997). 
Aryl Hydrocarbon Receptor (ahR) is a ligand activated transcription molecule that has been 
shown to regulate adipogenic factors and is involved in the induction of detoxifying enzymes 
such as cytochrome P450 (Yoshinari et al., 2006). Synthetic flavonoid α-Naphthoflavone is 
classified as an ahR antagonist and has been shown to promote adipogenesis and lipid 
accumulation in 3T3-L1 cells in vitro (Wang et al., 2015).  Inversely, utilizing ahR agonists such as 
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β-Naphthoflavone (BNF) are hypothesized to have an opposite effect and effectively inhibit or 
minimize lipid accumulation. BNF has been shown to be an effective inducer of important 
detoxifying enzymes such as CYP1A1 through the translocation of ahR receptor bound to BNF 
(Yoshinari et al., 2006).   
Aims: Taking into consideration the variation of information in the literature about caffeine and 
paracetamol about obesity, this developmental chapter of the study was designed to investigate 
the effects of caffeine and paracetamol either alone or combination in the absence and 
presence of the β-naphthoflavone, an ahR antagonist, on the differentiation of human adipose 
derived mesenchymal stem cells, a model of obesity. 
 
3.2 Materials and Methods 
As described in Chapter 2. 
 
3.3 Results 
3.1 Morphological Examination 
Upon arrival, the cells appeared healthy and had a stretched out, irregular shape which is 
characteristic of pre-adipocytes (Figure 3.1A). After 48 hours of addition of differentiation 
medium, the cells began to take on a more regular spherical appearance and clumps had begun 
to form indicating the initiation of the differentiation process (Figure 3.1B). Following the 
addition of differentiation media 2 after a period of 48 hours, the cells began to differentiate 
further to form mature adipocytes (Figure 3.1C). The formation of fat droplets in the cells and 
increased cell clumping was observed indicating successful differentiation. 
 
 
 
A B C 
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Figure 3.1: Figure showing the progression of the differentiation process in adipose cells from 
immature preadipocytes to mature adipose cells. Photographs are typical of 20 or more 
images. 
A. Undifferentiated cells.  
B. Adipose cells after the addition of differentiation medium 1 over a period of 48 hours.  
C. Adipose cells after the addition of differentiation medium 2 over a period of 48 hours. 
 
3.2 Measurement of cell viability by MTT Assay 
MTT assay was used to determine cell viability (cell death or proliferation) after the addition of 
drugs. Results are typical of 6 such different experiments.  
 
 
 
 
 
Figure 3.2: MTT assay absorbance readings of all wells compared to the control.  
 
Figure 3.2 illustrates the results of this test compared to the control. As observed, the wells 
treated with drugs had overall higher absorbance readings than the control indicating that their 
viability was higher. All samples show readings higher than the control. The last four bars in 
particular – BNF + caffeine + paracetamol, caffeine, paracetamol and caffeine + paracetamol- 
show the most significant  (p<0.05) difference when compared to the control. This observation 
indicates that all the cells were viable and that drug interactions may have contributed to this 
enhanced viability or cell proliferation. Data are mean ± SD, n=5, *p<0.05 **p<0.01 ***p<0.001    
were considered significant for test as compared to control. 
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 3.3 Quantitative measurement of Triglyceride Concentrations 
Adipose cells were treated with individual as well as in combination with eithercaffeine, 
paracetamol and BNF. Supernatant was collected on the 10th day of culture and triglycerides 
were measured using commercially available kits. 
 
 
Figure 3.3: Bar graphs showing comparative effects of caffeine and paracetamol 
independently and in combination on the triglyceride concentration after differentiation of 
adipose cells for a period of 10 days.  
 A. Elevated triglyceride concentration was seen when cells were treated with caffeine 
independently. This was the only case of elevation seen across all samples.  
B. Reduced triglyceride levels when cells are exposed to paracetamol.  
C. The effect of combining both caffeine and paracetamol appears to null the different effects 
exhibited by each drug independently giving lower triglyceride content than the control.  
Data are mean ± SD, n=5, *p<0.05 was considered significant for test as compared to control.  
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The cells that were treated only with caffeine had higher triglyceride concentration as compared 
to the control (Figure 3.3 A) as well as in comparison to all other independent and combinatory 
drug treatments. In contrast, significantly notable differences in triglyceride concentrations 
were observed in the well treated with paracetamol (Figure 3.3 B) whereby it had lower 
triglyceride content than the control. Interestingly, when both paracetamol and caffeine were 
used together, their individual effects seemingly balanced out and an overall lower 
concentration of triglyceride was expressed as compared to independent caffeine treatment 
(Figure 3.3 C). 
 
Figure 3.4: Bar graphs showing comparative effects of BNF alone and in combination with 
caffeine on the triglyceride concentration after differentiation of adipose cells for a period of 
10 days.  
A. Cells treated with BNF independently showed a significantly lower concentration of 
triglycerides than the control with no drugs.  
B. When cells are treated with both BNF and caffeine, the triglyceride concentration is raised 
when compared with the use of BNF alone. This provides further indication that caffeine causes 
an increase in triglyceride content as it seemingly attenuated the suppressive effect of BNF on 
triglyceride concentration of cells. Data are mean ± SD, n = 5,*p<0.05 for test compared to 
control.  
The treatment of cells using BNF independently displayed a dramatically lower triglyceride 
content compared to the control (Figure 3.4A) as well as in comparison to the cells treated with 
BNF + caffeine (Figure 3.4B).  
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3.4 Quantitative measurement of Free Glycerol Concentrations 
(A)  (B) 
 
 
 
 
 
 
(C) 
 
 
 
 
 
 
Figure 3.5: (Images A-C): Bar graphs showing the concentrations of glycerol with different 
combinations of treatment drugs. Data are mean±SD; n=5; *<0.05 while **p<0.01. 
 
A. Illustrates the glycerol concentration when BNF, caffeine and paracetamol are used in 
combination. The levels of glycerol are lower than the control under these conditions and 
therefore can suggest an inhibited or minimized rate of lipolysis.  
B. Glycerol concentration is significantly raised when BNF is excluded and only caffeine and 
Paracetamol are used in conjunction with each other. The glycerol content is higher than the 
preceding condition (5A) and the control.  
C. An approximate 2.5 times higher glycerol concentration observed in the well treated with 
caffeine alone when compared to the control. The use of caffeine independently showed the 
highest glycerol concentration overall indicating higher lipolysis levels.Data are mean ± SD, 
n=5,*p<0.05 for test compared to control.  
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Free glycerol content was used as an indicator of lipolytic activity within the cells as it is released 
when triglycerides are hydrolyzed and broken down. Bearing the above in mind, the wells 
treated with paracetamol, BNF and BNF + Caffeine had almost equal glycerol levels as compared 
to control. Alternatively, the cells treated with BNF + caffeine + paracetamol (Figures 3.5 A), had 
significantly lower glycerol concentrations than the control. Cells treated with caffeine + 
paracetamol showed higher glycerol levels (Figure 3.5 B). Most notably, out of all the samples 
taken, the well containing caffeine had the highest glycerol concentration overall with it being 
approximately 2.5 times more glycerol than the differentiated control (Figure 3.5 C). 
 
3.5 Discussion 
Triglycerides are biological molecules composed of a glycerol backbone and fatty acids which 
are stored in adipocytes (Prattes et al., 2000). Their content within cells can be used as a direct 
indicator of adipogenesis, that is, the higher the content, the more adipogenesis and adipocyte 
differentiation are occurring. The hydrolysis of triglycerides leads to the process of lipolysis- 
thereby releasing  glycerol (Ahmadian et al., 2007). Therefore, glycerol concentrations can be 
used as direct indicators of lipolytic activity in cells. The present results demonstrate that 
caffeine, paracetamol, BNF and their varying combinations may all have effects on the processes 
of adipogenesis and lipolysis. 
 
The triglyceride and glycerol concentrations of cells treated solely with caffeine reflect lipolytic 
properties. The use of caffeine resulted in the highest glycerol concentration among all tested 
drugs and combinations- the concentration was approximately 2.5 times higher than the 
differentiated control cells but with no addition of drug. As expected, triglyceride contents of 
caffeine were lower than glycerol- however; the triglyceride content of cells with caffeine was 
higher than all other samples. These traits could be an indicator that caffeine contains potent 
lipolytic effects, but no significant effect on the process of adipogenesis itself. Perhaps, caffeine 
can have an effect on existing triglycerides but cannot inhibit their formation. Conversely, 
paracetamol appears to have no significant effect on the process of lipolysis, but it can reduce 
triglyceride concentrations indicating that the independent use of paracetamol may contain 
anti-adipogenic effects and thereby preventing triglyceride formation. The suggested lipolytic 
and anti-adipogenic effects of caffeine and paracetamol are further emphasized when 
examining their combined effect on pre-adipocytes differentiation. The triglyceride and glycerol 
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concentrations under this condition are very similar to one another indicating a sort of 
homeostasis where the enhanced lipolytic effects expressed by caffeine are compensated by 
increased adipogenesis directed by paracetamol.  
The use of BNF to treat cells has varying effects based on whether it is used either alone or in 
combination with other drugs. When BNF is used independently, triglyceride concentrations are 
reduced in comparison with differentiated control cells. However, glycerol concentrations under 
treatment with BNF are equal to the differentiated control. To further examine the 
consequences of utilizing BNF, it was used as an additional supplement along with caffeine, 
paracetamol and their combination. When BNF is used with caffeine, the pronounced lipolytic 
effects of caffeine appear to become diminished and glycerol concentration levels become 
lower than the differentiated control. This effect on glycerol is also seen when BNF is used to 
supplement paracetamol and the combination of caffeine and paracetamol. This may suggest 
that BNF has inhibitory effects on lipolysis and it can attenuate any potent lipolytic effects 
expressed by the use of caffeine and paracetamol. In contrast to the observed inhibitory effect 
of BNF on lipolysis, its effects on adipogenesis favour anti-adipogenic properties. When used to 
treat cells independently, the triglyceride concentration of cells is lower than the differentiated 
control. This observation implied anti-adipogenic effect is also observed when BNF is used to 
supplement caffeine and the combination of caffeine and paracetamol. The triglyceride 
concentrations under these two conditions are reduced as compared to those expressed in the 
same conditions without BNF supplementation. This observation provides further indication that 
BNF can be used to significantly enhance anti adipogenic properties of caffeine and paracetamol 
through the attenuation of triglyceride expression. MTT analysis showed increased cell viability 
when treated with drugs in comparison to the differentiated control lacking drugs. This suggests 
that the use of drugs was not harmful or toxic to cells and may have had a role to play in 
enhancing their viability. 
 In conclusion, the results provide preliminary evidence towards the anti adipogenic and lipolytic 
properties of caffeine, paracetamol and BNF. The presence of underlying mechanisms that can 
potentially express these properties merits further research and exploration. BNF is known to 
induce detoxifying CYP450 enzymes which may be a contributing factor to the anti adipogenic 
effects. Future research to study the gene expression of CYP450 could provide further evidence 
of the adipogenic process that occurs during the differentiation of pre-adipocytes under the 
presence of different drugs.  
91 
 
 
 
 
 
 
Chapter 4 
 
 
 
Effects of Rilpivirine, 17β-Estradiol and β-Naphthoflavone on the 
inflammatory status of release of adipocytokines in 3T3-L1 
adipocytes in vitro. 
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4.1 Introduction 
Obesity is a major global health problem and if left untreated, it may lead to major 
complications (Zimmet et al., 2005). It is attributed to a number of factors including over-eating, 
sedentary lifestyle, lack of physical activity, genetics, diets rich in carbohydrate, frequency of 
eating, hormonal and various psychological factors as well as others. Some medications are also 
associated with weight gain. These include certain anti-depressants, anti-convulsants, some 
diabetes medication and certain hormones including  leptin, insulin, estrogens, androgens and 
growth hormones (Ness-Abramof et al., 2005; Ratliff et al., 2010). 
Rilpivirine is a prescription medicine for the treatment of HIV infection in adults and children. 
Although the drug was approved in 2011 by the U.S., the Food and Drug Administration (FDA), 
its approval document included fat re-distribution among its warnings and precautions. These 
contradictory results show its effect on the adipose tissue distribution and function which have 
been presented by previously conducted clinical trials (Cohen et al., 2011; Molina et al., 2011; 
Wilkin et al., 2012; Tebas et al., 2014). On the other hand, 17β-estradiol is a major component of 
hormonal contraceptives and it acts primarily as an agonist of the estrogen receptor (ER). 
Several studies have provided evidence of a hormonal regulation of pre-adipocyte proliferation 
(Hausman et al., 2001; Thorn et al., 2007). Estrogen promotes subcutaneous fat and regulates 
adipose tissue distribution through its receptors, ERα and ERβ (Matelski et al., 1985; Kuiper et 
al., 1996). Moreover, 17β-estradiol has been shown to have stimulatory effects on proliferation 
of female rat pre-adipocytes (Dieudonne et al., 2000) and in human pre-adipocytes (Anderson et 
al., 2001). The British HIV guideline for the management of HIV infection indicated that 
rilpivirine is an appealing option to consider in women of childbearing potential. At the same 
time, it also warns of the significant pharmacokinetic and pharmaco-dynamic interactions that 
have been reported between the anti-retroviral (ARV) drugs and hormonal agents. Inducers of 
hepatic enzymes by ARVs may result in increased breakdown of estrogen that can compromise 
contraceptive efficacy (Taylor et al., 2012). In addition, both of these drugs are known to alter 
lipid metabolism and fat distribution in the body (Rimsky et al., 2013). Therefore, a mechanistic 
insight into the elucidative role of concomitant use of rilpivirine and estradiol would provide 
more robust and reliable prediction of their potential interactions on the adipogenesis pathway. 
Organic pollutants such as β-naphthoflavone (BNF) tend to escape from the body metabolic 
system and accumulate in the white adipose tissue (WAT), thereby affecting its physiological 
role, and thus leading to the development of obesity-related disorders. The mechanisms 
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through which such chemicals modulate the differentiation, metabolism, and secretory function 
of adipocytes are numerous (Müllerová et al., 2007; Elobeid et al., 2008; Uemura et al., 2008; 
Feige et al., 2007). Aryl hydrocarbon receptor (AhR), a cytosolic ligand-activated transcription 
factor that participates in a variety of metabolic processes, including detoxification and 
adipogenesis, has been reported to be functionally present in rodent adipose tissue (Yoshinari et 
al., 2004, 2006). Activated AhR modulates expressions of various genes involved in xenobiotic-
metabolizing pathways, such as cytochrome P4501A1 (CYP1A1) (Shimada et al., 1998; Arinç et 
al.,2000; Safe et al.,2013). CYP1A induction may be used as a biomarker of exposure to toxic 
substances in order to ascertain whether in vitro models could be useful in investigating the bio 
activation potential of environmental contaminants.  
4.2 Aims: Therefore, this study was designed to investigate the effect of rilpivirine and estradiol 
either alone or in combination on the adipose cells measuring free glycerol and a number of 
inflammatory markers including leptin, and adiponectin, resistin and IL-8 which are associated 
with adipocyte function. In another series of experiments, rilpivirine and estradiol were 
combined with an environmental pollutant, BNF to determine any inhibitory or stimulating 
effects. 
4.3 Materials and Methods 
As discussed in Chapter 2. 
4.4 Results  
Figure 4.1 shows human pre-adipocytes that were differentiated in culture in the presence of 
different concentrations of rilpivirine or estradiol either alone or combined for a period of 10 
days. The results show that untreated cells on day 0 display spindle shaped, fibroblast-like 
appearance with undetectable lipids. However, with the progression of adipogenesis, mature 
adipocytes attain a round shape and become laden with lipids. 
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4.4.1 Morphological examination  
 
Figure 4.1: Confocal image photographs (A-F) taken at 10X magnification of human adipocytes 
showing the effects of rilpivirine, estradiol and their combination on the morphology of the 
cells. Each image is typical of 6 such different experiments. 
4.4.2 Cell viability assessment 
Cell viability was assessed for the two series of 3 different experiments measured in duplicates 
(n=6) by employing lactate dehydrogenase assay.  The results are shown in tables 4.1 and 4.2.  
Values were expressed as the percentage test cells surviving compared to control cells. The 
results in these tables show no significant (p>0.05) difference in cell viability with drug 
treatments compared untreated control. 
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Table 4.1: Cell viability measurement of human pre-adipocytes treated with rilpivirine and 
estradiol either alone or during combination. Pre-adipocytes were treated with the different 
concentrations of drugs for 10 days. Data are expressed as % viability ± SD relative to the 
control, p<0.05 for treatment compared to control; n=6. 
 
 
 
 
 
 
 
 Day 0 Day 5 Day 10 
Drugs Doses (µM) % Viability ± SD 
Control 0 97.23 ± 0.003 97.14 ± 0.002 96.47 ± 0.006 
Rilpivirine 1  97.27 ± 0.006 96.92 ± 0.003 96.71 ± 0.006 
Rilpivirine  5  96.89 ± 0.013 95.65 ± 0.05 95.17 ± 0.01 
Rilpivirine 10  97.23 ± 0.006 96.25 ± 0.01 95.82 ± 0.01 
Estradiol 0.01 97.27 ± 0.006 96.05 ± 0.02 95.68 ± 0.01 
Estradiol 0.05 97.13 ± 0.002 96.56 ± 0.03 95.86 ± 0.01 
Estradiol 0.1 97.23 ± 0.003 95.04 ± 0.003 95.68 ± 0.008 
Rilpivirine+Estradiol 1+0.01 97.23 ± 0.005 95.69 ± 0.04 95.47 ± 0.001 
Rilpivirine+Estradiol 5+0.05 97.58 ± 0.013 96.84 ± 0.004 94.71 ± 0.01 
Rilpivirine+Estradiol 10+0.1 97.23 ± 0.003 95.89 ± 0.04 94.75 ± 0.01 
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Table 4.2: Cell viability of human pre-adipocytes treated with rilpivirine and estradiol either 
alone or in combination but in the continuous presence of 200 µM BNF. Pre-adipocytes were 
treated with the different concentrations of drugs for 10 days. Data are expressed as % viability 
± SD relative to the control; note that p>0.05 for control compared to treatments; n=6. 
 
 Day 0 Day 5 Day 10 
Drugs Dosage (µM) % mean viability ± Standard Deviation (SD) 
Control 
0 97.23 ± 0.004 96.61 ± 0.075 96.64 ± 0.03 
Rilpivirine + BNF 
1 + 200 97.06 ± 0.005 96.86 ± 0.04 96.22 ± 0.004 
Rilpivirine +BNF 
5 + 200 97.23 ± 0.003 96.84 ± 0.01 96.82 ± 0.01 
Rilpivirine + BNF 
10 + 200 97.23 ± 0.003 96.72 ± 0.007 96.22 ± 0.001 
Estradiol + BNF 0.01+ 200 97.16 ± 0.009 96.74 ± 0.01 96.47 ± 0.004 
Estradiol+ BNF 0.05+ 200 97.09 ± 0.004 95.26 ± 0.04 96.54 ± 0.01 
Estradiol +BNF 0.1+ 200 97.23 ± 0.006 95.26 ± 0.05 96.82 ± 0.01 
Rilpivirine+Estradiol+BNF 1+0.01+ 200 97.09 ± 0.003 94.66 ± 0.01 96.43 ± 0.007 
Rilpivirine+Estradiol+BNF 5+0.05+ 200 96.96 ± 0.002 94.78 ± 0.05 96.78 ± 0.02 
Rilpivirine+Estradiol+BNF 10+0.1+ 200 97.09 ± 0.004 96.44 ± 0.01 96.43 ± 0.01 
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4.4.3 Measurement of levels of free glycerol and adipocytokines in untreated and treated 
adipocytes after 10 days 
Human adipose cells were treated with various concentrations of rilpivirine and estradiol either 
alone and in combination and supernatant was collected after 10 days of differentiation. 
Quantitative measurement of free fatty acids and adipocytokines was done using commercially 
available kits. 
 
Figure 4.2: Bar charts showing the effects of different concentrations of either rilpivirine or 
estradiol alone or in combination on the release of free glycerol from human adipocytes 
following 10 days in culture. In this and subsequent figures, values are presented as means ± SD 
from duplicate set of experiments expressed relative to values from untreated control cells. n=6; 
*p<0.05 for control compared to drug treatments. 
The data presented in figure 4.2 show the effects of different concentrations of either rilpivirine 
or estradiol alone or in combination on the release of free glycerol from human adipocytes. The 
results show that all drug treatments can evoke significant (p<0.05) increases in free glycerol 
release from human adipocytes compared to untreated control, except for 0.01 µM and 0.005 
µM estradiol, which induces only a small increase in free glycerol. 
 
 
98 
 
 
Figure 4.3: Bar charts showing the effect of rilpivirine and estradiol either alone or in 
combination on the release of leptin by human adipocytes in culture for 10 days. Values are 
means ± SD; * p<0.05 compared to untreated control cells; n=6. 
Figure 4.3 shows the effect of rilpivirine and estradiol either alone or in combination on the 
release of leptin by human adipocytes in culture for 10 days. The results show the different 
types of drug treatments had little or no effect on leptin release, except for 10 µM rilpivirine 
alone or when it was combined with 0.1 µM estradiol when a significant (p<0.05) decrease in 
leptin release were observed. 
 
Figure 4.4: Bar charts showing the effect of rilpivirine and estradiol either alone or in 
combination on the release of adiponectin from human adipocytes in culture for 10 days. Data 
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are means ± SD=6; *p<0.05 for all concentrations of the drugs compared to control, except for 1 
µM rilpivirine. 
The results presented in figure 4.4 show the effect of rilpivirine and estradiol either alone or in 
combination on the release of adiponectin from human adipocytes in culture for 10 days. The 
results show significant (p<0.05) decreases in adiponectin release for all drug treatments 
compared to untreated control, except for 1 µM rilpivirine and 0.05 µM estradiol. 
 
 
 
Figure 4.5: Bar charts showing the effect of rilpivirine and estradiol either alone or in 
combination on the release of resistin from human adipocytes in culture for 10 days. Values 
are means ± SD; n=6; *p<0.05 for all drug treatments compared to untreated control except for 
1 µM and 5 µM rilpivirine alone and when rilpivirine (1 µM and 5 µM) was combined with 
estradiol (0.1 µM and 0.5 µM). 
The results show effect of rilpivirine and estradiol either alone or in combination on the release 
of resistin from human adipocytes in culture for 10 days. The data reveal significant (p<0.05) 
release in resistin for all drug treatments compared to untreated control except for 1 µM and 5 
µM rilpivirine and rilpivirine (1 µM and 5 µM) combined with estradiol (0.1 µM and 0.5 µM). 
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Figure 4.6: Bar charts showing the effect of rilpivirine and estradiol either alone or in 
combination on the release of interleukin-8 from human adipocytes in culture for 10 days. 
Data as means ± SD; n=6; *p<0.05 for 10 µM rilpivirine compared to untreated control. 
Figure 4.6 shows the effect of rilpivirine and estradiol either alone or in combination on the 
release of IL-8 from human adipocytes in culture for 10 days. The data reveal a significant 
(p<0.05) release in IL-8 for only 10 µM rilpivirine compared to untreated control. The other drug 
treatments only evoked small increases (but not significant, p>0.05) in IL-8 compared to 
untreated control cells. 
4.4.4 Measurement of free glycerol and adipocytokines from human adipocytes treated with 
various concentrations of rilpivirine and estradiol either alone or in combination but in the 
continuous presence of 200 µM β-naphthoflavone (BNF) 
In this series of experiments, the human adipocytes were pretreated with BNF followed by 
treatment with either rilpivirine or estradiol alone or during their combination employing 
different doses. The rationale was to ascertain whether BNF might exert an attenuating or 
potentiating effect on lipolysis and the release of adipocytokines from human adipocytes. 
 
101 
 
 
Figure 4.7: Bar charts showing the effect of different concentrations of rilpivirine and estradiol 
either alone or following combination in the presence of 200 µM of BNF on the release of free 
glycerol from human adipocytes in culture over 10 days with the drugs. In this and subsequent 
figures human pre-adipocytes were differentiated in culture in the presence of the indicated 
concentrations of drugs. Values are means ± SD; n=6; *p<0.05 for all drug treatments compared 
to untreated control cells. 
Figure 4.7 shows the effect of different doses of rilpivirine and estradiol either alone or 
following combination in the presence of 200 µM of BNF on the release of free glycerol from 
human adipocytes in culture over 10 days with the drugs. The results show that all drug 
treatments can evoke significant (p<0.05) dose-dependent release in free glycerol compared to 
untreated control. These effects were much larger compared the results obtained in the 
absence of BNF (See figure 4.2 for comparison). 
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Figure 4.8: Bar charts showing the effect of different concentrations of rilpivirine or estradiol 
either alone or in combination and in the presence of 200 µM of BNF on the release of leptin 
by human adipocytes in culture for 10 days with the drugs. Values are means ± SD; n=6; 
*p<0.05. 
Figure 5.8 shows the effect of different concentrations of rilpivirine or estradiol either alone or 
in combination and in the presence of 200 µM of BNF on the release of leptin by human 
adipocytes in culture for10 days with the drugs. The results show that only 10 µM rilpivirine 
alone and 10 µM rilpivirine in combination with 0.1 µM estradiol with BNF can evoke significant 
(p<0.05) decreases in leptin compared to untreated control. 
 
Figure 4.9: Bar graphs showing the effect of different concentrations of rilpivirine and 
estradiol either alone or in combination and in the presence of 200 µM of BNF on the release 
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of adiponectin by human adipocytes in culture for 10 days with the drugs. Values are means ± 
SD; n=6; *p<0.05 for all drug treatments compared to untreated control. 
Figure 4.9 shows the effect of different concentrations of rilpivirine and estradiol either alone or 
in combination and in the presence of 200 µM of BNF on the release of adiponectin by human 
adipocytes in culture for 10 days with the drugs. The results show significant (p<0.05) decreases 
in adiponectin release for all drug treatments compared to untreated control. The decrease in 
adiponectin level was dose dependent, but much more marked in the presence of BNF. 
 
 
Figure 4.10: Bar graphs showing the effect of rilpivirine and estradiol either alone or in 
combination and in the presence of 200 µM of BNF on the release of resistin from human 
adipocytes in culture for all the drugs. Values are means ± SD; n=6; *p<0.05for drug treated 
cells untreated control cells.  
Figure 4.10 shows the effect of rilpivirine and estradiol either alone or in combination and in the 
presence of 200 µM of BNF on the release of resistin from human adipocytes in culture for all 
drugs. The results show a significant (p<0.05) release in resistin for 10 µM rilpivirine, all 
concentrations of estradiol and rilpivirine (10 µM) in combination with estradiol (0.1 µM) and 
BNF compared to untreated control.  
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Figure 4.11: Bar charts showing the effect rilpivirine and estradiol either alone or in 
combination and in the presence of 200 µM of BNF on the release of interleukin-8 from 
human adipocytes in culture for 10 days with all the drugs. Values are mean ± SD; n=6; *p<0.05 
for 1 µM and 5 rilpivirine, 0.01 µM and 0.05 µM estradiol compared to untreated cells. 
Figure 4.11 shows the effect rilpivirine and estradiol either alone or in combination and in the 
presence of 200 µM of BNF on the release of IL-8 from human adipocytes in culture for 10 days 
with all the drugs. The results show a significant (p<0.05) decrease in the release of IL-8 for 1 µM 
and 5 µM rilpivirine, 0.01 µM and 0.05 µM estradiol compared to untreated cells. 
4.5 Discussion 
The results of this study have demonstrated marked morphological changes in the adipocytes in 
culture over time. The cells were observed daily as they were proceeding through the foregoing 
stages of differentiation. Microphotographs were taken on day 0, day 5 and day 10 for 
comparison. The results show that the shape of the cells changed from the spindle- shaped 
fibroblast to the nearly spherical form of a mature adipose cell. There was an increasing 
accumulation of lipid, first as small inclusions concentrated towards one pole of the cell and 
then finally as large lipid masses in the central region of the cell. 
Viability of the cells were assessed on 0, 5 and 10th day of the adipocyte maturation process by 
employing lactate dehydrogenase as a marker to monitor cell death. Increasing concentrations 
of rilpivirine (1 µM, 5 µM and 10 µM) and estradiol (0.01 µM, 0.05 µM and 0.1 µM) were applied 
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individually and in combination. The results clearly show that neither rilpivirine nor estradiol 
either alone or in combination either with or without BNF had any deleterious effects on the 
viability of adipocytes compared to untreated cells. There was no significant release of LDH in 
either stimulated or treated cells as compared to untreated cells. The viability of cells at all 
stages of adipogenesis, as measured by the lactate dehydrogenase assay did not show any 
significant difference as compared to the control. Therefore, all these concentrations were 
determined as optimal for future experimental work. These results are in agreement with a 
previous study (Díaz-Delfín et al., 2012). 
Data from several previous studies have revealed that anti-retroviral and estrogen therapy can 
induce lipid alterations by activating lipolysis and thereby, enhancing the levels of free fatty acid 
and free glycerol in adipocyte cell cultures (Ranganathan et al., Kern, 2002; Jones et al., 2005; 
Mallon, 2007).  
The results of this study show an increasing trend in the lipolysis process in human adipocytes. 
The release of glycerol was dose-dependent with both rilpivirine and estradiol. Concomitant 
treatment of two drugs at all doses did not show any attenuation or potentiating effect on 
glycerol release, but only a small additive effect compared to the effect of either rilpivirine or 
estradiol alone. The observed results could be attributed to impaired GLUT4 translocation and 
are in keeping with another study that assessed the effect of nelfinavir on glucose uptake and 
lipolysis in differentiated 3T3-L1 adipocytes. An 18-h exposure to nelfinavir resulted in an 
impaired insulin-stimulated glucose uptake and activation of basal lipolysis with as low as 5 
μmol/l nelfinavir (Rudich et al., 2001). Another study conducted in vivo showed that exposure to 
high concentrations of estradiol led to region-and pathway-dependent modulation of 
subcutaneous adipose tissue lipolysis in pre-menopausal women (Gavin et al., 2013). 
Leptin has been reported to be related to adiposity and it increases in proportion to decreasing 
adipose tissue stores. It is of much interest in anti-retroviral and estrogen-based therapies 
where abnormalities of body fat distribution are characteristic features. A number of in vitro 
studies have demonstrated a reduction in leptin secretion when human adipocytes were treated 
with ARVs (Ambati et al., 2007; Díaz-Delfín et al., 2011). In this study, no significant release in 
leptin level were observed when adipocytes were treated with either all concentrations of 
estradiol or low doses of rilpivirine compared to a higher dose of 10 μM which elicited a 
significant decrease in leptin secretion compared to untreated cells. Similar results were 
obtained with the highest dose of each drug when they were combined. Previous in vivo and in 
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vitro studies reported that  estrogens can elevate the level of leptin (Ainslie et al., 2001; Geber 
et al., 2012). However, some reports have indicated either a nil or a reverse relationship 
between estrogens and leptin release (Rechberger et al., 1999; Xing et al., 2015). 
Adiponectin, an insulin-sensitizing adipokine, is induced during adipocyte differentiation 
(Scherer et al., 1995). Reduced levels of adiponectin have been reported by various studies in 
adipocytes treated with very high doses of ARV drugs. In the present study, except for at a low 
concentration (1 μM) of rilpivirine alone, all the other drug treatment doses elicited significant 
effects on the release of adiponectin levels from human adipocytes. Combining rilpivirine with 
estradiol produced a much larger decrease in the release of adiponectin compared to their 
individual concentrations alone. Adiponectin is known to enhance insulin-mediated glucose 
uptake in peripheral tissues (i.e., skeletal muscle) and in sensitizing liver to insulin-dependent 
suppression of glucose output (Kadowaki et al., 2006). This reduction may be considered as a 
major contributor to insulin resistance (IR). In this study, reduced levels of adiponectin were 
observed when cells were treated with increasing doses of 17β-estradiol. The present results are 
in agreement with a recent study that reported dramatically suppressed levels of adiponectin 
concentration when pre-adipocytes were exposed to increasing levels of 17β-estradiol (Pektaş 
et al., 2015).  
Originally, resistin was thought to be a link between diabetes and obesity. A single nucleotide 
polymorphism in the resistin gene has been associated with elevated lipids, insulin resistance 
and body composition changes among HIV-infected individuals on anti-retroviral therapies 
(Steppan et al., 2001). In another study, greater plasma resistin levels were observed in HIV 
patients compared with uninfected controls (Escoté et al., 2011). However, other workers have 
found no association between serum resistin and fat redistribution, and metabolic profile in HIV-
infected patients (Barb et al., 2005; Arama et al., 2014). The physiological role of resistin, 
therefore, is not fully understood and needs further studies. It is proposed to be an important 
peptide bringing about insulin resistance and obesity, although it is still debatable (Lappas et al., 
2005).In the present study, the levels of resistin were comparable to that of control and there 
was no significant difference for pre-adipocytes treated individually with rilpivirine at low doses.  
Only a slight increase in the resistin level was observed at 10 μM, indicating that rilpivirine may 
contribute to the fat re-distribution but only at high dosage. A positive correlation in estrogens 
and resistin levels has been demonstrated and resistin concentrations were found to be 
conspicuously elevated by 17β-estradiol (Chen et al., 2006; Pektaş et al., 2015). The present 
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study showed enhanced levels of resistin in adipose cells treated with different concentrations 
of 17β-estradiol as compared to control. Combination of rilpivirine and estradiol did not show 
any increase in resistin level for the lowest and median doses used in the study. However, an 
increase in the resistin concentrations was observed at the highest dosage of combination 
treatment (1 μM rilpivirine combined with 0.1 μM estradiol). 
Increased serum IL-8 levels have been previously reported in HIV patients with impaired glucose 
tolerance (Reeds et al., 2006), and this is consistent with findings in T2DM (Zozulinska et al., 
1999), obesity and non-alcoholic fatty liver disease (Jarrar et al., 2008). Chronic inflammatory 
state in HIV-infection may be associated with elevated fasting serum level of IL-8. Higher serum 
IL-8 may also reflect increased production and release from the larger adipose depots and may 
have an influence on lipid metabolism along with its effect on insulin resistance. Elevated levels 
of IL-8 have been observed in human subcutaneous and visceral adipose tissue obtained from 
HIV-infected people with fat redistribution and insulin resistance (Lihn et al., 2003). In the 
present study, IL-8 levels increased with an increase in the concentrations of rilpivirine. High 
concentrations of IL-8 were observed when the cells were treated with 10 μM of rilpivirine 
indicating its role in fat re-distribution. The present findings are in agreement with another 
study (Díaz-Delfín et al., 2012),which reported that rilpivirine did not have any effect on the 
release of IL-8 at concentrations up to 4 μM, but instead, it produced a marked and significant 
elevation only at 10 μM. Compared to rilpivirine, estradiol evoked a dose-dependent increase in 
the release of IL-8 from adipose cells. Enhanced levels of IL-8 were observed when the pre-
adipocytes were treated with increasing concentrations of estradiol. Moreover, increasing 
release in the level of IL-8 was observed when adipocytes were treated with a combination of 
rilpivirine and estradiol suggesting a major contribution of estradiol in eliciting the release of IL-
8. 
In the second series of experiments human adipocytes were pretreated with BNF in the absence 
and presence of either rilpivirine, estradiol or when the two drugs were combined for a period 
of 10 days. The results reveal elevated glycerol level with BNF alone. When BNF was combined 
with either rilpivirine, estradiol or both drugs, there was enhanced release of glycerol in a dose-
dependent manner. BNF seems to be potentiating the effect of either rilpivirine or estradiol on 
glycerol release (enhanced lipolysis) from human adipocytes. In contrast, BNF had no significant 
effect on the release of leptin from human adipocytes when combined with either rilpivirine, 
estradiol or with both. In this series, BNF also enhanced the decrease in adiponectin release 
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from human adipocytes in the presence of either rilpivirine, estradiol or when the two drugs 
were combined compared to the results obtained in the absence of BNF. In contrast, in the 
presence of BNF, individual treatment of adipose cells with either rilpivirine or estradiol alone or 
combined did not seem to have any significant effect on the resistin and IL-8 releases for all the 
doses used in the study compared to the results obtained in the absence of BNF. In fact, BNF 
seemed to induce a reduction in the levels of resistin and IL-8 as compared to levels in the 
absence of BNF. 
In conclusion, the results of this study show that a combination of rilpivirine and 17β-estradiol is 
completely non-toxic to pre-adipocytes at most concentrations tested. During the 10-day 
exposure to the drugs, only estradiol produced a modest cytotoxic effect at the highest 
concentrations tested. No profound deleterious effect was observed on adipose tissue 
development or the endocrine function of adipose tissue (adipokine and cytokine release) in 
treated 3T3-L1 human pre-adipocytes. However, caution should be maintained considering that 
other transcriptional factors play a crucial role in overall alterations of lipid metabolism. BNF 
does not seem to significantly interact with rilpivirine and 17β-estradiol except for the release of 
adiponectin. Moreover, to establish and elucidate a significant effect of these drugs on the 
adipogenic process, further studies at gene expression levels and involving the markers of 
oxidative stress are required. 
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Chapter 5 
 
 
 
 
 
Effect of rilpivirine on human subcutaneous adipose cells and its 
nutritional management using quercetin. 
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5.1 Introduction 
The widespread use of highly active antiretroviral treatment (HAART) has radically transformed 
the prognosis of HIV infected patients. Anti-retroviral therapy for HIV infection has transformed 
it from a terminal illness to a chronic manageable condition (Bailey et al., 2008; Palella et al., 
1998). However, long-term treatment of HIV 1-infected patients can result in the appearance 
of several secondary effects, the most frequent being the so-called ‘HIV-infection, HAART 
treatment-associated lipo-dystrophy syndrome (HALS) (Montessori et al., 2004).  
Lipo-dystrophy is associated with both morphological (lipo-atrophy, lipo-hypertrophy) and 
metabolic (dyslipidaemia, glucose intolerance, hypertension, endothelial dysfunction and 
atherosclerosis) alterations, which may occur singly or in combination. Moreover, they are 
associated with an increased risk of diabetes and cardiovascular diseases. HAART-induced 
adipocyte inflammation, oxidative stress and macrophage infiltration, as well as altered 
adipocyte function are considered as major contributors in the development of HALS. The 
adipocyte, therefore, represents a plausible target for treatment (Boss, 2003). Pharmacological 
and surgical treatment interventions have shown some effect. However, their use is associated 
with numerous adverse side effects and complications (Slaven et al., 2003; Rasmussen et al,. 
2011; Liu et al., 2012; Grulich et al., 2007). Targeted lifestyle interventions may provide a useful 
alternative for managing HALS owing to their safety and tolerability. 
The WHO recommends that nutrition interventions should be part of all HIV/AIDS control and 
treatment programme because adequate diet and nutrition can improve adherence to anti-
retroviral therapy (ART) and its effectiveness, as well as help tackling metabolic abnormalities in 
people living with HIV/AIDS (World Health Organization, 2003). In 1989, the World Health 
Organization (WHO) had declared the necessity to assess ethno-medicines and other natural 
products for the management of HIV/AIDS. To quote: “In this context, there is need to evaluate 
those elements of traditional medicine, particularly medicinal plants and other natural products 
that might yield effective and affordable therapeutic agents. This will require a systematic 
approach” (World Health Organization, 1989a,b). Moreover, because they are fairly not as 
expensive and have less side effects, phyto-medicines are retrieving patient approval (Vermani 
et al., 2002; Short, 2006). The use of complementary and alternative medicines, including herbal 
medicines, is common among individuals with HIV. The reported prevalence of herbal remedies 
use by HIV-infected individuals in the United States varies between 12% and 27.2  % (Abbot et 
al., 1997; KM et al., 1998; Sparber et al., 2000). Surveys have revealed that nearly 67% of HIV-
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infected patients receiving ARV therapy also take a natural health product (NHP)(Gore-Felton et 
al., 2003), of which the most common are vitamin C (63%), multivitamins (54%), vitamin E (53 
%), and garlic (53%); vitamin B12, beta-carotene, acidophilus, vitamin B6, zinc, ginseng, 
selenium, Echinacea species, vitamin A, aloe, folate, Chinese herbs, marijuana, goldenseal, and 
coenzyme Q10 which were reportedly taken by 20%–50% of patients (Standish et al., 2001). The 
major reasons reported by HIV-infected patients for using these complementary alternative 
medicines  modalities are a perceived additional efficacy, an increase in quality of life, a 
reduction of adverse effects of ARV therapy, and a feeling of control (Duggan et al., 2001). 
Rilpivirine (Trade name: Edurant), is a prescription medicine approved by the U.S. Food and 
Drug Administration (FDA) for the treatment of HIV infection in adults and children 12 years of 
age and older who have never taken HIV medicines before and who have a viral load (number of 
HIV RNA copies /mL of blood) of 100,000 copies/mL or less at the start of treatment. (Schrijvers 
et al.,2011). It belongs to a class (group) of HIV drugs called non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) and acts by binding directly to the enzyme at a site different 
from the nucleoside binding component, thereby causing an allosteric inhibition of the 
transcriptase.  
Quercetin, a plant pigment, is a potent antioxidant flavonoid and more specifically a flavonol, 
found mostly in onions, grapes, berries, cherries, broccoli, and citrus fruits. It is a versatile 
antioxidant known to possess protective abilities against tissue injury induced by various drug 
toxicities. It is an important bioflavonoid known for its anti-inflammatory, antihypertensive, 
vasodilator effects, anti-obesity, anti-hyper-cholesterolemic and anti-atherosclerotic activities 
(Sultana and Anwar, 2008; Salvamani et al., 2014).  
Aims: The main aims of the present study were to determine the metabolic alterations caused 
by rilpivirine and also to assess the nutritional effect of quercetin on preventing and improving 
these metabolic changes. 
5.2 Materials and methods 
As described in chapter 2. 
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5.3 Results  
5.3.1 Measurement of cyto-toxicity using lactate dehydrogenase assay 
The human subcutaneous pre-adipocytes were seeded at a density of 2 × 104 cells per well in 24-
well plates and cultured until 90 % confluence in culture medium. The cells were then treated 
with various concentrations of rilpivirine or quercetin either alone and in combination for a 
period of 15 days. As an indicator of cytotoxicity, the cytoplasmic enzyme lactate 
dehydrogenase (LDH) was measured in the culture supernatant of the control as well as treated 
differentiating adipose cells on day 3 and day 15 of culture. An optimized LDH test was used to 
quantify LDH activity in the medium of the treated differentiating adipose cells. The percentage 
of viable cells was calculated by defining the cell viability without treatment as 100%. 
 
Figure 5.1: Bar graph showing the effect of rilpivirine or quercetin either alone or in 
combination on the cell viability as measured by LDH on day 3 of culture. Human 
subcutaneous adipose cells were treated with various concentrations of indicated drugs either 
alone and in combination. Cytotoxicity was expressed as the percentage of LDH activity in the 
medium as compared to control on day 3 of incubation. The results represent mean ± SEM of 3 
parallel cell culture experiments. *p<0.05 compared to the control. 
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The results presented in figure 5.1 show no significant (p>0.05) changes in the viability of cells 
when treated with various concentrations of either rilpivirine or quercetin alone and in 
combination for day 3 of culture.   
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2: Bar graph showing the effect of rilpivirine or quercetin either alone or in 
combination on the cell viability as measured by LDH on day 15 of culture. Human 
subcutaneous adipose cells were treated with various concentrations of indicated drugs either 
alone and in combination. Cyto-toxicity was expressed as the percentage of LDH activity in the 
medium as compared to control on day 15 of incubation. The results represent mean ± SEM of 3 
parallel cell culture experiments. *p<0.05 compared to the control. 
The results presented in figure 5.2 show that rilpivirine at lower concentrations (10 µM and 15 
µM) and quercetin at 50 µM did not alter the viability rate of the cells. However, at a 
concentration of 20 µM, a slight and significant (p<0.05) decrease in the cell viability was 
observed indicating its effect at higher doses. A combination of rilpivirine and quercetin at drug 
concentration of 20 µM and 50 µM respectively, also showed a significant (p<0.05) decrease.  
 
* * 
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5.3.2 Morphological Examination of Adipose cells by AdipoRed Staining  
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Figure 5.3: Original representative images (A-I) showing the progression of adipogenesis as 
indicated by lipid formation for human adipose cells in culture. Human subcutaneous adipose 
cells were differentiated and treated with different concentrations of either rilpivirine or 
quercetin individually and then in combination. Images were taken for the 5th, 8th, 11th and 15th 
day of cells in culture at 20x magnification using a fluorescence microscope. Staining was done 
using adipored to visualize lipid content. Images are typical of 3 such different experiments in 
duplicate. These images reveal the following: 
A). Undifferentiated and untreated (no drugs) adipose cells.  
B). Differentiated and untreated (no drugs) adipose cells.  
C). Adipocytes differentiated and treated with 10 µM of rilpivirine.  
D). Adipocytes differentiated and treated with 15 µM of rilpivirine.  
E). Adipocytes differentiated and treated with 20 µM of rilpivirine.  
F). Adipocytes differentiated and treated with 50 µM of quercetin.  
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G). Adipocytes were differentiated and treated with a combination of 10 µM rilpivirine and 50 
µM quercetin.  
H). Adipocytes differentiated and treated with a combination of 15 µM rilpivirine and 50 µM 
quercetin. 
I). Adipocytes differentiated and treated with a combination of 20 µM rilpivirine and 50 µM 
quercetin.  
 
Morphological data from figure 5.3 show the accumulation of triglyceride in pre-adipocytes 
cultured and differentiated in the presence/absence of treatment drugs either alone or in 
combination. Image A represents undifferentiated and untreated pre-adipocyte cells in culture. 
These cells appeared elongated, fibroblast-like, spindle shaped and showed no lipid 
accumulation. Image B represents the progression of pre-adipocyte cells into mature adipose 
cells differentiated for 15 days without any drug treatment (Control). The process of 
adipogenesis progressed in a time-dependent manner as evidenced by the increasing lipid 
droplets (yellow). On day 5, almost nil or very little amount of lipid droplets were observed. 
However, by day 8 the cells began to attain a rounder shape and became laden with lipids and 
had accumulated substantial triglyceride content. These lipid vacuoles were observed to 
accumulate more triglycerides and grow more in size and number on day 11 and 15 in culture. 
Images C, D and E represent pre-adipocyte cells treated with a dosage concentration of 10 µM, 
15 µM and 20 µM of rilpivirine respectively over a period of 15 days. It was observed that 
rilpivirine inhibited the accumulation of triglycerides in a dose- and time- dependent manner. 
The formation of lipid droplets (yellow) decreased with increasing dosage and time in culture. 
Images F represents pre-adipocytes treated with 50 µM of quercetin. Pre-adipocytes treated 
with quercetin were shown to inhibit triglyceride accumulation with increasing number of days 
in culture. The number of lipid droplets decreased from day 8 until day 15 in culture. Images G, 
H and I represent pre-adipocyte cells treated with a combination of 10 µM, 15 µM, 20 µM of 
estradiol and 50 µM of quercetin, respectively. Adipose cells treated with these combinations of 
drugs showed attenuation in lipid formation in time- and dose- dependent manner. Day 8 of 
differentiation showed a substantial amount of triglyceride accumulation which almost became 
diminished until day 15. 
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5.3.3 Quantitative measurement of triglycerides 
Triglycerides accumulated over the differentiation period of 15 days were measured 
quantitatively by staining the cells with adipored reagent and the fluorescence was measured at 
OD value of 572 nm.  
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Figure 5.4 (A-D): Bar graphs showing the effect of rilpivirine and quercetin individually and 
then in combination on the accumulation of triglyceride by human adipocytes in culture. 
Human pre-adipocytes were differentiated in culture in the presence of indicated 
concentrations of rilpivirine and quercetin. Values represent concentration of triglyceride in cell 
supernatant for the 3rd, 5th, 8th and 11th day of culture. Statistical analysis was performed using a 
one-way ANOVA and are presented as mean ± S.D from triplicate set of experiments expressed 
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relative to values from untreated control cells; *p<0.05 **p<0.01 ***p<0.001 compared to the 
control. #, $, & indicate significance differences within the treatment groups. 
Figure 5.4 (Images A-D) shows the progression of undifferentiated pre-adipocytes into 
differentiated mature adipose cells over a period of 15 days either in the presence or absence of 
indicated concentrations of treatment drugs. Adipose cells that were not treated with any drugs 
(control) showed a significant progression in the accumulation of triglycerides over 15 days in 
culture. Image A shows the accumulation of triglycerides on the 5th day of culture. Rilpivirine at 
concentrations of 10 and 15 µM did not induce any significant change in the lipid accumulation. 
However, a small but significant (p<0.05) decrease was observed at a concentration of 20 µM of 
rilpivirine. Adipose cells treated with a dose of 50 µM of quercetin also evoked a slight reduction 
in the triglyceride levels. Combination of rilpivirine and quercetin decreased the triglyceride 
concentration in a dose dependent manner. 
The results of triglyceride accumulation were more pronounced on day 8 and day 11 of culture 
(Image B and C). Rilpivirine at concentrations of 15 µM and 20 µM showed a significant (p<0.05 
and p<0.01 for day 8 and p<0.01 and p<0.001 for day 11 respectively) decrease in triglyceride 
levels. Quercetin also inhibited the triglyceride level significantly (p<0.001). When the two drugs 
were combined, significant reduction in triglyceride were measured. Triglyceride levels for day 
15 (Image D) showed substantial reductions (p<0.001) for adipose cells treated with either 
rilpivirine or quercetin alone and in combination. This reduction was more prominant and 
significant when the two drugs were combined together.  
Overall, the results show that adipose cells treated with either rilpivirine or quercetin alone and 
in combination significantly (p<0.05 for day 8 and p<0.001 for day 11 and 15, respectively) 
inhibited lipid formation and attenuated triglyceride accumulation in a dose and time 
dependent manner. This reduction was more prominant when adipose cells were treated with a 
combination of estradiol and quercetin. 
5.3.4 Quantitative measurement of inflammatory adipocytokines 
Human subcutaneous adipose cells were cultured and differentiated over a period of 8 days in 
the presence of either rilpivirine or quercetin alone and in combination using maximal dose of 
each drug. Supernatant was collected on the 8th day of culture and the released adipocytokines 
(Adiponectin, leptin, resistin, IL-8) were measured quantitatively using commercially available 
kits. 
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5.3.4.1 Quantitative measurement of adiponectin   
 
 
Figure 5.5: Bar graphs showing the effect of rilpivirine and quercetin individually and then in 
combination on the release of adiponectin by human adipocytes in culture. Human pre-
adipocytes were differentiated in the presence of indicated concentrations of drugs (15 µM 
rilpivirine and 50 µM quercetin). Values represent concentrations of released adiponectin in the 
cell supernatant for the 8th day of culture. Statistical analysis was performed using a one-way 
ANOVA and are presented as mean ± S.D from triplicate set of experiments expressed relative to 
values from untreated control cells; *p<0.05 **p<0.01 ***p<0.001 compared to the control. #, $ 
indicate significant differences within the treatment groups. 
The results in figure 5.5 show marked significant reduction in the adiponectin concentration 
levels as compared to control when treated with rilpivirine alone (p<0.01). Significant 
differences were observed in the adipocytes treated with a combination of rilpivirine and 
quercetin when compared with control (p< 0.01) as well as with quercetin alone (p< 0.01). 
Quercetin alone showed significant (p<0.01) increase in adiponectin levels when compared to 
the untreated or control group. 
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5.3.4.2 Quantitative measurement of leptin 
 
Figure 5.6: Bar charts showing the effect of rilpivirine and quercetin individually and then in 
combination on the release of leptin by human adipocytes in culture. Human pre-adipocytes 
were differentiated in culture in the presence of the indicated concentrations of drug (15 µM 
rilpivirine and 50 µM quercetin). Values represent concentrations of leptin in the cell 
supernatant for the 8th day of culture. Statistical analysis was performed using a one-way 
ANOVA and the results are presented as means ± SD from triplicate set of experiments 
expressed relative to values from untreated control cells; *p<0.05 **p<0.01 ***p<0.001 
compared to the control. #, $ indicate significant differences within the treatment groups. 
The results in figure 5.5 show small and insignificant decrease in the adipocytes treated with 
rilpivirine alone. Treatment with quercetin alone showed significant (p<0.001) decrease in leptin 
levels when compared to rilpivirine alone. Adipose cells treated with a combination of rilpivirine 
and quercetin showed significant (p<0.01) decrease in the leptin levels as compared to control. 
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5.3.4.3 Quantitative measurement of Resistin   
 
 
Figure 5.7: Bar charts showing the effect of rilpivirine and quercetin individually and then in 
combination on the release of resistin by human adipocytes in culture. Human pre-adipocytes 
were differentiated in culture in the presence of the indicated concentrations of drugs (15 µM 
rilpivirine and 50 µM quercetin). Values represent concentrations of resistin in the cell 
supernatant for the 8th day of culture. Statistical analysis was performed using a one-way 
ANOVA and are presented as mean ± SD from triplicate set of experiments expressed relative to 
values from untreated control cells; *p<0.05 **p<0.01 ***p<0.001 compared to the control. #, $ 
indicate significant differences within the treatment groups. 
The data in figure 5.7 show significant increase in resistin levels of adipose cells when treated 
with rilpivirine alone (p<0.05) or in combination with quercetin (p<0.01) as compared to control. 
The results also show that 50 µM of quercetin alone elicited only a small increase but 
insignificant release of resistin as compared to control. 
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5.3.4.4 Quantitative measurement of IL-8   
 
Figure 5.8: Bar charts showing the effect of rilpivirine and quercetin individually and then in 
combination on the release of Interleukin-8 by human adipocytes in culture. Human pre-
adipocytes were differentiated in culture in the presence of the indicated concentrations of 
drugs (15 µM rilpivirine and 50 µM quercetin). Values represent concentration of adiponectin in 
the cell culture medium for the 8th day of culture. Statistical analysis was performed using a one-
way ANOVA with levene’s test for equality of variances and are presented as mean ± SD from 
triplicate set of experiments expressed relative to values from untreated control cells; *p<0.05 
**p<0.01 ***p<0.001 compared to the control. 
The results in figure 5.8 show significant increase in the levels of IL-8 for adipose cells treated 
with rilpivirine (p<0.01) as compared to control. Treatment with quercetin alone showed a small 
reduction in IL-8 levels. However, when the two drugs were combined, there was a significant 
(p<0.001) reduction in Il-8 concentration in the cell supernatant. 
5.3.5 Quantitative measurement of Oxidative stress markers 
Markers of oxidative stress (Nitric oxide, Superoxide dismutase, Glutathione and Catalase) were 
measured quantitatively using commercially available kits. 
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5.3.5.1 Quantitative measurement of Catalase activity   
 
 
Figure 5.9: Bar charts showing the effect of rilpivirine and quercetin individually and then in 
combination on the catalase activity by human adipocytes in culture. Human pre-adipocytes 
were differentiated in the presence of indicated concentrations of drugs (15 µM rilpivirine and 
50 µM quercetin). Values represent concentrations of catalase enzyme in the cell lysates for the 
8th day of culture. Statistical analysis was performed using a one-way ANOVA and are presented 
as means of ± S.D from triplicate set of experiments expressed relative to values from untreated 
control cells; *p<0.05 **p<0.01 ***p<0.001 compared to the control. # represents significance 
difference within the treatment groups. 
Data from figure 5.9 show significant difference in the catalase activity for adipose cells treated 
with rilpivirine or quercetin alone (p<0.05 and p<0.01 respectively) as compared to control. The 
results also show significant differences (p<0.01) among the adipose cells treated with quercetin 
alone. The results for combination of the two drugs showed values almost comparable to that of 
control.  
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5.3.5.2 Quantitative measurement of SOD activity   
 
Figure 5.10: Bar graph showing the effect of rilpivirine and quercetin individually and then in 
combination on the Superoxide dismutase activity by human adipocytes in culture. Human 
pre-adipocytes were differentiated in the presence of indicated concentrations of drugs (15 µM 
rilpivirine and 50 µM quercetin). Values represent concentrations of superoxide dismutase 
enzyme in the cell lysates for the 8th day of culture. Statistical analysis was performed using a 
one-way ANOVA with for equality of variances and are presented as means of ± S.D from 
triplicate set of experiments expressed relative to values from untreated control cells; *p<0.05 
**p<0.01 ***p<0.001 compared to the control. # represents significance difference within the 
treatment groups. 
Data from figure 5.10 show significant decrease (p<0.01) in SOD levels for adipose cells treated 
with rilpivirine alone. Adipose cells treated with quercetin alone showed a small but significant 
(p<0.05) increase in the SOD activity. A combination of rilpivirine and quercetin also showed a 
small but significant (p<0.05) increase as compared to adipose cells treated with rilpivirine 
alone.  
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5.3.5.3 Quantitative measurement of Nitric oxide   
 
Figure 5.11: Bar charts showing the effect of rilpivirine and quercetin individually and then in 
combination on the concentration of nitric oxide by human adipocytes in culture. Human pre-
adipocytes were differentiated in the presence of indicated concentrations of drugs (15 µM 
rilpivirine and 50 µM quercetin). Values represent concentrations of nitric oxide enzyme in the 
cell lysates for the 8th day of culture. Statistical analysis was performed using a one-way ANOVA 
with for equality of variances and are presented as means of ± S.D from triplicate set of 
experiments expressed relative to values from untreated control cells; *p<0.05 **p<0.01 
***p<0.001 compared to the control. # represents significance difference within the treatment 
groups. 
The results presented in figure 5.11 show significant differences in the treatment groups as 
compared to control. Treatment of adipose cells with rilpivirine alone elicited a marked increase 
(p<0.05) in the NO levels as compared to control. Nitric oxide levels were significantly (p<0.01) 
reduced in adipose cells treated with quercetin or its combination with rilpivirine (p<0.05).  
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5.3.5.4 Quantitative measurement of Glutathione   
 
Figure 5.12: Bar graph showing the effect of rilpivirine and quercetin individually and then in 
combination on the concentration of glutathione by human adipocytes in culture. Human pre-
adipocytes were differentiated in the presence of indicated concentrations of drugs (15 µM 
rilpivirine and 50 µM quercetin). Values represent concentrations of glutathione enzyme in the 
cell lysates for the 8th day of culture. Statistical analysis was performed using a one-way ANOVA 
with for equality of variances and are presented as means of ± S.D from triplicate set of 
experiments expressed relative to values from untreated control cells; *p<0.05 **p<0.01 
***p<0.001 compared to the control. # represents significance difference within the treatment 
groups. 
The results presented in figure 5.12 show significant decrease (p<0.01) in glutathione activity for 
adipose cells treated with rilpivirine alone. Quercetin alone evoked a marked significant 
(p<0.001) elevation in GSH activity. Adipose cells treated with a combination of rilpivirine and 
quercetin also showed a significant (p<0.01) increase in the GSH activity as compared to control. 
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5.3.6 Immuno-fluorescence staining with adipogenic marker antibodies 
This set of experiment was designed to demonstrate both the presence and the subcellular 
localization of crucial protein markers involved in the process of adipogenesis. Briefly, adipose 
cells were grown, treated with either rilpivirine or quercetin alone and in combination, fixed and 
stained directly in 96 well black-coloured plates using primary antibodies for specific adipogenic 
markers. goat anti-rabbit fluorochrome-conjugated secondary antibody, Alexa Fluor was used to 
stain subcellular proteins while DAPI was used to stain the nuclei. 
6.3.6.1 Morphological and quantitative measurement of PPAR γ 
 
Figure 5.13: Images A-E showing the expression of PPARγ adipogenic marker in human 
subcutaneous adipose cells differentiated for a period of 8 days in the presence of treatment 
drugs using immuno-fluorescence dual staining. PPARγ (green) was detected using PPARγ 
primary antibody diluted at 1:100 concentration. Nuclei (blue) were stained with DAPI. Cells 
were imaged at 20X magnification with a scale bar of 100 µM.  
A. Negative control without the primary antibody.  
B. Differentiated adipose cells without any drug treatment (Control).  
C. Differentiated adipose cells treated with 15 µM rilpivirine.  
D. Differentiated adipose cells treated with 50 µM quercetin.  
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E. Differentiated adipose cells treated with a combination of 15 µM rilpivirine and 50 µM 
quercetin. These images are typical of 3 different experiments. 
Morphological data presented in figure 5.13 (A-E) show a reduced expression of PPARγ for 
adipose cells treated with either rilpivirine or quercetin alone and in combination as compared 
to control. These images for PPAR expression were quantified and the results are shown in 
figure 6.14. 
 
Figure 5.14: Bar charts showing the quantitative measurement of PPAR in human adipose cells 
treated with either rilpivirine or quercetin alone and in combination. Human pre-adipocytes 
were differentiated in the presence of indicated concentrations of drugs (15 µM rilpivirine and 
50 µM quercetin) individually and then in combination. Fluorescence was measured at an 
excitation wavelength of 495 nm and emission at 519 nm for adipose cells on day 8 in culture. 
Statistical analysis was performed using a one-way ANOVA and are presented as means of ± S.D 
from triplicate set of experiments expressed relative to values from untreated control cells; 
*p<0.05 **p<0.01 ***p<0.001 compared to the control. # represents significance difference 
within the treatment groups. 
The data presented in figure 5.14 show significant decreases (p<0.05) in PPAR expression for 
adipose cells treated with rilpivirine as compared to control. Quercetin showed a statistically 
sharp reduction (p<0.001) in PPAR levels as compared to control as well as rilpivirine. Treatment 
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with a combination of rilpivirine and quercetin also showed a significant (p<0.001) decrease in 
PPAR expression as compared to control. 
5.3.6.2 Morphological and quantitative measurement of CEBP 
 
Figure 5.15: Images A-E showing expression of CEBP adipogenic marker in human 
subcutaneous adipose cells differentiated for a period of 8 days in the presence of treatment 
drugs using immuno-fluorescence dual staining. CEBP (green) was detected using CEBP primary 
antibody diluted at 1:100 concentration. Nuclei (blue) were stained with DAPI. Cells were 
imaged at 20X magnification with a scale bar of 100 µM.  
A. Negative control without the primary antibody.  
B. Differentiated adipose cells without any drug treatment (Control). 
 C. Differentiated adipose cells treated with 15 µM rilpivirine.  
D. Differentiated adipose cells treated with 50 µM quercetin. 
 E. Differentiated adipose cells treated with a combination of 15 µM rilpivirine and 50 µM 
quercetin. These images are typical of 3 different experiments. 
The morphological data presented in figure 5.15 (Images A-E) show a reduced expression of 
CEBP adipogenic marker for adipose cells treated with either rilpivirine or quercetin alone and in 
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combination. These images for CEBP expression were quantified and the results are shown in 
figure 6.16. 
 
Figure 5.16: Bar graphs showing the quantitative measurement of CEBP in human adipose 
cells treated with either rilpivirine or quercetin alone and in combination. Human pre-
adipocytes were differentiated in the presence of indicated concentrations of drugs (15 µM 
rilpivirine and 50 µM quercetin) individually and then in combination. Fluorescence was 
measured at an excitation wavelength of 495 nm and emission at 519 nm for adipose cells on 
day 8 in culture. Statistical analysis was performed using a one-way ANOVA and are presented 
as means of ± S.D from triplicate set of experiments expressed relative to values from untreated 
control cells; *p<0.05 **p<0.01 ***p<0.001 compared to the control. # represents significance 
difference within the treatment groups. 
The data presented in figure 5.16 show a statistically significant decrease (p<0.05) in CEBP 
expression for the adipose cells treated with rilpivirine as compared to control. Treatment with 
quercetin alone or its combination with rilpivirine also showed significant reduction (p< 0.01) in 
CEBP expression levels as compared to control. 
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5.3.6.3 Morphological and quantitative measurement of Perilipin 
 
Figure 5.17: Images A-E showing expression of Perilipin adipogenic marker in human 
subcutaneous adipose cells differentiated for a period of 8 days in the presence of treatment 
drugs using immuno-fluorescence dual staining. Perilipin (green) was detected using periplin 
primary antibody diluted at 1:200 concentration. Nuclei (blue) were stained with DAPI. Cells 
were imaged at 20X magnification with a scale bar of 100 µM.  
A. Negative control without the primary antibody. 
B. Differentiated adipose cells without any drug treatment (Control).  
C. Differentiated adipose cells treated with 15 µM rilpivirine.  
D. Differentiated adipose cells treated with 50 µM quercetin.  
E. Differentiated adipose cells treated with a combination of 15 µM rilpivirine and 50 µM 
quercetin. These images are typical of 3 different experiments. 
The data, presented in figure 5.17 (Images A-E), show a marked increase in the perilipin protein 
levels for adipose cells treated with either rilpivirine alone and in combination. These images for 
perilipin expression were quantified and the results are shown in figure 5.18. 
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Figure 5.18: Bar charts showing the quantitative measurement of Perilipin in human adipose 
cells treated with either rilpivirine or quercetin alone and in combination. Human pre-
adipocytes were differentiated in the presence of indicated concentrations of drugs (15 µM 
rilpivirine, 50 µM quercetin) individually and then in combination. Fluorescence was measured 
at an excitation wavelength of 495 nm and emission at 519 nm for adipose cells on day 8 in 
culture. Statistical analysis was performed using a one-way ANOVA and are presented as means 
of ± S.D from triplicate set of experiments expressed relative to values from untreated control 
cells; *p<0.05 **p<0.01 ***p<0.001 compared to the control. # represents significance 
difference within the treatment groups. 
The results presented in figure 5.18 show significant increases (p<0.05) in perilipin expression 
for adipose cells treated with either rilpivirine or quercetin. Combination of rilpivirine and 
quercetin showed a dramatic and significant (p<0.01) elevation in perilipin expression as 
compared to control. 
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5.3.6.4 Morphological and quantitative measurement of Fatty acid synthase 
 
Figure 5.19: Images A-E showing the expression of fatty acid synthase adipogenic marker in 
human subcutaneous adipose cells differentiated for a period of 8 days in the presence of 
treatment drugs using immuno-fluorescence dual staining. Fatty acid synthase (green) was 
detected using FAS primary antibody diluted at 1:50 concentration. Nuclei (blue) were stained 
with DAPI. Cells were imaged at 20X magnification with a scale bar of 100 µM.  
A. Negative control without the primary antibody.  
B. Differentiated adipose cells without any drug treatment (Control).  
C. Differentiated adipose cells treated with 15 µM rilpivirine. 
D. Differentiated adipose cells treated with 50 µM quercetin.  
E. Differentiated adipose cells treated with a combination of 15 µM rilpivirine and 50 µM 
quercetin. These images are typical of 3 different experiments. 
The morphological data, presented in figure 5.19 (Images A-E), show a reduced expression of 
fatty acid synthese for adipose cells treated with either rilpivirine or quercetin alone and in 
combination. These images for fatty acid synthase expression were quantified and the results 
are shown in figure 5.20. 
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Figure 5.20: Bar charts showing the quantitative measurement of fatty acid synthase in human 
adipose cells treated with either rilpivirine or quercetin alone and in combination. Human pre-
adipocytes were differentiated in the presence of indicated concentrations of drugs (15 µM 
rilpivirine and 50 µM quercetin) individually and then in combination. Fluorescence was 
measured at an excitation wavelength of 495 nm and emission at 519 nm for adipose cells on 
day 8 in culture. Statistical analysis was performed using a one-way ANOVA and are presented 
as means of ± S.D from triplicate set of experiments expressed relative to values from untreated 
control cells; *p<0.05 **p<0.01 ***p<0.001 compared to the control. # represents significance 
difference within the treatment groups. 
The data presented in figure 5.20 show a small but significant (p<0.05) decrease in fatty acid 
synthase levels for adipose cells treated with rilpivirine. Significant reduction (p<0.001) in FAS 
was observed for adipocytes treated with quercetin alone or its combination with rilpivirine. 
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5.3.6.5 Morphological and quantitative measurement of Fatty acid binding protein-4 (FABP4) 
 
Figure 5.21: Images A-E showing the expression of FABP4 adipogenic marker in human 
subcutaneous adipose cells differentiated for a period of 8 days in the presence of treatment 
drugs using immuno-fluorescence dual staining. Fatty acid binding proteins (green) were 
detected using FABP4 primary antibody diluted at 1:200 concentrations. Nuclei (blue) were 
stained with DAPI. Cells were imaged at 20 X magnification with a scale bar of 100 µM.  
A. Negative control without the primary antibody.  
B. Differentiated adipose cells without any drug treatment (Control).  
C. Differentiated adipose cells treated with 15 µM rilpivirine.  
D. Differentiated adipose cells treated with 50 µM quercetin.  
E. Differentiated adipose cells treated with a combination of 15 µM rilpivirine and 50 µM 
quercetin. These images are typical of 3 different experiments. 
The morphological data, presented in figure 5.21 (Images A-E), show a reduced expression of 
FABP4 for adipose cells treated with either rilpivirine or quercetin alone and in combination. 
These images for FABP4 expression were quantified and the results are shown in figure 5.22. 
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Figure 5.22: Bar charts showing the quantitative measurement of fatty acid binding proteins in 
human adipose cells treated with either rilpivirine or quercetin alone and in combination. 
Human pre-adipocytes were differentiated in the presence of indicated concentrations of drugs 
(15 µM rilpivirine and 50 µM quercetin) individually and then in combination. Fluorescence was 
measured at an excitation wavelength of 495 nm and emission at 519 nm for adipose cells on 
day 8 in culture. Statistical analysis was performed using a one-way ANOVA and are presented 
as means of ± S.D from triplicate set of experiments expressed relative to values from untreated 
control cells; *p<0.05 **p<0.01 ***p<0.001 compared to the control. # represents significance 
difference within the treatment groups. 
The data presented in figure 5.22 show significant (p<0.001) differences for all treatment groups 
as compared to control. The results show that rilpivirine can significantly (p<0.001) reduce the 
levels of FABP4. Treatment with quercetin alone and in combination with quercetin also showed 
a sharp and significant (p<0.001) reduction in FABP4 expression.  
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5.3.6.6 Morphological and quantitative measurement of Acetyl coenzyme carboxylase (ACC) 
 
Figure 5.23: Images A-E showing the expression of Acetyl-CoA carboxylase adipogenic marker 
in human subcutaneous adipose cells differentiated for a period of 8 days in the presence of 
treatment drugs using immuno-fluorescence dual staining. ACC (green) was detected using ACC 
primary antibody diluted at 1:200 concentrations. Nuclei (blue) were stained with DAPI. Cells 
were imaged at 20X magnification with a scale bar of 100 µM.  
A. Negative control without the primary antibody.  
B. Differentiated adipose cells without any drug treatment (Control).  
C. Differentiated adipose cells treated with 15 µM rilpivirine.  
D. Differentiated adipose cells treated with 50 µM quercetin.  
E. Differentiated adipose cells treated with a combination of 15 µM rilpivirine and 50 µM 
quercetin. These images are typical of 3 different experiments. 
The morphological data, presented in figure 5.23 (Images A-E), show a reduced expression of 
ACC for adipose cells treated with either rilpivirine or quercetin alone and in combination. These 
images for ACC expression were quantified and the results are shown in figure 5.24. 
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Figure 5.24: Bar charts showing the quantitative measurement of Acetyl-CoA carboxylase in 
human adipose cells treated with either rilpivirine or quercetin alone and in combination. 
Human pre-adipocytes were differentiated in the presence of indicated concentrations of drugs 
(15 µM rilpivirine and 50 µM quercetin) individually and then in combination. Fluorescence was 
measured at an excitation wavelength of 495 nm and emission at 519 nm for adipose cells on 
day 8 in culture. Statistical analysis was performed using a one-way ANOVA and are presented 
as means of ± S.D from triplicate set of experiments expressed relative to values from untreated 
control cells; *p<0.05 **p<0.01 ***p<0.001 compared to the control. # represents significance 
difference within the treatment groups. 
The results presented in figure 5.24 show a small but significant decrease (p<0.05) in the ACC 
expression for adipose cells treated with rilpivirine. Quercetin also reduced the ACC levels, but 
not significantly (p<0.05) different as compared to control. A combination of quercetin and 
rilpivirine evoked a significant (p<0.05) reduction in ACC levels compared to control. 
5.3.7 Gene expression analysis using RT-PCR 
Reverse Transcription-Polymerase Chain Reaction (RT-PCR) was performed to determine the 
level of mRNA expression for adipocyte-specific genes and major adipogenic transcriptional 
factors (PPAR-γ, SREBP-1, C/EBP, LPL, aP2 and FAS) using specific primers and commercially 
available kits. Briefly, on day 8 after differentiation, total RNA was extracted from cultured cells 
and reverse transcribed. PCR analyses were then performed on cDNA preparation aliquots to 
detect mRNA expression. The amount of cDNA templates used for PCR was determined within 
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the linear range. A 10 μL aliquot from each PCR reaction was electrophoresed in a 1.5 % agarose 
gel containing 0.2 μg/mL ethidium bromide. The gel was then photographed under ultraviolet 
transillumination.  The levels of adipogenic marker genes were expressed after normalization 
with the β-actin signal from the same sample. 
 
 
Figure 5.25: Original RT-PCR analysis of the mRNA expression of adipogenic markers. Human 
pre-adipocytes were differentiated in the presence of indicated concentrations of drugs (15 µM 
rilpivirine, 50 µM quercetin) individually and then in combination. After 8 days, the mRNA 
expression levels of PPARγ, C/EBPα, SREBP-1, LPL, FABP4 and FAS were measured using RT-PCR.  
Data from figure 5.25 show that the expression of adipogenic markers is markedly reduced for 
adipose cells treated with either rilpivirine or quercetin when compared to control. This 
reduction is more pronounced when both the drugs are combined. 
5.4 Discussion  
The introduction of highly active antiretroviral therapy (HAART) in the mid-1990s has 
dramatically decreased morbidity and mortality rates among HIV-infected patients (Detels et al., 
1998; Palella et al., 1998).  However, multiple morphologic and metabolic abnormalities have 
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been observed among HAART-treated patients with well-controlled HIV, including subcutaneous 
adipose tissue wasting (lipo-atrophy), central adipose tissue accumulation (lipo-hypertrophy), 
severe dyslipidemia and abnormalities of glucose metabolism. Previous data on anti-retroviral 
drug therapy have demonstrated serious metabolic consequences (FRAM, 2005). Although the 
new anti-retroviral drugs are not free of metabolic abnormalities, previous studies determining 
the effects on metabolic indices and body composition are limited. With this preview, the 
present study was therefore designed and conducted to determine any detrimental effects of 
rilpivirine on adipose cells, a newly developed HIV drug and its nutritional management using 
quercetin. Besides being an anti-inflammatory and anti-oxidative agent,  quercetin has been 
shown to possess anti-viral properties as well  (Mendonça-Murata et al., 2014). 
The experiments in the present study were conducted in two series. In the first series of 
experiments, human subcutaneous adipose cells were treated with rilpivirine or quercetin 
alone. The second series of experiments were conducted to test the role of rilpivirine on the 
adipogenesity of adipose cells in combination with quercetin. 
To measure the cyto-toxicity of cells, human subcutaneous adipose cells were treated with 
various drug concentrations of either rilpivirine or quercetin alone and in combination and 
viability was assessed on day 3 and 15 of culture. The results show that rilpivirine at lower 
concentrations (10 µM and 15 µM) and quercetin at 50 µM   did not alter the viability rate of the 
cells. However, at a concentration of 20 µM, a slight and significant (p<0.05) decrease in the cell 
viability was observed indicating its effect at higher doses. A combination of rilpivirine and 
quercetin at drug concentration of 20 µM and 50 µM respectively, also showed a significant 
(p<0.05) decrease.  
In the next series of experiments, human subcutaneous adipose cells were treated with various 
concentrations of rilpivirine or quercetin alone and then in combination with quercetin for a 
period of 15 days to determine triglyceride accumulation. Previous clinical trials conducted to 
measure the blood triglycerides, total cholesterol, low and high density lipoprotein in patients 
treated with rilpivirine showed substantial increases in these parameters compared to other 
NNRTIs belonging to the same class of antiretroviral drugs (Cohen et al., 2011; Molina et al., 
2011; Nelson et al., 2013). These findings were confirmed by further studies (Wilkin et al., 2012). 
The results from the present study show substantial reduction in the accumulation of 
triglyceride levels for adipose cells treated with either rilpivirine or queretin alone and in 
combination, as evidenced by morphological pictures and quantitative measurement of 
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triglycerides on the 5th, 8th, 11th and 15th day of the differentiation process. As compared to 
control, an altered lipid accumulation was observed in a dose- and time- dependent manner. 
Higher dose concentration of rilpivirine (20 µM) alone or in combination with quercetin severely 
inhibited triglyceride accumulation during adipocyte differentiation. Based on these results, a 
median drug concentration of 15 µM of rilpivirine and differentiation for a period of 8 days was 
chosen for further experiments. 
One of the insights that changed our appreciation of the role of adipocytes over recent years has 
been the discovery of their hormonal role in the regulation of metabolism, energy intake and fat 
storage. It is currently known to secrete a large number of proteins termed adipokines that act 
in an autocrine, paracrine or endocrine fashion to control various metabolic 
functions. Alterations in inflammatory status of adipose tissue with obesity feed a growing 
recognition that obesity represents a state of chronic low-level inflammation. In the present 
study, human subcutaneous adipose cells were treated with various concentrations of either 
rilpivirine or quercetin individually and in combination with quercetin for a period of 8 days. 
Rilpivirine showed a marked reduction in adiponectin levels. Levels of other inflammatory 
markers such as resitin and IL-8 were increased as compared to the untreated cells. No 
significant changes in leptin were observed on treatment of adipose cells with rilpivirine alone 
and its levels were almost comparable to control. However, significant reduction in 
inflammatory markers was observed for adipose cells treated with quecetin alone, thereby, 
revealing its ant-inflammatory properties. Combination of the two drugs together, markedly 
reduced the inflammatory makers. 
Antiretroviral therapy may often result in biochemical and physiological changes e.g. oxidative 
damage resulting from the presence of free radicals or the absence of antioxidants. So far, 
sufficient evidence to substantiate the role of free radicals in mediating oxidative injury is not 
present. Data from a series of previously  conducted studies have reported an increase in 
oxidative stress, in addition to the  persistent redox imbalance associated with HIV-1 infection 
manifested by an increase in oxidants and a decrease in antioxidant serum levels (Masiá et al., 
2007; Mandas et al., 2009; Deavall et al., 2012). Specifically, a study done in 84 HIV infected 
patients during a 6-month period of ART demonstrated a significant increase in serum per-
oxidation potential, total hydro-peroxide and advanced oxidation protein product levels as well 
as a decrease in glutathione level, compared to their levels before the treatment and to healthy 
controls (Gil et al., 2011). An aggravation of the oxidative stress by certain ART regimens in the 
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form of a significant decrease in the levels of GSH (sulfhydryl group) has also been registered 
(Ngondi et al., 2006).  In order to reveal the oxidative status of the adipose cells treated with a 
concentration of 15 µM of rilpivirine individually and then in combination with 50 µM of 
quercetin, biomarkers of oxidative stress were measured quantitatively using commercially 
available kits. The generated oxidative profile in this study revealed a significant decrease in the 
levels of anti-oxidant enzymes like superoxide dismutase, catalase and glutathione for adipose 
cells treated with rilpivirine. The results also show a significant increase in the nitric oxide levels 
indicating its role in mitochondrial dysfunction. This reduction in the anti-oxidant species may 
possibly be attributed to the production of  more oxidized metabolites deriving from the 
interaction between ROS and infected cell biomolecules (de la Asunción et al., 1998; Kumar et 
al., 1999; Hulgan et al., 2003; Lewis, 2003; Cossarizza et al., 2004; Day et al., Lewis, 2004). It may 
further be explained and  supported by several biochemical mechanisms, such as mitochondrial 
interference following treatment with ART (de la Asunción et al., 1998; Cossarizza et al., 2004; 
Day et al., 2004) and activation of the P450 hepatic system (Kumar et al., 1999). Either 
insufficient intake or mal-absorption of nutrients—common in HIV patients—may further 
worsen these conditions (Tang et al., 2005; Drain et al., 2007) .  
 In hope to lessen the side effects of antiretroviral therapy like lipo-dystrophy syndrome, 
rilpivirine at a concentration of 15 µM was supplemented with 50 µM of an anti-oxidant, 
quercetin. The results show that quercetin supplementation significantly ameliorated rilpivirine- 
induced oxidative stress. It was able to prevent injury caused by free radicals by scavenging of 
ROS, activate antioxidant enzymes and mitigate the oxidative stress caused by nitric oxide. In 
previously conducted preclinical in vitro studies, quercetin was shown to  significantly reduce  
levels of inflammatory mediators such as NO synthase  in human hepatocyte-derived cell line 
(García-Mediavilla et al., 2007). Nitric oxide reacts with free radicals, thereby producing high 
damaging peroxynitrite. Peroxynitrite can directly oxidize low density lipoproteins resulting in 
irreversible damage to cell membranes. Quercetin causes scavenging of free radicals; therefore 
can no longer react with nitric oxide, resulting in less damage  (Shutenko et al., 1999). The 
overall increase in the levels of anti-oxidant enzymes when supplemented with quercetin, may 
be attributed to its much reported anti-oxidative and direct radical scavenging properties. 
Quercetin, thus seems to be a  powerful flavonoid for protecting the body against reactive 
oxygen species, produced during the normal oxygen metabolism or are induced by exogenous 
damage (Groot, 1994; Grace, 1994).  
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The process of adipogenesis involves the differentiation of pre-adipocytes into mature 
adipocytes and it plays a key role in the expansion of adipose tissue mass and subsequent 
metabolic syndrome. This process is regulated by an elaborate network of transcription factors 
that coordinate expression of hundreds of proteins responsible for establishing the mature fat-
cell phenotype. At the center of this network are the two principal adipogenic 
factors, PPARγ and C/EBPα, which oversee the entire terminal differentiation process. PPARγ in 
particular is considered as the master regulator of adipogenesis; without it, precursor cells are 
incapable of expressing any known aspect of the adipocyte phenotype (Rosen et al., 2000). On 
the other hand, cells deficient in C/EBPα are capable of adipocyte differentiation; however, 
these C/EBPα-deficient cells are insulin resistant (El-jack et al., 1999; Wu et al., 1999). Both 
PPARγ and C/EBPα are greatly induced during adipogenesis, and they are necessary for the 
expression of many adipogenic genes such as perilipin, ACC, fatty acid synthase (FAS), adipocyte 
fatty acid-binding protein (aP2) (Wu et al., 1999; Farmer, 2005; White et al., 2010), and 
lipoprotein lipase (LPL) (Bae et al., 2014). As described earlier, secondary effects, including 
disturbances in lipid metabolism and ultimately, in adipose tissue distribution and function, are 
common concerns associated with antiretroviral treatments tested so far. It may, therefore, be 
important to study the expression of some of these markers involved in the process of 
adipogenesis. This study provides the first assessment of the effect of rilpivirine on the protein 
and gene expression of important markers involved in the process of adipogenesis. In this study, 
when pre-adipocytes were differentiated in the presence of 15 µM of rilpivirine, the expression 
of PPARγ, C/EBPα and their related genes and markers were highly altered, indicating an 
essential role for these transcription factors in the regulation of adipogenesis.  
In parallel with the suppression of PPARγ and C/EBPα expression by rilpivirine, the expression of 
SREBP-1 and its target genes like FAS, aP2 and LPL were all significantly decreased by rilpivirine 
treatment displaying the lipoatrophic effects of rilpivirine. The results demonstrate that 
rilpivirine alters adipogenesis through the down-regulation of adipogenic transcriptional factors 
and their target genes.  
As adipogenesis plays a key role in obesity, the marked inhibition of adipogenesis by rilpivirine 
treatment and its subsequent amelioration by an herbal supplement may provide a significant 
clue as to the potential mechanisms by which flavonoid supplementation alter the adverse 
metabolic affects induced by antiretroviral drugs. The results from this study, show that 
quercetin treatment at a dosage concentration of 50 µM suppressed the expression of PPARγ, 
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C/EBPα, SREEBP-1 and their target genes. Co-administration of rilpivirine and quercetin further 
down regulated the expression of these markers. 
 In summary, this study reflects the lipoatrophic effects of rilpivirine at high dosage 
concentrations (15 µM) via inhibition of triglyceride accumulation and suppression of crucial 
markers of adipogenesis. It elucidates an increase in the inflammatory markers and suppresses 
the anti-oxidant enzymes. The study also, for the first time, reports co-administration of 
rilpivirine and quercetin. The results demonstrate the potential abilities of quercetin to 
attenuate oxidative damage and decrease inflammatory markers. However, it failed to 
overcome the lipoatrophic affects of rilpivirine. Therefore, the study warrants further 
mechanistic and clinical research studies to develop quercetin as a proven natural and effective 
agent for the ART-induced prevention or treatment of metabolic disturbances. Knowledge of the 
potential interactions between ARVs and plant-derived products is very limited and scanty. 
More research needs to be done to identify potential harmful interactions. The information 
generated needs to be documented and made available to traditional healers, health 
practitioners and also to the HIV-infected individuals so that they can understand the impact 
that those interactions can have on the development of drug resistance and treatment failure. 
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Chapter 6 
 
 
 
 
Effect of 17β-estradiol and quercetin on human subcutaneous 
adipose cells in vitro 
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6.1 Introduction 
It is well established that adipose tissue is a dynamic structure that is involved in the regulation 
of glucose and lipid metabolism, energy homeostasis and inflammation. Functional failure or 
dysfunction of adipose tissue may result in primary defects of obesity and may link excessive fat 
accumulation to several health problems including increased risk of insulin resistance, type 2 
diabetes, fatty liver disease, hypertension, dyslipidemia, atherosclerosis, dementia, and certain 
forms of cancer (Blüher,2013). The female sex hormone, estrogen, has been largely 
demonstrated to regulate adipose development (Björntorp, 1997; Schomberg et al., 1999;  
Heine et al., 2000; Clegg et al., 2006). It is known to promote, maintain, and control the typical 
distribution of body fat and adipose tissue metabolism and improve systemic glucose 
homeostasis in both males and females (Kim et al., 2014). 
Estrogens are a family of compounds that include 17 alpha-estradiol (17α-E2) as well as 17 beta-
estradiol (17 β-E2). 17 β-E2 is the main circulating and biologically most active form of estrogen 
(Mauvais-Jarvis et al., 2013). Although clinical and experimental evidences report estradiol as a 
major regulator of adiposity and regional distributor of fat (Gavin et al., 2013), its exact role on 
the inflammatory and oxidative status during adipocyte differentiation is currently still 
debatable. The underlying mechanisms linking estrogenic regulation in adipose tissue and 
systemic fatty acid metabolism has not yet been fully elucidated and is mainly reported to 
include interactions of estrogen receptor signaling events involving lipolytic and/or lipogenic 
enzyme activity, free fatty acid metabolism and adipocytokine production. An understanding of 
the effects of estrogen replacement on adipose tissue biology and metabolism is therefore 
important in determining the risk of developing obesity-related metabolic disorders in patients 
undergoing treatment for sex hormone deficiency. 
Several plant compounds have been reported to possess estrogenic properties (Badger et al., 
2002; Bhathena et al., 2002; Salleh et al., 2013). Quercetin [2-(3,4-dihydroxyphenyl)-3,5,7-
trihydroxychromen-4-one], the most widely distributed plant flavonoid is one of the major 
constituents of the human diet and is abundantly present in the outer skin of onions, apples, 
and berries (Peluso, 2006; Boots et al., 2008). This compound possesses a broad range of 
biological activities, including anti-inflammatory, anti-pathogenic, anti-oxidant, and immune-
modulatory (Russo et al., 2012).  Due to its ability to bind to the estrogen receptor (ER),  
quercetin has been categorized as a phyto-estrogen (Kuiper et al., 1996; Muthian et al., 2004). 
Apart from ER, quercetin was also reported to bind to the type II estrogen-binding site 
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(Caltagirone et al., 1997). Despite its reported estrogen-like activities, the effect of quercetin on 
uterine morphology and proliferation is currently unknown.  
Aims: Therefore, the aims of the present study were to assess the effects of estradiol and 
quercetin on adipogenic markers, inflammatory markers and intracellular redox processes which 
may be involved in the pathogenesis of adiposity. 
6.2 Materials and methods 
As described in chapter 2. 
6.3 Results 
6.3.1 Measurement of cytotoxicity using lactate dehydrogenase assay 
The human subcutaneous pre-adipocytes were seeded at a density of 2 × 104 cells per well in 24-
well plates and cultured until 90 % confluence in culture medium. The cells were then treated 
with various concentrations of rilpivirine or quercetin either alone and in combination for a 
period of 15 days. As an indicator of cytotoxicity, the cytoplasmic enzyme lactate 
dehydrogenase (LDH) was measured in the culture supernatant of the control as well as treated 
differentiating adipose cells on day 3 and day 15 of culture. An optimized LDH test was used to 
quantify LDH activity in the medium of the treated differentiating adipose cells. The percentage 
of viable cells was calculated by defining the cell viability without treatment as 100 %. 
 
Figure 6.1: Bar graph showing the effect of either estradiol or quercetin either alone or in 
combination on the cell viability as measured by LDH on day 3 of culture. Human 
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subcutaneous adipose cells were treated with various concentrations of indicated drugs either 
alone and in combination. Cytotoxicity was expressed as the percentage of LDH activity in the 
medium as compared to control on day 3 of incubation. Results represent mean ± SEM of 3 
parallel cell culture experiments.  
The results presented in figure 6.1 show no significant (P>0.05) changes in the viability of cells 
when treated with various concentrations of either estradiol or quercetin alone and in 
combination for day 3 of culture.   
 
Figure 6.2: Bar graph showing the effect of either estradiol or quercetin either alone or in 
combination on the cell viability as measured by LDH on day 15 of culture. Human 
subcutaneous adipose cells were treated with various concentrations of indicated drugs either 
alone and in combination. Cytotoxicity was expressed as the percentage of LDH activity in the 
medium as compared to control on day 15 of incubation. Results represent mean ± SEM of 3 
parallel cell culture experiments. *p<0.05 **p<0.01 ***p<0.001 compared to the control. 
The results presented in figure 6.2 show that estradiol at lower concentrations (0.001 µM and 
0.01 µM) and quercetin at 50 µM did not affect the viability rate of the cells. However, at a 
concentration of 0.1 µM of estradiol either alone or in combination with 50 µM of quercetin, a 
significant decrease in cell viability (cell death) (p<0.05 and p<0.01) respectively, was observed 
compared to non-treated cells.  
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6.3.2 Morphological examination of adipose cells using adipoRed staining  
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Figure 6.3: Photographs (36 in all) showing representative time course images (A-I) of 
triglyceride accumulation indicated by lipid formation for human adipose cells in culture. 
Human subcutaneous pre-adipocytes were differentiated and treated with different 
concentrations of either 17β-estradiol (E2) or quercetin individually and then in combination. 
Images were taken for the 5th, 8th, 11th and 15th day of cells in culture at 20x magnification using 
a fluorescence microscope. Staining was done using adipored to visualize lipid content. Images 
are typical of 3 such parallel experiments. 
A. Undifferentiated and untreated (no drugs) adipose cells.  
B. Differentiated and untreated (no drugs) adipose cells.  
C. Adipocytes differentiated and treated with 0.001 µM of estradiol.  
D. Adipocytes differentiated and treated with 0.01 µM of estradiol.  
E. Adipocytes differentiated and treated with 0.1 µM of estradiol.  
F. Adipocytes differentiated and treated with 50 µM of quercetin.  
G. Adipocytes differentiated and treated with a combination of 0.001 µM estradiol and 50 µM 
quercetin. 
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H. Adipocytes differentiated and treated with a combination of 0.1 µM estradiol and 50 µM 
quercetin. 
 I. Adipocytes differentiated and treated with a combination of 0.1 µM estradiol and 50 µM 
quercetin.  
Morphological data presented in figure 6.3 show the accumulation of triglyceride in pre-
adipocytes cultured and differentiated in the presence/absence of treatment drugs either alone 
or in combination. Image A represents undifferentiated and untreated pre-adipocyte cells in 
culture. The data show that the undifferentiated pre-adipocytes appear elongated, fibroblast-
like and spindle shaped and showed no lipid accumulation. Image B represents pre-adipocyte 
cells differentiated for a period of 15 days without any drug treatment (Control). The process of 
adipogenesis progressed in a time-dependent manner (5-15 days) as evidenced by the 
increasing lipid droplets (yellow colour). On day 5, almost none or very little amount of lipid 
droplets was observed. However, by day 8 the cells began to attain a round shape in structure 
and became laden with triglycerides and accumulated substantial lipid content. These lipid 
vacuoles were observed to accumulate more triglycerides and grow more in size and number on 
day 11 and 15 in culture. Images C, D and E represent pre-adipocyte cells treated with different 
concentrations of 0.001 µM, 0.01 µM and 0.1 µM of estradiol respectively. It was observed that 
estradiol inhibited the accumulation of triglycerides in both dose- and time-dependent manner. 
The formation of lipid droplets (yellow colour) decreased with increasing doses and time in 
culture. Image F represents pre-adipocytes treated with 50 µM of quercetin. Pre-adipocytes 
treated with quercetin were shown to inhibit triglyceride accumulation with increasing time in 
culture. The number of lipid droplets decreased from day 8 until day 15 in culture. Images G, H 
and I represent pre-adipocyte cells treated with a combination of 0.001 µM, 0.01 µM, 0.1 µM 
concentrations of estradiol and 50 µM of quercetin, respectively. Adipose cells treated with 
these combinations of drugs showed further attenuation in lipid formation in a time- and dose-
dependent manner. At day 8 of differentiation the adipocyte cells accumulated a substantial 
amount of triglyceride which subsequently diminished gradually until day 15. 
6.3.3 Quantitative measurement of triglycerides 
Triglycerides accumulated over the differentiation period of 15 days were measured 
quantitatively by staining the cells with adipored reagent and the fluorescence was measured at 
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OD value of 572 nm. The data are presented in figure 6.4 (Images A-D for days 5, 8, 11 and 15, 
respectively). 
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Figure 6.4: (For Images A-D): Bar charts showing the effect of estradiol and quercetin 
individually and when in combination on the accumulation of triglyceride by human 
adipocytes in culture. Human pre-adipocytes were differentiated in the presence of indicated 
concentrations of estradiol and quercetin. Values represent concentration of triglyceride in cell 
supernatant for the 5th, 8th, 11th and 15th day of culture. Statistical analysis was performed using 
one-way ANOVA and results are presented as mean ± S.D from triplicate set of experiments 
expressed relative to values from untreated control cells; *p<0.05 **p<0.01 ***p<0.001 
compared to the control. #, $, & indicate significance differences within the treatment groups. 
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The data, presented in figure 6.4 (Taken from Images A-D), show the progression of 
undifferentiated pre-adipocytes into differentiated mature adipose cells over a period of 15 
days either in the presence or absence of indicated concentrations of treatment drugs. Adipose 
cells that were not treated with any drugs (control) showed a significant progression in the 
accumulation of triglycerides over 15 days in culture. Image A shows the accumulation of 
triglycerides on the 5th day of culture. Estradiol at a concentration of 0.001 µM did not exert 
any change in the lipid content. A small, but significant (p<0.05) decrease was observed at a 
concentration of 0.01 µM of estradiol. Adipose cells treated with a dosage of 50 µM evoked a 
significant (p<0.01) reduction in the triglyceride levels. Combination of estradiol and quercetin 
also decreased the triglyceride concentration in a dose-dependent manner. 
The results of triglyceride accumulation were more pronounced on day 8 and day 11 of culture 
(Image B and C). Estradiol at concentrations of 0.01 µM and 0.1 µM induced a significant 
(p<0.001 and p<0.05 for day 8 and p<0.001 and p<0.01 for day 11, respectively) decreases in 
triglyceride levels. Quercetin also inhibited the triglyceride level significantly (p<0.001). When 
the two drugs were combined together, a significant reduction in triglyceride was measured. 
Triglyceride levels for day 15 (Image D) showed substantial reductions for adipose cells treated 
with either estradiol or quercetin alone. This reduction was more pronounced and significant 
(p<0.05) when the two drugs were combined together.  
Overall, the results show that adipose cells treated with either estradiol or quercetin alone and 
in combination significantly (p<0.05) inhibited lipid formation and attenuated triglyceride 
accumulation in a dose- and time-dependent manner. This reduction was more prominent when 
adipose cells were treated with a combination of estradiol and quercetin.  
 6.3.4 Quantitative measurement of pro-inflammatory and anti-inflammatory adipocytokines 
Inflammatory markers of the adipocytokines, including leptin, adiponectin, resistin and 
interleukin-8, were measured quantitatively using commercially available kits. The data are 
presented in figures 6.5 -6.8. 
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6.3.4.1 Quantitative measurement of leptin 
 
 
Figure 6.5: Bar charts showing the effect of estradiol and quercetin individually and when in 
combination on the release of leptin for human adipocytes in culture. Human pre-adipocytes 
were differentiated in the presence of indicated concentrations of drugs (0.01 µM estradiol and 
50 µM quercetin). Values represent the levels of released leptin in the cell supernatant for the 
8th day of culture. Statistical analysis was performed using one-way ANOVA and are presented as 
mean ± S.D from triplicate set of experiments expressed relative to values from untreated 
control cells; *p<0.05 **p<0.01 ***p<0.001 compared to the control. #, $ indicate significant 
differences within the treatment groups. 
The results presented figure 6.5 show a significant elevation in the leptin concentration as 
compared to control when treated with estradiol alone (p<0.001). However, when the 
adipocytes were treated with quercetin alone or in combination with estradiol, leptin levels 
remained largely unaltered. 
 
157 
 
6.3.4.2 Quantitative measurement of adiponectin 
  
Figure 6.6: Bar charts showing the effect of estradiol and quercetin individually and then in 
combination on the release of adiponectin by human adipocytes in culture. Human pre-
adipocytes were differentiated in the presence of indicated concentrations of drugs (0.01 µM 
estradiol and 50 µM quercetin). Values represent concentrations of released adiponectin in the 
cell supernatant for the 8th day of culture. Statistical analysis was performed using one-way 
ANOVA and are presented as mean ± S.D from triplicate set of experiments expressed relative to 
values from untreated control cells; *p<0.05 **p<0.01 ***p<0.001 compared to the control. #, $ 
indicate significant differences within the treatment groups. 
The results presented in figure 6.6 show a small but significant reduction in the levels of 
adiponectin as compared to control when treated with estradiol alone (p<0.05).  Significant 
increases (p<0.01) were observed in the adiponectin concentrations for adipocytes treated with 
quercetin alone or in combination with estradiol. 
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6.3.4.3 Quantitative measurement of resistin 
 
Figure 6.7: Bar graph showing the effect of estradiol and quercetin individually and then in 
combination on the release of adiponectin by human adipocytes in culture. Human pre-
adipocytes were differentiated in the presence of indicated concentrations of drugs (0.01 µM 
estradiol and 50 µM quercetin). Values represent concentrations of released resistin in the cell 
supernatant for the 8th day of culture. Statistical analysis was performed using a one-way 
ANOVA and are presented as mean ± S.D from triplicate set of experiments expressed relative to 
values from untreated control cells; *p<0.05 **p<0.01 ***p<0.001 compared to the control. #, $ 
indicate significant differences within the treatment groups. 
The results presented in figure 6.7 show a significant increase in the resistin concentration as 
compared to control when treated with estradiol alone (p<0.05).  Quercetin alone exerted a 
substantial reduction in the resistin levels when compared to the untreated or control group. A 
significant decrease (p<0.01) in resistin level was observed in the adipocytes treated with a 
combination of estradiol and quercetin when compared to control. 
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6.3.4.4 Quantitative measurement of Interleukin-8  
 
Figure 6.8: Bar charts showing the effect of estradiol and quercetin individually and then in 
combination on the release of interleukin-8 by human adipocytes in culture. Human pre-
adipocytes were differentiated in the presence of indicated concentrations of drugs (0.01 µM 
estradiol and 50 µM quercetin). Values represent concentrations of released interleukin-8 in the 
cell supernatant for the 8th day of culture. Statistical analysis was performed using a one-way 
ANOVA and are presented as mean ± S.D from triplicate set of experiments expressed relative to 
values from untreated control cells; *p<0.05 **p<0.01 ***p<0.001 compared to the control. #, $ 
indicate significant differences within the treatment groups. 
The results presented in figure 6.8 show a significant (p<0.05) reduction in the levels of 
interleukin-8 as compared to control when treated with either estradiol or quercetin alone. 
Similarly, there was a significant (p<0.001) decrease in IL-8 level when estradiol was combined 
with quercetin. 
6.3.5 Quantitative measurement of markers of oxidative stress 
Markers of oxidative stress including nitric oxide, superoxide dismutase, glutathione and 
catalase were measured quantitatively using commercially available kits. The data are presented 
in figures 6.9 -6.12. 
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6.3.5.1 Quantitative measurement of Nitric oxide 
 
 
Figure 6.9: Bar charts showing the effect of estradiol and quercetin individually and then in 
combination on the release of nitric oxide by human adipocytes in culture. Human pre-
adipocytes were differentiated in the presence of indicated concentrations of drugs (0.01 µM 
estradiol and 50 µM quercetin). Values represent concentrations of nitric oxide in the cell 
lysates for the 8th day of culture. Statistical analysis was performed using one-way ANOVA and 
are presented as mean ± S.D from triplicate set of experiments expressed relative to values from 
untreated control cells; *p<0.05 **p<0.01 ***p<0.001 compared to the control. #, $ represents 
significance difference within the treatment groups. 
The data from figure 6.9 show significant reduction in the nitric oxide concentration for adipose 
cells treated with estradiol or quercetin alone (p<0.05 and p<0.01 respectively) as compared to 
control. When the two drugs were combined, further significant decrease (p<0.01) in the nitric 
oxide levels were observed. 
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6.3.5.2 Quantitative measurement of catalase 
 
Figure 6.10: Bar graphs showing the effect of estradiol and quercetin individually and then in 
combination on the catalase activity by human adipocytes in culture. Human pre-adipocytes 
were differentiated in the presence of indicated concentrations of drugs (0.01 µM estradiol and 
50 µM quercetin). Values represent concentrations of catalase enzyme in the cell lysates for the 
8th day of culture. Statistical analysis was performed using a one-way ANOVA and are presented 
as mean ± S.D from triplicate set of experiments expressed relative to values from untreated 
control cells; *p<0.05 **p<0.01 ***p<0.001 compared to the control. #, $ represent significance 
difference within the treatment groups. 
The data from figure 6.10 represent significant increase in the catalase activity for adipose cells 
treated with either estradiol or quercetin alone (p<0.05 and p<0.01 respectively) as compared to 
control. This increase is further enhanced significantly (p<0.01) when the two drugs are 
combined together. 
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6.3.5.3 Quantitative measurement of Superoxide dismutase 
 
 
Figure 6.11: Bar graphs showing the effect of estradiol and quercetin individually and then in 
combination on the superoxide dismutase activity by human adipocytes in culture. Human 
pre-adipocytes were differentiated in the presence of indicated concentrations of drugs (0.01 
µM estradiol and 50 µM quercetin). Values represent concentrations of superoxide dismutase 
enzyme in the cell lysates for the 8th day of culture. Statistical analysis was performed using one-
way ANOVA for equality of variances and are presented as means of ± S.D from triplicate set of 
experiments expressed relative to values from untreated control cells; *p<0.05 **p<0.01 
***p<0.001 compared to the control. #, $ represents significance difference within the 
treatment groups. 
The data from figure 6.11 show significant increase (p<0.05) in SOD levels for adipose cells 
treated with either estradiol or quercetin alone or in combination as compared to control.  
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6.3.5.4 Quantitative measurement of glutathione 
 
 
Figure 6.12: Bar graph showing the effect of estradiol and quercetin individually and then in 
combination on the concentration of glutathione by human adipocytes in culture. Human pre-
adipocytes were differentiated in the presence of indicated concentrations of drugs (0.01 µM 
estradiol and  50 µM quercetin). Values represent concentrations of glutathione enzyme in the 
cell lysates for the 8th day of culture. Statistical analysis was performed using one-way ANOVA 
for equality of variances and are presented as means ± S.D from triplicate set of experiments 
expressed relative to values from untreated control cells; *p<0.05 **p<0.01 ***p<0.001 
compared to the control. #, $ represents significance difference within the treatment groups. 
The results from figure 6.12 show significant increase (p<0.01) in glutathione activity for adipose 
cells treated with a combination of estradiol and quercetin. Only a slight increase (not 
significant) was observed in the glutathione levels of adipose cells treated individually with 
either estradiol or quercetin. 
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6.3.6 Immuno-fluorescence staining using adipogenic marker antibodies 
This series of experiment was designed to demonstrate both the presence and the subcellular 
localization of crucial protein markers involved in the process o adipogenesis. Briefly, adipose 
cells were grown and then treated with either estradiol or quercetin alone and in combination, 
fixed and stained directly in 96 well black-coloured plates using primary antibodies for apecific 
adipogenic markers. Goat anti-rabbit fluorochrome-conjugated secondary antibody, Alexa Fluor 
was used to stain sub-cellular proteins while DAPI was used to stain the nuclei. 
6.3.6.1 Morphological and quantitative measurement of Perilipin 
 
Figure 6.13: Images A-E showing expression of perilipin adipogenic marker in human 
subcutaneous adipose cells differentiated for a period of 8 days in the presence of treatment 
drugs using immuno-fluorosence dual staining. Perilipin (green) was detected using perilipin 
primary antibody diluted at 1:200 concentration. Nuclei (blue) were stained with DAPI. Cells 
were imaged at 20X magnification with a scale bar of 100 µM. Images are typical of triplicate 
series of experiments. 
A). Negative control without the primary antibody.  
B). Differentiated adipose cells without any drug treatment (Control).  
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C). Differentiated adipose cells treated with 0.01 µM estradiol.  
D). Differentiated adipose cells treated with 50 µM quercetin.  
E). Differentiated adipose cells treated with a combination of 0.01 µM estradiol and 50 µM 
quercetin. These images are typical of 3 different experiments. 
Morphological results obtained from figure 6.13 (Images A-E) show increased expression of 
perilipin in adipose cells treated with 0.01 µM estradiol as compared to control. Quercetin also 
induced increased levels of perilipin which subsequently decreased with the combination of the 
two drugs together. 
 
 
Figure 6.14: Bar graphs showing the quantitative measurement of perilipin in human adipose 
cells treated with estradiol and quercetin. Human pre-adipocytes were differentiated in the 
presence of indicated concentrations of drugs (0.01 µM estradiol and 50 µM quercetin) 
individually and then in combination. Fluorescence was measured at an excitation wavelength 
of 495 nm and emission at 519 nm for adipose cells on day 8 in culture. Statistical analysis was 
performed using a one-way ANOVA and are presented as mean ± S.D from triplicate set of 
experiments expressed relative to values from untreated control cells; *p<0.05 **p<0.01 
***p<0.001 compared to the control. #, $ represents significance difference within the 
treatment groups. 
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The results from figure 6.14 show significant (p<0.001) increase in the level of perilipin for 
adipose cells treated with estradiol as compared to control. Treatment with quercetin alone or 
in combination with eatradiol did not show much increase in the perilipin levels and was almost 
comparable to control.  
6.3.6.2 Morphological and quantitative measurement of Fatty acid synthase 
 
 
Figure 6.15: Images A-E showing expression of fatty acid synthase adipogenic marker in 
human subcutaneous adipose cells differentiated for a period of 8 days in the presence of 
treatment drugs using immuno-fluorescence dual staining. Fatty acid synthase (green) was 
detected using fatty acid synthase primary antibody diluted at 1:50 concentration. Nuclei (blue) 
were stained with DAPI. Cells were imaged at 20X magnification with a scale bar of 100 µM.  
Images are typical of triplicate series of experiments. 
A). Negative control without the primary antibody.  
B). Differentiated adipose cells without any drug treatment (Control).  
C). Differentiated adipose cells treated with 0.01 µM estradiol.  
D). Differentiated adipose cells treated with 50 µM quercetin.  
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E). Differentiated adipose cells treated with a combination of 0.01 µM estradiol and 50 µM 
quercetin. These images are typical of 3 different experiments. 
The results from figure 6.15 show a significant  (p<0.05) decrease in the expression of fatty acid 
synthase marker for adipose cells treated with either estradiol or quercetin alone as compared 
to control. This decrease was more pronounced (p<0.05) when adipose cells were treated with a 
combination of these two drugs.  
 
 
Figure 6.16: Bar graph showing the quantitative measurement of periplin in human adipose 
cells treated with estradiol and quercetin. Human pre-adipocytes were differentiated in the 
presence of indicated concentrations of drugs (0.01 µM estradiol and 50 µM quercetin) 
individually and then in combination. Fluorescence was measured at an excitation wavelength 
of 495 nm and emission at 519 nm for adipose cells on day 8 in culture. Statistical analysis was 
performed using a one-way ANOVA and are presented as means of ± S.D from triplicate set of 
experiments expressed relative to values from untreated control cells; *p<0.05 **p<0.01 
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***p<0.001 compared to the control. #, $ represents significance difference within the 
treatment groups. 
The data from figure 6.16 show significant (p<0.001) decrease in the level of fatty acid synthase 
for adipose cells treated with either estradiol or quercetin as compared to control. This 
reduction in fatty acid synthase level was more significantly reduced (p< 0.001) when adipose 
cells were treated with a combination of the two drugs together. 
 
6.3.6.3 Morphological and quantitative measurement of FABP4/aP2 
 
Figure 6.17: Images A-E showing expression of FABP4/aP2 adipogenic marker in human 
subcutaneous adipose cells differentiated for a period of 8 days in the presence of treatment 
drugs using immuno-fluorescence dual staining. FABP4/aP2 (green) was detected using 
FABP4/aP2 primary antibody diluted at 1:200 concentrations. Nuclei (blue) were stained with 
DAPI. Cells were imaged at 20X magnification with a scale bar of 100 µM. The images are typical 
of triplicate set of experiments. 
A). Negative control without the primary antibody.  
B). Differentiated adipose cells without any drug treatment (Control).  
C). Differentiated adipose cells treated with 0.01 µM estradiol.  
D). Differentiated adipose cells treated with 50 µM quercetin.  
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E). Differentiated adipose cells treated with a combination of 0.01 µM estradiol and 50 µM 
quercetin. These images are typical of 3 different experiments. 
Th morphological observations obtained from figure 6.17 show a decrease in the expression of 
FABP4/aP2 marker when the adipose cells were treated with either estradiol or quercetin alone 
or in combination. 
 
 
Figure 6.18: Bar graphs showing the quantitative measurement of FABP4/aP2 in human 
adipose cells treated with estradiol and quercetin. Human pre-adipocytes were differentiated 
in the presence of indicated concentrations of drugs (0.01 µM estradiol and 50 µM quercetin) 
individually and then in combination. Fluorescence was measured at an excitation wavelength 
of 495 nm and emission at 519 nm for adipose cells on day 8 in culture. Statistical analysis was 
performed using a one-way ANOVA and are presented as means of ± S.D from triplicate set of 
experiments expressed relative to values from untreated control cells; *p<0.05 **p<0.01 
***p<0.001 compared to the control. #, $ represents significance difference within the 
treatment groups. 
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The results from figure 6.18 show a significant reduction (p< 0.001) in the level of FABP4/aP2 
when adipose cells were treated with either estradiol or quercetin alone. Also, a significant 
reduction (p <0.001) was measured in the FABP4/aP2 level when the adipose cells were treated 
with a combination of both estradiol and quercetin together. 
7.3.6.4 Morphological and quantitative measurement of acetyl coenzyme-A carboxylase 
 
Figure 6.19: Images A-E showing expression of acetyl coenzyme-A carboxylase adipogenic 
marker in human subcutaneous adipose cells differentiated for a period of 8 days in the 
presence of treatment drugs using immuno-fluorescence dual staining. Acetyl coenzyme-A 
carboxylase (green) was detected using acetyl coenzyme-A carboxylase primary antibody diluted 
at 1:200 concentrations. Nuclei (blue) were stained with DAPI. Cells were imaged at 20X 
magnification with a scale bar of 100 µM. These images are typical of triplicate set of 
experiments. 
A). Negative control without the primary antibody.  
B). Differentiated adipose cells without any drug treatment (Control).  
C). Differentiated adipose cells treated with 0.01 µM estradiol.  
D). Differentiated adipose cells treated with 50 µM quercetin.  
E). Differentiated adipose cells treated with a combination of 0.01 µM estradiol and 50 µM 
quercetin. These images are typical of 3 different experiments. 
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Morphological data from figure 6.19 shows that both estradiol and quercetin evoke a reduction 
in the acetyl coenzyme-A carboxylase expression when adipose cells were treated with estradiol 
or quercetin alone or in combination. 
 
Figure 6.20: Bar graph showing the quantitative measurement of acetyl coenzyme-A 
carboxylase in human adipose cells treated with estradiol and quercetin. Human pre-
adipocytes were differentiated in the presence of indicated concentrations of drugs (0.01 µM 
estradiol and 50 µM quercetin) individually and then in combination. Fluorescence was 
measured at an excitation wavelength of 495 nm and emission at 519 nm for adipose cells on 
day 8 in culture. Statistical analysis was performed using a one-way ANOVA and are presented 
as means of ± S.D from triplicate set of experiments expressed relative to values from untreated 
control cells; *p<0.05 **p<0.01 ***p<0.001 compared to the control. #, $ represents 
significance difference within the treatment groups. 
The results from figure 6.20 show a significant decrease (p<0.01) in the levels of acetyl 
coenzyme-A carboxylase when adipose cells were treated with either estradiol or quercetin 
alone. However, when the two drugs were combined together, a non-significant reduction was 
observed in comparison to the control. 
 
172 
 
6.3.6.5 Morphological and quantitative measurement of PPARγ 
 
 
Figure 6.21: Images A-E showing expression of PPARγ adipogenic marker in human 
subcutaneous adipose cells differentiated for a period of 8 days in the presence of treatment 
drugs using immuno-fluorescence dual staining. PPARγ (green) was detected using PPARγ 
primary antibody diluted at 1:200 concentrations. Nuclei (blue) were stained with DAPI. Cells 
were imaged at 20X magnification with a scale bar of 100 µM. Images are typical of 3 different 
experiments. 
A). Negative control without the primary antibody.  
B). Differentiated adipose cells without any drug treatment (Control).  
C). Differentiated adipose cells treated with 0.01 µM estradiol.  
D). Differentiated adipose cells treated with 50 µM quercetin.  
E). Differentiated adipose cells treated with a combination of 0.01 µM estradiol and 50 µM 
quercetin. These images are typical of 3 different experiments. 
The results from figure 7.21 show an attenuated expression of the PPARγ marker for adipose 
cells treated with either estradiol or quercetin alone or in combination. 
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Figure 6.22:  Bar graph showing the quantitative measurement of PPARγ in human adipose 
cells treated with estradiol and quercetin. Human pre-adipocytes were differentiated in the 
presence of indicated concentrations of drugs (0.01 µM estradiol and 50 µM quercetin) 
individually and then in combination. Fluorescence was measured at an excitation wavelength 
of 495 nm and emission at 519 nm for adipose cells on day 8 in culture. Statistical analysis was 
performed using a one-way ANOVA and are presented as means of ± S.D from triplicate set of 
experiments expressed relative to values from untreated control cells. *p<0.05 **p<0.01 
***p<0.001 compared to the control. #, $ represent significant difference within the treatment 
groups. 
The data from figure 6.22 show significant (p<0.05, p<0.01) attenuation in the PPARγ expression 
for adipose cells treated with either estradiol or quercetin respectively. A significant decrease 
(p<0.01) in PPARγ was measured for adipose cells treated with a combination of estradiol and 
querectin in comparison to control. 
 
 
174 
 
6.3.6.6 Morphological and quantitative measurement of CCAAT/enhancer-binding protein 
(CEBP) 
 
Figure 6.23: Images A-E showing expression of CCAAT/enhancer-binding protein adipogenic 
marker in human subcutaneous adipose cells differentiated for a period of 8 days in the 
presence of treatment drugs using immuno-fluorescence dual staining. CCAAT/enhancer-
binding protein (green) was detected using CCAAT/enhancer-binding protein primary antibody 
diluted at 1:200 concentration. Nuclei (blue) were stained with DAPI. Cells were imaged at 20X 
magnification with a scale bar of 100 µM. The images are typical of 3 different experiments.  
A). Negative control without the primary antibody.  
B). Differentiated adipose cells without any drug treatment (Control).  
C). Differentiated adipose cells treated with 0.01 µM estradiol.  
D). Differentiated adipose cells treated with 50 µM quercetin.  
E). Differentiated adipose cells treated with a combination of 0.01 µM estradiol and 50 µM 
quercetin. These images are typical of 3 different experiments. 
Morphological data presented infigure 6.23 show a repression in the CCAAT/enhancer-binding 
protein marker when adipose cells were treated with either estradiol or quercetin alone or in 
combination. 
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Figure 6.24: Bar graphs showing the quantitative measurement of CCAAT/enhancer-binding 
protein in human adipose cells treated with estradiol and quercetin. Human pre-adipocytes 
were differentiated in the presence of indicated concentrations of drugs (0.01 µM estradiol and 
50 µM quercetin) individually and then in combination. Fluorescence was measured at an 
excitation wavelength of 495 nm and emission at 519 nm for adipose cells on day 8 in culture. 
Statistical analysis was performed using a one-way ANOVA and are presented as mean ± S.D 
from triplicate set of experiments expressed relative to values from untreated control cells; 
*p<0.05 **p<0.01 ***p<0.001 compared to the control. #, $ represents significance difference 
within the treatment groups. 
The results presented in figure 6.24 show a significant (p< 0.01) decrease in CCAAT/enhancer-
binding protein when adipose cells were treated with either estradiol or quercetin alone in 
comparison to the control. However, when adipose cells were treated with a combination of 
estradiol and quercetin, the results show a non-significant reduction (p>0.05) as compared to 
control. 
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6.3.7 Gene expression analysis using RT-PCR 
Reverse Transcription-Polymerase Chain Reaction (RT-PCR) was performed to determine the 
level of mRNA expression for adipocyte-specific genes and major adipogenic transcriptional 
factors (PPAR-γ, SREBP-1, C/EBP, LPL, aP2 and FAS) using specific primers and commercially 
available kits. Briefly, on day 8 after differentiation, total RNA was extracted from cultured cells 
and reverse transcribed. PCR analyses were then performed on cDNA preparation aliquots to 
detect mRNA expression. The amount of cDNA templates used for PCR was determined within 
the linear range. A 10 μL aliquot from each PCR reaction was electrophoresed in a 1.5% agarose 
gel containing 0.2 μg/mL ethidium bromide. The gel was then photographed under ultraviolet 
transillumination.  The levels of adipogenic marker genes were expressed after normalization 
with the β-actin signal from the same sample. 
 
 
Figure 6.25: RT-PCR analysis of the mRNA expression of adipogenic markers. Human pre-
adipocytes were differentiated in the presence of indicated concentrations of drugs (0.01 µM 
estradiol, 50 µM quercetin) individually and then in combination. After 8 days, the mRNA 
177 
 
expression levels of PPARγ, C/EBPα, SREBP-1, LPL, FABP4 and FAS were measured using RT-PCR. 
The PCR gel are typical of 3 different experiments. 
The data from figure 6.25 show that the expression of adipogenic markers is significantly 
(p<0.05) reduced for adipose cells treated with either estradiol or quercetin when compared to 
control. This reduction is more pronounced when both the drugs are combined. 
 
6.4 Discussion 
It is now well acknowledged that adipose tissue is a true endocrine-secreting organ, releasing 
such hormones as cytokines, chemokines, growth factors and others which in turn can influence 
metabolism. It is also recognized as a target for sex steroids since sex steroid receptors are 
expressed both in rat and human adipose tissues. In particular, 17β-estradiol (E2) has been 
recognized as a major factor in regulating adipose tissue metabolism in females. It has been 
reported that ovary-ectomy in rodents leads to weight gain, primarily in the form of adipose 
tissue, which is reversed by physiologic estrogen replacement (Jeong et al., 2004; Jeong et al., 
2012). Loss of circulating estrogen has been shown to be associated with an increase in 
adiposity during menopause, whereas postmenopausal women who receive estrogen 
replacement therapy do not display the characteristic abdominal weight gain pattern usually 
associated with menopause (Carani et al., 1997). Estradiol also plays an important role in 
regulating adipocyte differentiation and development. It has been reported to repress 
adipogenic differentiation and maturation via an estrogen receptor (ER)-dependent mechanism 
in human and mouse bone marrow stromal cells (Okazaki et al., 2002). In parallel, several plant 
compounds have been reported to mimic estrogenic properties. The phytoestrogen genistein, 
which has high affinity for estrogen receptors has been demonstrated to inhibit  adipocyte 
differentiation, lipid accumulation, and the expression of adipocyte-specific genes in primary 
human adipocytes (Heim et al., 2004; Park et al., 2009). Estradiol was also reported to stimulate 
the proliferation of human pre-adipocytes, which can remain undifferentiated cells, into 
adipocytes (Roncari et al., 1978).  
In order to understand the effect of 17β-estradiol (E2) on the differentiation of human 
subcutaneous adipose cells and determine the optimal dose concentration, pre-adipocytes were 
treated with pharmacological concentrations of 17β-estradiol and the viability of the cells was 
determined by LDH assay. Initial results show that 7β-estradiol treatment up to a dosage 
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concentration of 0.1 µM had no significant effect on cell viability on day 3 of culture. However, 
on day 15, the results show that either estradiol at lower concentrations (0.001 µM and 0.01 
µM) or quercetin at 50 µM did not affect the viability rate of the cells. However, at a 
concentration of 0.1 µM of estradiol either alone or in combination with 50 µM of quercetin, 
significant decreases in cell viability (p<0.05 and p<0.01) respectively, were observed.  
These doses were also tested to assess their effects on triglyceride accumulation. The 
triglyceride content of intracellular fat droplets, as evidenced by adipo-red staining and 
quantitative measurement using fluorimeter, was attenuated by 17β-estradiol in both a dose-
dependent and time dependent manner suggesting that 17β-estradiol treatment reduces 
triglyceride accumulation in human subcutaneous pre-adipocyte cells undergoing 
differentiation. The present literature indicates that estradiol (E20 can have an effect on 
adipocyte differentiation, although the reports in this area are not entirely consistent. Studies 
with rat pre-adipocytes indicate that E2 stimulates differentiation of these cells into adipocytes 
(Dieudonne et al., 2000). In contrast to these findings, other results have indicated that E2 can 
inhibit differentiation of adipocytes in the 3T3-Ll cell line (Lea-Currie et al., 1999). The inhibitory 
effects of estrogen on adipocyte differentiation reported in this study are consistent with 
numerous other reports (Okazaki et al., 2002; Heim et al., 2004; Dang et al., 2009) showing that 
estrogen inhibits adipogenesis in primary bone marrow stromal cell cultures or bone marrow 
stroma cell lines.  
Based on these preliminary studies, optimal concentrations of 0.01 µM of estradiol and 50 µM 
of quercetin were chosen for subsequent experiments. The finding that obesity is associated 
with a systemic low-grade inflammatory state and that inflammation mediates many of the 
pathological consequences of obesity has opened up new avenues to the study of the 
interactions between metabolic and immunological processes (Mathis et al., 2011). Besides its 
role as a fat storing organ, adipose tissue is well recognized as an endocrine organ secreting a 
number of adipocytokines such as adiponectin, leptin, resistin and IL-8 (Ordovas et al., 2008). 
Some of these factors have been reported to be the culprit of low-grade inflammation in obesity 
(Kershaw et al., 2004; Lafontan, 2004). Since estrogens have a role in adipocyte metabolism, as 
well as fat distribution, studying the modulation of adipokine production and its release may be 
of patho-physiological importance.  
The next series of experiments was thus conducted to study the role of either estradiol or 
quercetin alone or in combination on adipose cells in vitro on some of these inflammatory 
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markers.  Several previously conducted studies have shown that estrogen may contribute to the 
prevention and/or improvement of obesity-related metabolic syndromes by altering the 
production of adipocytokines in rodents, monkeys and humans (Hong et al., 2007; Kafkas et al., 
2012; Shaw et al., 2013). One of the adipo-cytokines that shows a strong correlation with 
estrogen is leptin. It is a key metabolic hormone involved in the central regulation of 
metabolism and transfers a catabolic signal to the brain to inhibit food intake and increase 
energy expenditure (Ahima et al., 1999; Elmquist et al., 1999). Data from the present study 
show increased leptin levels when adipose cells were treated with estradiol in comparison to 
non-treated cells. These results are in parallel with other studies showing increased levels of 
leptin in adipose tissue when treated with estrogen (Shimizu et al., 1997; Fungfuang et al., 
2013). Leptin levels remained unaltered when adipose cells were treated with either quercetin 
alone or in combination with estradiol. Adiponectin is another insulin-sensitive hormone and 
plays a central role in lipid and glucose metabolism. However, unlike other adipokines, the 
plasma level of adiponectin is inversely correlated with body mass index. In the present study, 
17β-estradiol dramatically suppressed the level of adiponectin. This decrease in adiponectin 
concentration seems to be associated with insulin resistance and other related disorders 
(Kowalska et al., 2008). In another study on adipocytes, estrogen treatment suppressed 
adiponectin mRNA and protein expression, and this effect was blocked by treatment with an 
estrogen antagonist (Combs et al., 2003). It may therefore be indicated that estradiol may exert 
protective effects against insulin resistance and obesity through the regulation of adiponectin 
production.  Treatment of adipose cells with quercetin alone or in combination with estradiol 
significantly increased adiponectin levels demonstrating the anti-inflammatory properties of 
quercetin.   
Resistin is a  cysteine-rich hormone that was first isolated from adipose tissues and found to link 
obesity to T2DM in rodents (Steppan et al., 2001).  The involvement of resistin in obesity and 
insulin resistance in humans is still controversial. Several studies have shown no relationship of 
resistin gene expression with body weight or insulin resistance (Koerner et al., 2005), while 
others found that resistin mRNA expression in adipose tissues of obese humans is higher than 
that in normal subjects (McTernan et al., 2002). A single-nucleotide polymorphism in the resistin 
gene promoter was reported to be  associated with obesity and diabetes (Engert et al., 2002; 
Pizzuti et al., 2002) and that the plasma resistin levels were elevated in patients with obesity 
(Degawa-Yamauchi et al., 2003) and T2DM (Youn et al., 2004). The present study showed 
copiously elevated resistin concentration levels when adipose cells were treated with estradiol. 
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This increase in resistin concentration may be attributed to the expression of CEBPα which acts 
as a transcriptional activator of resistin. This implication is also indirectly supported by the 
findings that a functional C/EBP-binding site was found in the proximal resistin promoter of both 
murine and human adipocytes to be necessary for the stimulation of transcription from resistin 
promoter (Hartman et al., 2002; Song et al., 2002; Seo et al., 2003) and that endogenous C/EBP 
was bound to the resistin promoter in adipocytes in association with p300 and CREB-binding 
protein, which are viewed as co-activators involved in ER activation (Nilsson et al., 2001). 
Adipose cells treated with quercetin alone or in combination with estradiol showed decreased 
resistin concentration in adipose cells. 
 Although not much studied, IL-8 has been reported to be produced and released from human 
adipose tissue in regulated manner (Bruun et al., 2001; Gerhardt et al., 2001). Besides the 
participation in inflammatory processes, its involvement has been suggested in the 
development of obesity-associated insulin resistance (Kern et al., 2001), atherosclerosis and 
cardiovascular disease (Boisvert et al., 2000; Schieffer et al., 2000). The present study showed 
significant reduction in IL-8 levels when adipose cells were treated with either estradiol or 
quercetin alone or in combination, suggesting the protective effects of these two drugs on the 
development of metabolic syndrome.  
Oxidative stress reflects an imbalance between systemic production of reactive oxygen species 
(ROS) and a biological system's ability to readily detoxify the reactive intermediates or repair the 
resulting damage. Disturbances in the normal redox state of cells can cause toxic effects through 
the production of peroxides and free radicals that damage all components of the cell, including 
proteins, lipids, and DNA (Lu et al., 2009). Furthermore, some reactive oxidative species act as 
cellular messengers in redox signaling.  Thus, oxidative stress can cause disruptions in the 
normal mechanisms of cellular signaling. In humans, oxidative stress is thought to be involved in 
the pathogenesis and development of metabolic syndrome. The present study, on human 
adipocytes in vitro, shows that both estradiol and quecetin can decrease the nitric oxide levels 
and increase the anti-oxidant enzyme activities suggesting a protective role of these drugs in 
adipose tissue. 
The differentiation of preadipocytes into adipocytes involves exposure of a confluent, quiescent 
population of cells to a variety of effectors that activate a cascade of transcription factors. This 
cascade begins with the CCAAT/enhancer-binding protein (C/EBP)-β and C/EBP-γ, which finally 
induce the expression of C/EBP-α and peroxisome proliferator-activated receptor PPAR-γ 
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(Morrison and Farmer, 1999; Rosen et al., 2000). These transcription factors coordinate the 
expression of genes involved in creating and maintaining the adipocyte phenotype, including the 
genes for adipocyte fatty acid binding protein (aP2), lipoprotein lipase (LPL) and leptin 
(Tontonoz et al., 1994). The present study aimed to study the protein and gene expression of 
some of these adipogenic markers in human subcutaneous adipose cells treated with either 
estradiol or quercetin alone or in combination. In addition to measuring PPAR-γ and C/EBPα as 
indicators of adipogenesis, lipid accumulation and lipogenic genes, such as SREBP1-c and its 
target genes like perilipin, fatty acid synthase (FAS), acetyl-CoA carboxylase (ACC) and adipocyte 
fatty acid binding protein (aP2) were used to determine the degree of differentiation and 
lipogenesis. Interestingly, the protein levels of lipid droplet protein, perilipin were significantly 
elevated for adipose cells treated with either estradiol or quercetin individually or in 
combination. Increased perilipin expression has been reported to suppress basal lipolysis and 
increase stimulated lipolysis (Souza et al., 2002). The results suggest that both estradiol and 
quercetin treatment enhance the lipolytic rate and may induce reductions in adipocyte size. The 
results of this study also reveal reduced expression of adipogenic markers that promote 
adipocyte lipid storage. These include lipoprotein lipase (LPL), which promotes adipocyte uptake 
of circulating lipids for triglyceride formation, and the lipogenic markers such as acetyl-CoA 
carboxylase, fatty acid binding protein and fatty acid synthase. Fatty acid metabolism is 
stringently controlled to balance synthesis (e.g., lipogenesis) and degradation (e.g., β-oxidation) 
in response to various physiological signals. Sterol regulatory element-binding proteins (SREBPs), 
transcription factors have been reported to be associated with lipogenesis and known to 
regulate the expression of ACC and FAS (Kolehmainen et al., 2001). SREBP-1c expression was 
markedly reduced by estradiol and quecetin treatment. Consequently, the expression of its 
downstream target genes such as ACC and FAS was also suppressed, suggesting that both 
estradiol and quercetin can effectively reduce lipid accumulation by inhibiting lipid synthesis 
through the SREBP-1c pathway. In parallel to the reduced expression of adipogenic markers 
promoting lipid storage, both estradiol and quercetin greatly reduced the expression of PPARγ 
and CCCAT/enhancer binding protein-α (C/EBPα). Both of these transcriptional factors play a 
crucial role in adipocyte differentiation. It may therefore be indicated that the inhibitory effects 
of estradiol and quercetin on differentiation of pre-adipocytes might be due to the inhibition of 
PPARγ and C/EBPα expression.  
In conclusion, the data from the present study suggest that both estradiol and quercetin can 
promote leanness in part by reducing adipocyte size through reduced uptake of fatty acids and 
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reduced lipogenesis. Quercetin, at a concentration of 50 µM, mimics estrogenic properties and 
acts as a phyto-estrogen. It could be used to replace estrogen, for example, in the therapy of 
postmenopausal estrogen deficiency. However, it should be applied with great precaution since 
most phyto-estrogens have antagonistic effects at different doses. More studies are therefore 
warranted in this regard. 
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General Discussion, Conclusion, Limitations and Scope for Future 
Study. 
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7.1 Discussion and Conclusion 
Numerous epidemiological studies report a global increase in the prevalence of obesity at 
alarming rates in the current modern societies (Kosti et al.,2006; Bn et al., 2007; Knai et al., 
2007; Kim et al., 2012). It is a major global health problem currently affecting over 50% of the 
world’s population. It is prevalent at all ages including babies. Both visceral as well as 
subcutaneous adipose tissue can accumulate fat, mainly as a result of poor nutritional habits 
and lack of physical activity. In turn, these are clearly responsible for increased body weight, 
which in turn underlies an elevated risk of diabetes and cardiovascular complications. Although 
it seems that individuals with higher body mass index (BMI) are prone to cardiovascular events, 
reasons for this connection are not entirely clear. Over the last few decades some mechanisms 
of diseases, especially in association with recently described dysregulation of the adipose tissue 
due to certain medications/drugs were discovered, shedding light on the pathophysiology of 
obesity-associated metabolic alterations.  
On the grounds of the deregulated physiology of adipose tissue, investigation of the functions of 
distinct cytokines, overall redox status, transcriptional regulation and protein expression of 
crucial adipogenic markers may provide new insights and comprehension of the 
pathophysiology of T2DM and cardiovascular diseases, as well as specific targets for future 
therapeutic approaches. Furthermore, diagnostic tools based on knowledge about the complex 
interactions between metabolic and inflammatory pathways, might indicate more precisely 
which patients are under increased risk, prompting physicians to offer differentiated and 
optimized therapeutic approaches.  
This study was therefore, particularly designed with the knowledge that certain medications or 
many drugs such as paracetamol, caffeine, rilpivirine, estradiol, β-naphthoflavone (BNF), to 
name a few, may contribute significantly to the process of adipogenesis, broadly termed as 
drug-induced metabolic alterations. The findings of the study have been presented in chapters 
3-8 of this thesis. The study employed an in vitro adipocyte cell model in tackling the scientific 
problems. The main findings are summarized in figure 7.1. 
The major findings of this study included the following: 
1. Caffeine contains potent lipolytic effects, but no significant effect on the process of 
adipogenesis itself. 
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2. Paracetamol appears to have no significant effect on the process of lipolysis, but it can 
reduce triglyceride concentrations indicating that the independent use of paracetamol may 
contain anti-adipogenic effects and thereby prevent triglyceride formation. 
3. BNF has inhibitory effects on lipolysis and attenuates any potent lipolytic effects 
expressed by the use of caffeine and paracetamol. 
4. A combination of rilpivirine and 17β-estradiol at dose concentrations of 10 µM and 0.1 
µM respectively, is completely non-toxic to pre-adipocytes at most concentrations tested. 
During the 10-day exposure to the drugs, only estradiol alone produced a modest cytotoxic 
effect. No profound deleterious effect was observed on adipose tissue development or the 
endocrine function of adipose tissue (adipokine and cytokine release) in treated 3T3-L1 human 
pre-adipocytes. 
5. This study reflects the lipo-atrophic effects of rilpivirine at high dosage concentrations 
(15 µM) via inhibition of triglyceride accumulation and suppression of crucial markers of 
adipogenesis. 
6. The results of this study demonstrate the potential abilities of quercetin to attenuate 
oxidative damage and decrease inflammatory markers. However, it failed to overcome the lipo-
atrophic effects of rilpivirine. 
7. Both estradiol and quercetin can promote leanness in part by reducing adipocyte size 
through reduced uptake of fatty acids and reduced lipogenesis. Quercetin at a dosage 
concentration of 50 µM mimics estrogenic properties and acts as a phytoestrogen. 
This discussion will now focus on the results present in each chapter critically comparing the 
present results with other studies. 
Chapter 3 of this study investigated the effects of caffeine, paracetamol and β-naphthoflavone 
(BNF) on the differentiation of human adipose derived mesenchymal stem cells. Adipose cells 
were cultured in vitro using differentiation inducing media with and without the presence of 
different combinations of the drugs. Markers of adipogenesis were evaluated using biochemical 
assays including triglyceride and glycerol quantification. The results show an increase in glycerol 
levels for cells treated with caffeine suggesting its anti-adipogenic characteristics through the 
enhancement of the lipolytic process. This inhibition of adipogenesis by caffeine has been 
previously supported by other studies (Su et al., 2013). Paracetamol also appears to have anti-
186 
 
adipogenic effects due to its apparent role in suppressing the accumulation of triglycerides. In 
addition, the use of β-naphthoflavone, an artificially synthesized flavanoid, in combination with 
caffeine and paracetamol further attenuated triglyceride accumulation as compared to the drug 
used without its supplementation. These results suggest important anti-adipogenic properties of 
β-naphthoflavone. From these findings, it is possible to conclude that caffeine, paracetamol and 
BNF can exert anti-adipogenic and lipolytic properties during obesity. Preliminary data obtained 
from this study show that these drugs may be utilized as therapeutic targets for the treatment 
of obesity. The results obtained in the current study corroborate similar finds by other workers 
(Zheng et al., 2014; Han et al., 1999; Astrup et al., 1990; Astrup et al., 1992). 
Chapter 4 investigated the inflammatory status of 3T3-L1 human pre-adipocytes when treated 
with different concentrations of either rilpivirine or estradiol alone and in combination with β-
naphthoflavone, (BNF), a potent agonist of the aryl hydrocarbon receptor. Rilpivirine is a non-
nucleoside reverse transcriptase inhibitor, recently developed as a drug of choice for initial anti-
retroviral (ARV) treatment of HIV-1 infection, whereas estradiol is a major component of 
hormonal contraceptives. Both of these drugs have effects on lipid metabolism, impairment of 
adipocyte differentiation and alteration of adipose tissue distribution and function. After 10 
days of differentiation procedure, cells were examined for their morphology and viability. 
Glycerol, adiponectin, leptin, resistin and interleukin-8 (IL-8) were quantified using commercially 
available kits. The results show that either rilpivirine or estradiol individually or during their 
combination can evoke significant increases in glycerol release and a concomitant significant 
decrease of adiponectin from adipocytes. These effects were dose–dependent. The effects of 
combined treatments were much larger than individual concentration for each drug. Both drugs 
had little or no effect on leptin levels, except for a small decrease with 10 µM rilpivirine alone or 
when combined with estradiol. In addition, both drugs evoked small increases in the release of 
resistin and interleukin-8 with significant values at higher doses compared to untreated 
adipocytes. When adipocytes were pretreated with BNF or combined with either rilpivirine or 
estradiol, they evoked a much larger release in glycerol and a much larger decrease in 
adiponectin compared to the absence of BNF. In contrast, BNF treatment had little or no effect 
on either leptin, resistin or IL-8 metabolism compared to the results obtained in the presence of 
either rilpivirine or estradiol alone or in combination. These results show that rilpivirine and 
estradiol either alone or when combined or pretreated with BNF can evoke marked effects on 
glycerol and cytokines levels from adipocytes.  
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From the results of this study, it is possible to conclude that a combination of rilpivirine and 17β-
estradiol is completely non-toxic to pre-adipocytes at most concentrations tested. During the 
10-day exposure to the drugs, only estradiol produced a modest cytotoxic effect at the highest 
concentrations. No profound deleterious effect was found on either adipose tissue development 
or the endocrine function of adipose tissue (adipokine and cytokine release) in treated 3T3-L1 
human pre-adipocytes. However, caution should be maintained considering that other 
transcriptional factors play a crucial role in overall alterations of lipid metabolism. BNF does not 
seem to significantly interact with rilpivirine and 17β-estradiol except for the release of 
adiponectin. Moreover, in order to establish and elucidate a significant effect of these drugs on 
the adipogenic process, studies at gene expression levels and involving the markers of oxidative 
stress are required. 
Lower atherogenic lipid profile may be among the various factors to consider when selecting the 
most appropriate initial anti retroviral regimen, particularly for those HIV-1 patients with a 
significant prior coronary heart disease risk. Including such a consideration seems warranted, 
since treatment of the ART-induced lipid changes with currently licensed lipid lowering agents is 
not without problems. The newer classes of ART, including rilpivirine, are still in the early phase 
of treatment, and studies determining the effects on metabolic indices and body composition 
are limited. Data to date suggest fewer metabolic consequences of newer ART compared with 
older regimens. However, potential metabolic complications have been identified early in the 
development of these agents which warrants awareness and merits further long -term studies.  
Chapter 5 of this study provides a detailed assessment of the action of rilpivirine on human 
adipocytes. The study concludes that rilpivirine exerts lipo-atrphic effects on adipose cells by 
impairing triglyceride accumulation, increasing inflammation, repressing anti-oxidant enzymes 
and inhibiting the expression of genes controlling adipogenesis (PPARg, C/EBPa, SREBP-1c, fatty 
acid synthase and aP2). The results confirm previous findings of mitochondrial DNA depletion, 
inflammation, and disturbances in adipogenesis in lipoatrophic fat in adipose cells on treatment 
with other antiretroviral drugs. The effects of rilpivirine were qualitatively similar to those of 
efavirenz reported previously in closely related human cell culture models (Gallego-Escuredo et 
al., 2010; Díaz-Delfín et al., 2011, 2012). An analysis of the effects of efavirenz and elvitegravir at 
similar concentrations, especially in the range between 0.5 and 2 mM, indicated that efavirenz 
exerted similar but somewhat stronger deleterious effects on adipogenesis (e.g. adipose 
morphology, PPARg and GLUT4 expression) than elvitegravir. 
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 Administration of ART can greatly reduce HIV-related inflammation. This inflammation is 
normally exerted in the form of altered cytokine release, adipocyte dysfunction, metabolic 
disturbances and oxidative stress are part of the body's effort to fight the virus. Unfortunately, 
medications do not completely eliminate the inflammation. The immune system continues to be 
activated and low-level inflammation persists even when the viral load is undetectable. In the 
recent years, research findings on the benefits of anti-oxidant foods and supplements like 
ginger, turmeric, cherries, onions, garlic, vitamin c and E, foods rich in omega -3 fatty acids etc. 
have been employed in countering both oxidative stress and inflammation and to reduce the 
adverse side effects of ART. Combining the presently available natural flavanoids with anti-
inflammatory and anti oxidative properties and help to overcome the side effects incurred due 
to the anti-retroviral therapy. The present study also focused on the combinatory effects of 
rilpivirine and quercetin. The results conclude that quercetin was able to decrease inflammation 
and restore the levels of anti-oxidant enzymes but failed to overcome the lipoatrophic effects of 
rilpivirine (Asrer et al., 2005; Murata et al., 2014; Saravanan et al., 2015). 
As more research studies are trying to progress towards a cure to prevent HIV, novel ART are 
actively being developed, which may be able to control viral suppression and simultaneously 
inhibit critical inflammatory and atherogenic pathways. Taken together, the positive effects of 
ART on viral suppression far outweigh negative effects on metabolic indices, but future studies 
should focus on the development of even more potent novel strategies with optimal 
immunomodulatory and metabolic profiles. So far, the data from the present study seem to 
suggest that the use of antioxidative dietary flavonoids such as quercetin may not be seen as a 
promising approach in the prevention of adverse metabolic syndrome induced by ART. 
Estrogens are crucial hormonal regulators of systemic energy homeostasis in both sexes, and 
there is increasing evidence that E2 treatment exhibits a protective effect in humans and 
rodents against the development of obesity-related metabolic disorders such as type 2 diabetes 
via the regulation of adipose tissue metabolism. Quercetin is a phytoestrogen that exerts both in 
vitro agonistic and antagonistic activities on estrogen receptors. Chapter 6 of this study was 
designed to elucidate the role of 17β-estradiol on human subcutaneous cells in vitro either 
individually or in combination with quercetin. Despite data demonstrating that estrogen 
functions as a negative regulator of adipose development, it has also been suggested that E2 
can stimulate adipocyte proliferation and differentiation. It is further reported that E2 can 
enhance the proliferative capacities of subcutaneous preadipocytes from female rats, but not 
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from male rats (Dieudonne et al., 2000). In human preadipocytes, E2 stimulates cell proliferation 
in a dose-dependent manner with a higher response to E2 in women than in men (Anderson et 
al., 2001). A more recent report showed that estrogen sulfotransferase (EST), a cytoplasmic 
enzyme that inactivates estrogens through sulfation of their hydroxyl group, inhibited adipocyte 
differentiation in 3T3-L1 cells, and overexpression of EST in the adipose tissue of female mice 
resulted in a smaller adipocyte size (Wada et al., 2011). Taken together, estrogens may regulate 
adipose development with depot- and gender-specific differences, but their effects in the 
context of adipose tissue function remain unclear. In the present study both estradiol and 
quercetin eitherindividually and in combination attenuated lipid accumulation as determined by 
adipo red staining and quantitative triglyceride measurement in a dose-dependent manner. 
Number of previously conducted studies have shown that estrogen may contribute to the 
prevention and/or improvement of obesity-related metabolic syndromes by altering the 
production of adipocytokines in rodents, monkeys and humans (Hong et al., 2007; Kafkas et al., 
2012; Shaw et al., 2013). One of the adipocytokines that shows a strong correlation with 
estrogen is leptin. Data from the present study show increased leptin levels when adipose cells 
were treated with estradiol in comparison to non-treated cells. These results are in parallel with 
other studies showing increased levels of leptin in adipose tissue when treated with estrogen 
(Shimizu et al., 1997; Fungfuang et al., 2013). Leptin levels remained unaltered when adipose 
cells were treated with quercetin alone or in combination with estradiol. In the present study, 
17β-estradiol dramatically suppressed the level of adiponectin. This decrease in adiponectin 
concentration seems to be associated with insulin resistance and other related disorders 
(Kowalska et al., 2008). Treatment of adipose cells with quercetin alone or in combination with 
estradiol significantly increased adiponectin levels demonstrating the anti-inflammatory 
properties of quercetin.  The present study showed copiously elevated resistin concentration 
levels when adipose cells were treated with estradiol. This increase in resistin concentration 
may be attributed to the expression of CEBPα which acts as a transcriptional activator of 
resistin. This implication is also indirectly supported by the findings that a functional C/EBP-
binding site was found in the proximal resistin promoter of both murine and human adipocytes 
to be necessary for the stimulation of transcription from resistin promoter (Hartman et al., 
2002; Song et al., 2002; Seo et al., 2003) and that endogenous C/EBP was bound to the resistin 
promoter in adipocytes in association with p300 and CREB-binding protein, which are viewed as 
co-activators involved in ER activation (Nilsson et al., 2001). Adipose cells treated with quercetin 
alone or in combination with estradiol showed decreased resistin concentration in adipose cells. 
190 
 
Although not much studied, IL-8 has been reported to be produced and released from human 
adipose tissue in regulated manner (Bruun et al., 2001; Gerhardt et al., 2001). Besides the 
participation in inflammatory processes, its involvement has been suggested in the 
development of obesity-associated insulin resistance (Kern et al., 2001), atherosclerosis and 
cardiovascular disease (Boisvert et al., 2000; Schieffer et al., 2000). The present study showed 
significant reduction in IL-8 levels when adipose cells were treated with estradiol or quercetin 
alone and in combination, suggesting the protective effects of these two drugs on the 
development of metabolic syndrome. In humans, oxidative stress is thought to be involved in 
the pathogenesis and development of metabolic syndrome. The results of the present study on 
human adipocytes in vitro show that both estradiol as well quecetin decreased the nitric oxide 
levels and increased the anti-oxidant enzyme activities suggesting a protective role of these 
drugs in adipose tissue. 
The differentiation of preadipocytes into adipocytes is regulated by a complex network of 
transcription factors. In the present study, both estradiol and quercetin treatment markedly 
reduced the expression levels of C/EBPα and PPARγ compared with those in differentiated 
control cells. Since both of these markers are master regulators of adipogenesis; their 
maintenance is critical to the progression of the final stages of adipocyte differentiation. Thus, 
these results indicate that both estradiol, as well as quercetin can significantly reduce lipid 
accumulation by down-regulation of these adipogenic markers. Experimental data also show a 
dramatic down-regulation of SREBP1-c expression. Because the mature form of SREBP1-c is 
known to promote lipogenic gene expression (Foufelle et al., 2002), its decreased levels may 
contribute significantly to impaired lipogeneis in estradiol and quercetin-treated adipose cells. 
The data in this study also show a decrease in the expression of its target genes such as FAS, 
FABP2 and ACC suggesting anti-adipogenic as well as anti-lipogenic action of estradiol and 
quercetin in adipose cells.  
Conclusion:  
The main conclusions from this study include the following:- 
1. Caffeine, paracetamol and BNF can exert anti-adipogenic and lipolytic properties during 
obesity. 
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2. A combination of rilpivirine and 17β-estradiol is completely non-toxic to pre-adipocytes 
at most concentrations tested. During the 10-day exposure to the drugs, only estradiol produced 
a modest cytotoxic effect at the highest concentrations. 
3. The results show that rilpivirine and estradiol either alone or when combined or 
pretreated with BNF can evoke marked effects on glycerol and cytokines levels from adipocytes. 
The present study also focused on the combinatory effects of rilpivirine and quercetin and from 
the results it is possible to conclude that quercetin was able to decrease inflammation and 
restore the levels of anti-oxidant enzymes but failed to overcome the lipo-atrophic effects of 
rilpivirine. 
4. The results of this study show a decrease in the expression of its target genes such as 
FAS, FABP2 and ACC suggesting anti-adipogenic as well as anti-lipogenic action of estradiol and 
quercetin in adipose cells.  
5. The main conclusion from this study is that some antiviral drugs can induce obesity, but 
it they are used in combination with some plant-based antioxidant drugs then their adverse 
effects can be avoided. 
7.2 Limitations of the study  
Some of the limitations to the present study included:- 
1. In order to establish and elucidate a significant effect of caffeine, paracetamol and BNF 
on the adipogenic process, further experiments at gene expression levels and involving the 
markers of oxidative stress should have been done. 
2. Apart from quercetin, other natural flavonoids should have been tested to study 
potential interactions between ARVs and plant-derived products. 
3. Combinations of ARVs, PPARγ agonists/antagonists were not used and lipolysis was not 
investigated; thus it is important to address these points in future studies to mimic current use 
of fixed dose drug combinations among patients, to determine whether adipocyte dysfunction is 
mediated via PPAR-γ and to determine the contribution of lipid mobilizing factors and lipolysis 
to the pathogenesis of HALS. 
4. Most phytoestrogens have antagonistic effects at different doses. The present study 
tested quecetin at a dose concentration of 50 µM only. More concentrations must be tried. 
 
192 
 
7.3 Scope for Future Studies 
The results from the present study have opened up new avenues and opportunities in the field 
of obesity research. Some of these are briefly described below: 
1. Many natural products and bioactive compounds such as possess remarkable 
pharmacological activities against obesity and hold great promise for development into 
potential anti-obesity drugs, current knowledge of their exact mechanism of actions remained 
to be fully elucidated. For instance, further studies are needed to help us understand their effect 
on the epigenetic regulation of obesigenic genes. 
2. Data from present obesity research studies as well as other disorders with a complex 
aetiologies support that alleles in a number of genes can contribute to obesity. However, the 
extent to which these common alleles exert their impact or rare alleles with more measurable 
effects on a given susceptibility background is still uncertain. Different ethnicity of analyzed 
cohorts and different ascertainment criteria, as well as different analyzed obesity phenotypes, 
make it more difficult to compare multiple allelic association studies of the same obesity 
candidate gene. This may partially explain the difficulty to confirm reported association 
between specific gene alleles and obesity. Defining gene alleles that are associated with obesity 
will contribute to our understanding of the underlying mechanisms behind its development and 
potentially provide therapeutic targets. 
3. The chronic and co-morbid nature of HIV infection has necessitated the use of multiple 
drugs including herbs to overcome its adverse side effects with a possible increase in herb–drug 
interaction cases. The present study shows the effect of quercetin to overcome the lipo-
dystrophic effects caused due to rilpivirine treatment. The therapeutic potential of other 
flavanoids and supplements must be explored. However, one must bear in mind that most of 
the ART drugs are metabolized by cytochrome P450 (CYP) enzymes similar to flavanoids. 
Concurrent use of herbal drug may result in an interaction that may significantly inhibit or 
induce these enzymes, potentially resulting in toxicity or therapeutic failure, 
respectively. Further experiments are required in this area of herbal drug combination therapy. 
4. The recent demonstration of ubiquitous presence of xenobiotic molecules in living 
organisms with endocrine disrupting properties with the ability to change estrogen signaling 
also deserves attention and may provide clues to the epidemic growth of obesity-related 
metabolic complications. Even so, there is general agreement that estrogens can improve 
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inflammation related to endocrine-disrupting chemicals which in turn may mediate their actions 
on metabolism. Although it seems evident that it acts indirectly through metabolic amelioration, 
the direct regulation of inflammation pathways is also documented. However, much work still 
needs to be performed in this respect to allow broadening the knowledge and understanding on 
estrogens’ mechanisms of action and establishing the rationale for the development and use of 
estrogen signaling modulation as a therapeutic tool for metabolic improvement.  
Hopefully, this thesis will provide novel ideas for development of treatment strategies for this 
21st century "obesity bomb" and its related disorders.  
 
 
 
 
Figure 7.1: Flow diagram highlighting the main findings from the present study. 
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Fabp-2 and Ppar-y genes as risk factors for dyslipidemia in type 2 
diabetes mellitus in residents of United Arab Emirates. 
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Introduction: Diabetes mellitus (DM) is one of the most prevalent chronic disorders worldwide 
and poses a great health concern due to its associated risks. Its elevated prevalence, morbidity 
and mortality rates and the social and economic repercussions of its chronic long-term 
complications compromise both the quality of life and productivity of those affected, making it a 
serious public health problem (Gulliford et al., 2009). According to the World Health 
Organization, 450 million people worldwide suffer from diabetes and the prevalence is expected 
to rise to 650 million by 2030 (Mihardja et al., 2014).  Statistical figures from the International 
Diabetes Federation (IDF) revealed that in 2017, 17.3 % of the UAE population, between the 
ages of 20 and 79 years of age had type 2 diabetes (T2DM).  Currently, the percentage has 
increased to around 20 %.There are over 1 million people living with diabetes in the United Arab 
Emirates (UAE) and another 3 million with pre-diabetes, placing the country 15th worldwide for 
age-adjusted comparative prevalence. It is important to note that diabetes is a regional affliction 
with Saudi Arabia, Bahrain, Kuwait and Qatar all featuring in the top twenty countries in terms 
of prevalence worldwide (International Diabetes Federation, 2017). Current trend also indicates 
that the prevalence of diabetes in the UAE is rising at a faster rate than both the Middle East 
and Northern Emirates (MENA) region and the rest of the world. Rapid economic growth, 
sedentary lifestyle and unhealthy diets characteristic of the UAE are all risk factors, leading to 
the number of people with diabetes expecting to double to 2.2 million by 2040. This number not 
only symbolizes colossal societal costs in terms of morbidity and mortality, but also in terms of 
healthcare system and productivity. T2DM presents a crucial health problem due to its 
constantly elevating rate of morbidity and mortality, which is related to metabolic disorders and 
cardiovascular risks, comprising of insulin resistance, obesity, dyslipidemia, hypertension, 
atherosclerosis, and endothelial dysfunction. Dyslipidemia, one of the major risks arising from 
diabetes, is defined as the abnormal change in levels of plasma cholesterol, triglycerides (TGs), 
or both, or a low high density lipoprotein level that results in the development of 
atherosclerosis. The characteristic features of dyslipidemia demonstrate decreased high-density 
lipoprotein cholesterol (HDL-C) levels, raised low- density lipoprotein cholesterol (LDL-C), and 
elevated triglyceride levels. Insulin resistance  is known to introduce this triad of low HDL, high 
LDL and triglyceride levels (Reaven, 1988; Hoenig et al., 2010). The incidence of lipid abnormality 
is very common in patients with T2DM than in general population. This is because in diabetes, 
insulin resistance or deficiency affects key enzymes and pathways in lipid metabolism. These 
abnormalities arise from increased secretion of VLDL (very-low-density lipoprotein) particles due 
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to elevated concentrations of free fatty acids and glucose (Eckel, 2014; Filippatas et al., 2017; 
Verges, 2015; Ginsberg, 1987)  
Data from a study, conducted on Argentina population by the National University of San Luisin 
in 2014 showed an association of FABP2 (Fatty Acid Binding Protein-2) and PPAR-y (Peroxisome 
proliferator-activated receptor) genes with dyslipidemia in diabetic patients. It was concluded 
that in T2DM, the additive effects of the Threonine-Proline (Thr-Pro) Haplotypes of FABP2 and 
PPAR-y genes altered the lipid metabolism (Conlara et al., 2016). FABP-2 gene has been 
proposed to be a suitable candidate gene for diabetes since this gene is involved in the 
absorption of fatty acids across intestinal mucosa. The risk of lipid metabolic disorders 
occurrence in individuals carrying mutational FABP2 gene (Ala54/Thr54, Thr54/Thr54) has been 
reported to be  higher than those carrying wild type homozygote (Ala54/Ala54) when they were 
exposed to the same environment  (Liu et al., 2015). Peroxisome Proliferator Activated Receptor 
(PPAR-γ) is a transcription factor protein with chief role in adipogenesis and insulin sensitization. 
It is highly expressed in adipose tissue, where it plays an indispensible role in the regulation of 
adipocyte differentiation, lipid storage , glucose metabolism and the transcriptional regulation 
of a number of genes involved in these metabolic  processes (Semple et al., 2006; Azhar, 2010). 
Frequent mutations in the PPAR-γ gene have been reported to be associated with obesity and 
diabetes-related phenotypes. Previous studies have confirmed that the common structural 
polymorphism with a proline to alanine substitution affects the function (Deeb et al., 1998). In 
comparison with the Pro allele, the Ala allele is also associated with reduced activity of PPAR-γ. 
Several studies conducted on PPAR- γ polymorphisms have been extensively investigated by 
different researchers have suggested its relation with obesity and T2DM and is considered to be 
one of the best replicated genetic risk factors of common T2DM (Altshuler et al., 2000; 
Lohmueller et al., 2003; Tönjes et al., 2006). Basically, the Ala allele variant has a reduced 
activity of PPAR-γ compared to the Pro allele; so this mutation causes reduced insulin sensitivity 
leading to the development of T2DM.  
Aims: Considering the importance of allelic polymorphisms in these genes in the development 
of obesity, the present study was designed to evaluate the association between single 
nucleotide polymorphisms and haplo-types of the FABP2 and PPARγ and lipid profile in the 
residents of United Arab Emirates. 
Materials and methods 
Blood Sampling  
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Blood samples were obtained from patients with overnight fasting for a minimum of 12 hours by 
trained laboratory personal and stored at 4 oC. A volume of 3 ml of blood was collected in tubes 
containing 0.1 % EDTA.  
Biochemical Measurements 
 Fasting Plasma Glucose 
Plasma glucose was measured by strip-based assay using glucometer from AccucheckTM. 
Quantification of total Cholesterol 
Total cholesterol was measured using the Total Cholesterol Quantification Kit from Sigma (Cat. 
#: MAK043) as per the manufacturer’s protocol. The kit was shipped on wet ice and stored at -
20ºC upon receipt. For the assay procedure, all samples and standards were run in duplicate. In 
order to perform the colorimetric detection, a volume of 20 mL of the 2 mg/mL Cholesterol 
Standard solution was diluted with 140 mL of the Cholesterol Assay Buffer to prepare a 0.25 
mg/mL standard solution. A volume of 0, 4, 8, 12, 16, and 20 mL of the 0.25 mg/mL Cholesterol 
Standard solution was added into a 96 well plate, generating 0 (blank), 1, 2, 3, 4, and 5 mg/well 
standards. This was followed by addition of Cholesterol Assay Buffer to each well to bring the 
final volume to 50 mL. Serum samples (0.5–5 mL/well) were added directly to each of the 
sample wells. For the assay reaction, reaction mixes were prepared according to the scheme in 
table 1. 
Table 1: Table showing scheme for preparing the reaction mixes for cholesterol assay 
Reagents Total cholesterol and 
standards 
Free cholesterol 
Cholesterol Assay buffer 44 µl 46 µl 
Cholesterol Probe 2 µl 2 µl 
Cholesterol Enzyme Mix 2 µl 2 µl 
Cholesterol Esterase 2 µl - 
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A volume of 50 mL of the appropriate reaction mix was added to each of the wells followed by 
incubation for 60 minutes at 37°C. The plate was protected from light and absorbance was 
measured at 570 nm. The amount of cholesterol present in the samples was determined from 
the standard curve. Concentration of Cholesterol was calculated using the following equation: 
Sa/Sv = C  
Where, 
Sa = Amount of cholesterol in unknown sample (mg) from standard curve  
Sv = Sample volume (mL) added into the wells  
C = Concentration of cholesterol in sample 
Quantitative measurement of High-Density Lipoprotein and Low-Density Lipoprotein  
Abcam's HDL and LDL/VLDL Cholesterol Quantification Kit (Cat. # ab65390) was used as per the 
manufacturer’s protocol. The kit was stored at -20°C in the dark immediately upon receipt. The 
kit components included cholesterol assay buffer, 2x LDL/VLDL precipitation buffer, cholesterol 
standard (2 µg/µL), cholesterol probe, cholesterol esterase and enzyme mix. Lyophilized 
cholesterol esterase and enzyme mix were dissolved in 220 µL of cholesterol assay buffer and 
kept on ice during the assay. A volume of 200 µL of 0.25 µg/µL cholesterol standard was 
prepared by diluting 25 µL of the provided cholesterol standard (2 µg/µL solution) with 175 µL of 
cholesterol assay buffer. This was further used to prepare working cholesterol standards as 
outlined in table 2 below. 
Table 2: Preparation of cholesterol standards using serial dilution 
Standard 
# 
Cholesterol 0.25 µg/µL 
Standard (µL) 
Assay Buffer 
(µL) 
Final Volume 
Standard in well 
(µL) 
End amount 
cholesterol in 
well (µg/well) 
1 0 150 50 0 
2 12 138 50 1 
3 24 126 50 2 
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4 36 114 50 3 
5 48 102 50 4 
6 60 90 50 5 
   
For the quantification of total cholesterol, serum samples were used directly. For the separation 
of HDL and LDL/VLDL fraction, a volume of 100 µL of sample was mixed with a volume of 100 µL 
of 2x precipitation buffer in micro-centrifuge tubes and incubated for 10 minutes at room 
temperature. This was followed by centrifugation at 5000 rpm for 10 minutes. The supernatant 
was then transferred to a new tube. This was the HDL fraction. The remaining precipitate was 
re-suspended in 200 µL of PBS. This was the LDL/VLDL fraction. 
For the assay procedure, all materials and prepared reagents were gently agitated and 
equilibrated to room temperature prior to use. All standards, controls and samples were 
assayed in duplicate. For setting up the reaction wells, a total volume of 50 µl of standard 
dilutions as well as samples were loaded onto the plate. This was followed by the addition of 50 
µL of total cholesterol reaction mix (44 µL of cholesterol assay buffer + 2 µL of cholesterol probe 
+ 2 µL of enzyme mix and 2 µL of cholesterol esterase) and 50 µL of free cholesterol reaction mix 
(46 µL of cholesterol assay buffer + 2 µL of cholesterol probe + 2 µL of the enzyme mix) into 
each of the wells. Enough reagents for the number of assays to be performed were prepared 
and a master mix was prepared to ensure consistency. All the wells were mixed thoroughly and 
incubated at 37°C for 60 minutes protected from light. Absorbance was taken at OD 570 nm 
using a micro-plate reader. For data analysis, corrected absorbances were calculated by 
subtracting mean value of blank (standard # 1) from all standards and samples. Corrected values 
for each standard were plotted as a function of the final concentration of triglyceride. Corrected 
sample OD was applied to the standard curve to get cholesterol (A) amount in the sample wells. 
Concentration of cholesterol in (µg/µL) in the test samples was calculated using the following 
equation: 
Cholesterol concentration = (A/V*D) * DF 
Where: 
A= Amount of cholesterol in the sample well calculated from the standard curve (µg) 
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V= Sample volume added in the sample wells (µL) 
D= Sample dilution factor: For total cholesterol = 1; for HDL and LDL/VLDL fractions =2 
DF = Additional dilution factor if sample has been diluted further to fit within the standard curve 
range. 
DNA Extraction and Restriction Fragment Length Polymorphism for Genotyping Analysis  
DNA was extracted from packed blood cells using the QiAmp Mini KitTM from Qiagen (Cat. #     
51104) following the manufacture’s protocol. The kit components included QIAamp Mini Spin   
Columns, 2 ml collection tubes, Buffer AL, Buffer ATL, Buffer AW1 (concentrate), Buffer AW2 
(concentrate), Buffer AE, QIAGEN® Protease, Protease Solvent and Proteinase K. Figure 1 
showed a simplified procedure for the extraction of DNA using spin column method. 
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Figure 1: Diagrammatic scheme for the extraction of DNA using Spin column method. 
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PCR amplifications and genotype determinations were conducted as follows: 
FABP-2 (Ala54Thr):  Ala54Thr (G/A) in exon 2 of FABP2 (rs1799883). DNA from the samples were 
amplified using a total volume of 20 μl containing 100 ng of genomic DNA, 12 pmol of each 
primer and 1 unit of DNA polymerase. These reactions were performed in a 2X Master Mix 
containing 1.5 mmol/L MgCl2, 50 mmol/L KCl, 20 mmol/L Tris-HCl (pH 8.4), and 200 pmol/L of 
each deoxynucleotide triphosphate. The primers were as follows: forward primer: 
5’ACAGGTGTTAATATAGTGAAAAG3’ and reverse primer: 5’TACCCTGAGTTCAGTTCCGTC3’. The 
template DNA was denatured for 3 minutes at 95˚C before undergoing 30 cycles of 
amplification. Each amplification cycle included: Denaturation for 30 seconds at 95˚C, primer 
annealing for 30 seconds at 55˚C, and extension for 45 seconds at 72 ˚C; followed by a final 
extension at 72 ˚C for 3 minutes. 
For Restriction Fragment Length Polymorphism (RFLP) analysis, 1 μl of PCR product was 
incubated with 1 μl of CfoI enzyme (10 U/μl, in a final volume of 20 μl for 1 hour at 37 ˚C. The 
products were run on a 2% non-denaturing Polyacrylamide gel electrophoresis (PAGE) for 30 
minutes at 100 V. Bands was observed after ethidium bromide staining and ultraviolet (UV) light 
exposure. Visualization of two DNA fragments of the CfoI treated amplicon at 99 and 81 bp will 
indicate a G allele (Ala54—presence of the restriction site), whereas an intact 180 bp will 
indicate an A allele (Thr54—absence of the restriction site). 
PPAR-γ (Pro12Ala). The PPAR-γ polymorphism (rs1801282) Pro12Ala (C/G) was analyzed by 
Tetra Primer AMRS-PCR. Two pairs of primers were used, one which amplifies a fragment of 553 
bp, common to both alleles (outer primers: forward 5’AGACAGTGTGGCAATATTTTCCCTGTAA3’ 
and reverse 5’GGTTCTGAACATGTTTTTAAATGAACGC3’ and another pair specific for the SNP 
(inner primers): forward 5’GAAACTCTGGGAGATTCTCCTATTGTCC3’ for the C allele (Pro12) and 
reverse 5’GTATCAGTGAAGGAATCGC TTTCAGC3’ for the G allele (Ala12). Nucleotide sequence 
and single nucleotide polymorphism (SNP) details were obtained from National Center for 
Biotechnology Information (NCBI) website (http://www.ncbi.nlm.nih.gov/). The primers were 
synthesized by Accuvis Bio (Abu Dhabi, UAE). Each PCR reaction was carried out in a total 
volume of 20 μL, containing 200 ng of template DNA, 1 pmol of each inner primer, and 1 pmol of 
each outer primer (1:1 ratio of outer to inner primer). These reactions were performed in 2X 
Master Mix containing 200 μM dNTPs, 2.5 mM MgCl2, and 1 unit of DNA polymerase. The 
template DNA was denatured for 3 minutes at 95 ˚C before undergoing 35 cycles of de-
naturation for 1 minute at 95˚C, primer annealing for 1 minute at 58.9˚C, and extension for 1 
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minute at 72˚C, and final extension at 72˚C for 5 minutes. The resultant products were obtained 
after PCR were separated by electrophoresis on 1 % agarose gel containing ethidium bromide. 
The image was visualized and photographed under UV trans-illuminator. This resulted in 3 DNA 
fragments: one of 553 bp, one of 253 bp for the C allele (Pro12) and one of 354 bp for the G 
allele (Ala12). 
Randomly selected 20% of samples were re-genotyped for cross validating initial genotypes. In 
case of unclear genotyping results, the samples were repeated again in duplicates until clear 
genotype was available. Unclear genotyping results, even after repetition, were excluded from 
the study. No genotyping error was observed during cross validation. 
Results 
Biochemical analysis 
Table 3: Table showing the effect of dyslipidemia on the biochemical characteristics  
Characteristics Dyslipidemia 
(present/absent) 
N Mean ± SEM 
Low density 
lipoprotein (LDL) 
Present 44 145.02 ± 15.46 
Absent 20 106.95 ± 6.37 
High density 
lipoprotein (HDL) 
Present 44 33.98 ± 1.44 
Absent 20 49.35 ± 2.66 
Triglycerides (TG) Present 44 170.30 ± 15.80 
Absent 20 108.75 ± 11.01 
Total cholesterol (TC) Present 44 195.86 ± 8.43 
Absent 20 177.95 ± 7.88 
Fasting plasma glucose 
(FPG) 
Present 44 129.14 ± 6.73 
Absent 20 103.10 ± 4.09 
 
Table 4: The effect of gender on the biochemical characteristics  
Characteristics Dyslipidemia 
(present/absent) 
N Mean ± SEM 
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Low density 
lipoprotein (LDL) 
Male 38 132.55 ± 17.00 
Female 26 133.96 ± 11.19 
High density 
lipoprotein (HDL) 
Male 38 38.74 ± 1.77 
Female 26 38.85 ± 2.90 
Triglycerides (TG) Male 38 168.37 ± 16.75 
Female 26 125.77 ± 15.11 
Total cholesterol (TC) Male 38 184.39 ± 7.82 
Female 26 198.85 ± 10.62 
Fasting plasma glucose 
(FPG) 
Male 38 122.47 ± 7.66 
Female 26 118.85 ± 5.37 
Table 5: The effect of nationality (UAE Local and Expatriates) on the biochemical 
characteristics. Data are expressed as Mean ± SEM; *p<0.05. 
Characteristic Dyslipidemia(present/absent) N Mean ± SEM 
Low density 
lipoprotein (LDL) 
UAE Local 20 129.65 ± 10.06 
Expatriates 44 134.71 ± 15.40 
High density 
lipoprotein (HDL) 
UAE Local 20 34.95 ± 1.85 
Expatriates 44 40.52 ± 2.07* 
Triglycerides (TG) UAE Local 20 139.60 ± 14.46 
Expatriates 44 156.27 ± 16.05 
Total cholesterol (TC) UAE Local 20 196.40 ± 11.72* 
Expatriates 44 187.48 ± 7.60 
Fasting plasma 
glucose (FPG) 
UAE Local 20 114.05 ± 5.44 
Expatriates 44 124.16 ± 6.85* 
 
The results for the effect of dyslipidemia on the different biochemical analysis as illustrated in 
tables 3-5 show that dyslipidemia has significant (p<0.05)  effect on high density lipoproteins, 
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triglycerides and fasting plasma glucose compared to subjects who did not have dyslipidemia. 
No significant (p>0.05) effect was observed for the low-density lipoproteins and total 
cholesterol. Statistical analysis for each of gender and nationality also showed no significant (p> 
0.05) effect on the biochemical characteristics as illustrated in tables 4 and 5, respectively. 
Frequencies for genotyping polymorphisms 
Table 6: Description of the Selected SNPs for FABP-2 and PPAR-γ Genes 
SNP ID Chromosome Position Exon/Intron Substitution Functional 
consequence 
MAFa 
FABP-2 4 120241902 Exon 2 G/A Missense 0.30 
PPAR-γ 3 12393125 Exon A1 C/G Missense 0.25 
MAFa: in the total group of this study. MAF, Minor Allele Frequency; SNP, Single Nucleotide 
Polymorphism 
Table 6 provides detailed information of the selected SNPs, including their features, allelic 
variants, and the minor allele frequency. The frequencies of the Ala54Ala, Ala54Thr, and 
Thr54Thr genotypes in the whole population of the FABP-2 polymorphism were 34.37%, 46.87%, 
and 18.75, respectively, while the frequencies of Pro12Pro, Pro12Ala, and Ala12Ala genotypes of 
the PPAR-γ polymorphism were 70.31%, 20.31%, and 9.37%, respectively. The distribution and 
the allele frequency of the 2 polymorphisms followed Hardy- Weinberg equilibrium. 
 Inheritance Model 
Table 7: Frequencies of FABP-2 genotypes according to T2DM 
Modelsa Genotypesb Control Subjects n (%) 
c 
Diabetic Subjects n (%) c 
Co-dominant AlaAla 
AlaThr 
ThrThr 
7(63.63) 
1(9.09) 
3(27.27) 
15(28.30) 
29(54.71) 
9(16.98) 
Dominant AlaAla 
AlaThr/ThrThr 
7(63.63) 
4(36.36) 
15(28.30) 
38(71.69) 
Recessive AlaAla/ThrThr 
ThrThr 
8(72.72) 
3(27.27) 
44(83.01) 
9(16.98) 
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Over-dominant AlaAla/ThrThr 
AlaThr 
10(90.90) 
1(9.09) 
24(45.28) 
29(54.71) 
aInheritance Models; bGenotypes and their grouping for the FABP-2 polymorphism (rs1799883); 
cGenotype Frequency expressed as number of individuals. N-value in parenthesis indicates 
percentage. 
The genotypes of FABP-2 were associated with T2DM according to all possible genetic models 
(Codominant, Dominant, Recessive, and Over-dominant). In addition, there was no association 
of FABP-2 Ala54Thr polymorphism found with T2DM according to any genetic model used (Table 
7). For the PPAR-γ Pro12Ala polymorphism, no association found with T2DM according to any 
genetic model used (SeeTable 8). 
Table 8: Frequencies of PPAR-γ genotypes according to T2DM 
Modela Genotypeb Control Subject n (%) c Diabetic Subject n (%) c 
Co-dominant ProPro 
ProAla 
AlaAla 
5(45.45) 
1(9.09) 
5(45.45) 
40(75.47) 
12(22.64) 
1(1.88) 
Dominant ProPro 
ProAla/AlaAla 
5(45.45) 
6(54.54) 
40(75.47) 
13(24.52) 
Recessive PrpPro/ProAla 
AlaAla 
6(54.54) 
5(45.45) 
52(97.11) 
1(1.88) 
Over-dominant ProPro/AlaAla 
ProAla 
10(90.9) 
1(9.09) 
41(77.35) 
12(22.64) 
aInheritance Models; bGenotypes and their grouping for the PPAR-γ polymorphism (rs1801282); 
cGenotype Frequency expressed as number of individuals. N-value in parenthesis indicates 
percentage 
Table 9: Genotypes and allele frequencies for the FABP-2 and PPAR-γ polymorphisms in 
control and T2DM 
SNP Allele Control Diabetic Genotype Control N (%) b Diabetic N (%) b 
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Fa Fa 
rs1799883 
FABP-2 
Ala 
Thr 
0.68 
0.32 
0.56 
0.44 
AlaAla 
AlaThr 
ThrThr 
7(63.63) 
1(9.09) 
3(27.27) 
15(28.30) 
29(54.71) 
9(16.98) 
rs1801282 
PPAR-γ 
Pro 
Ala 
0.5 
0.5 
0.87 
0.13 
ProPro 
ProAla 
AlaAla 
5(45.5) 
1(.09) 
5(45.5) 
40(75.5) 
12(22.6) 
1(1.9) 
 
Table 9 shows the frequency of the rare Thr54 allele of the FABP-2 polymorphism in control 
(0.32) and this value was not different from the frequency in T2DM (0.44). The frequency of the 
rare Ala12 allele of the PPAR-γ polymorphism in control was however different from the 
frequency in T2DM (0.5 and 0.13, respectively). Since the homozygous genotype had very low 
frequencies, the Thr54Thr of the FAPB2 and the Ala12Ala of the PPARγ were examined in the 
same category as the corresponding heterozygote genotype, i.e non Ala54Ala (Thr carriers) and 
non Pro12Pro (Ala carriers), respectively.  
Table 10: Anthropometric and clinical characteristics by the FABP-2 polymorphism in controls and 
T2DM  
Clinical 
Characteristics 
(mg/dL) 
Control (n=11) Mean ± SD Diabetic (n=53) Mean ± SD 
Ala54Ala 
 
Non Ala54Ala 
 
Ala54Ala 
 
Non Ala54Ala 
 
Fasting plasma 
glucose (FPG) 
94.57 ± 11.85 107.25 ± 4.64 109 ± 18.70 132.05 ± 47.43 
Triglycerides (TG) 11.14 ± 58.87 175 ± 67.05 108.13 ± 42.69 172.28 ± 110.79 
Total cholesterol 
(TC) 
193.57 ± 39.52 193 ± 58.73 178.2 ± 36.85 194.13 ± 57.15 
High density 
lipoprotein (HDL) 
55.91 ± 16.78 41.75 ± 19.82 43.74 ± 8.44 33.46 ± 8.14 
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Low density 
lipoprotein (LDL) 
118.62 ± 25.80 124.75 ± 51.51 111.64 ± 52.31 145.60 ± 109.01 
 
Table 10 shows the anthropometric and clinical characteristics of controls and T2DM for the 
Ala54Thr polymorphism (rs1799883) of the FABP-2 gene. The differences between control 
patients with Ala54Ala and non-Ala54Ala genotypes were associated with LDL-c, whereas in 
T2DM the presence of the non-Ala54Ala genotype was associated with an increase in 
triglycerides and LDL-c compared with the Ala54Ala homozygotes. 
Table 11: Anthropometric and Clinical characteristics by the PPAR-γ polymorphism in controls 
and T2DM 
Clinical 
Characteristic 
(mg/dL) 
Control (n=11) Mean ± SD Diabetic (n=53) Mean ± SD 
Pro12Pro 
 
Non Pro12Pro 
 
Pro12Pro 
 
Non Pro12Pro 
 
Fasting plasma 
glucose (FPG) 
102.6 ± 9.4 96.3 ± 13.1 122± 38.2 136.4 ± 54.0 
Total cholesterol 
(TC) 
196.6 ± 55.1 190 ± 38.7 183.4 ± 48.2 208.7 ± 61.8 
High density 
lipoprotein (HDL) 
50.3 ± 15.4 51.2 ± 22.0 36.6 ± 8.9 35.7 ± 11.3 
Low density 
lipoprotein (LDL) 
121.4 ± 43.8 120.4 ± 29.5 116.5 ± 44.8 196.1 ± 166.0 
Triglycerides (TG) 127 ± 72.1 144 ± 66.6 159.1 ± 102.1 139 ± 97.1 
 
The comparison of the anthropometric and clinical characteristics by the polymorphism PPAR-γ 
(rs1801282) in controls and diabetic patients revealed no statistically important associations 
with anthropometric and clinical characteristics as were seen for this polymorphism in controls. 
Also, no statistically significant (p>0.05) links with anthropometric and clinical characteristics 
were observed for this polymorphism in controls. It is particularly noteworthy that in diabetic 
subjects, there were statistically significant differences (p<0.05) in total cholesterol (TC) values, 
with carriers of the Ala12 allele (non Pro12Pro) having higher TC values than Pro12 homozygotes 
(See Table 11). 
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Genotyping using Restriction Fragment Length Polymorphism 
Briefly, DNA from the samples was extracted using commercially available kit from Qiagen. PCR 
amplifications for both genes was performed using specific primers. For Restriction Fragment 
Length Polymorphism (RFLP) analysis, 1 μl of PCR product was incubated with 1 μl of CfoI 
enzyme (10 U/μl, in a final volume of 20 μl for 1 hour at 37 ˚C. The products were run on a 2% 
non-denaturing polyacrylamide gel electrophoresis (PAGE) for 30 minutes at 100 V. Bands was 
observed after ethidium bromide staining and UV light exposure. 
 
Figure 2: Original representative gel showing polymorphisms in FABP2 gene.  
Data from figure 2 shows PCR-RFLP non-denaturing PAGE gel after digestion with CfoI enzyme. 
The 180 bp band corresponds to the G allele (Ala) and the 99 and 81 bp bands correspond to the 
A allele (Thr) of the FABP2 gene. The representative gel is typical of 6-7 different experiments. 
 
 
Figure 3: Representative gel showing PPAR-γ genotyping.  
Data from figure 3 shows PPAR-γ genotyping by tetra primer ARMS-PCR. The 553 bp band is the 
product of the outer primers, the 354 bp band, of an outer primer and the inner primer for allele 
245 
 
G (Ala) and the 253 bp band, of the other outer primer and the inner primer for the C allele 
(Pro). The representative gel is typical of 6-7 different experiments. 
Discussion 
The role of the FABP2 and PPAR γ polymorphisms in many diseases, including obesity, diabetes, 
and insulin resistance, has been assessed in different ethnicities, but the results of associations 
across different populations are contradictory and inconsistent (Tavares et al., 2004; Barbieri et 
al., 2005; Yilmaz-Aydogan et al., 2011; Alharbi et al., 2014; Raza et al., 2017).  
The FABP-2 gene has been contemplated as a possible choice for diabetes because this protein 
is involved in the absorption and metabolism of fatty acids and may, therefore, affect insulin 
sensitivity and glucose homeostasis. The most broadly studied variant is the mis-sense Ala54Thr 
variation, which is common in various populations and results in increased fatty acid absorption 
in vivo. This is the first study showing the prevalence of Thr54 FABP variant in the United Arab 
Emirates population.  
Comparing the present results with other studies especially in samples of patients from this 
current study with T2DM, the frequency of the Thr54 allele was 0.27. This value was similar to a 
Brazilian study that reported a Thr54 frequency 0.25 in T2DM individuals (Almeida et al., 2010). 
On the other hand, the frequency of the Thr54Thr genotype was 4.00% in T2DM patients in this 
study, whereas the frequency of the Thr54Thr genotype was 6.25% in Brazilian diabetic patients 
and 4.00% in American patients with T2DM (Canani et al., 2005). 
In order to prove that defects in the FABP-2 gene could be linked with T2DM and their related 
metabolic traits, the current study investigated the effects of Ala54Thr variant in UAE resident 
population. Studies investigating the association of FABP-2 A54T polymorphism with T2DM were 
inconsistent. Several studies have reported the association between the Ala54Thr polymorphism 
of FABP-2 with insulin resistance and diabetes (Yamada et al., 1997; Chiu et al., 2001; Kim et al., 
2001; Duarte et al., 2003; Albala et al., 2012). Other studies have reported no association 
between this polymorphism and T2DM (Rissanen et al., 1997; Ito et al., 1999; Lei et al., 1999). 
There are some differences among studies on the design as well as the genetic models used to 
assess associations of FABP-2 Ala54Thr polymorphism with this disease. The current study 
investigated the association of FABP-2 Ala54Thr polymorphism with T2DM according to all 
possible genetic models. No association of FABP-2 Ala54Thr plymorphism was found with T2DM 
according to any genetic model used in this study, a finding shared by other studies that 
examined such an association (Weiss et al., 2002). 
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The present study did not find differences in glycaemia, HbA1c and serum lipids between FABP-2 
genotype groups although significant differences in BMI were attained in diabetic group carriers 
of the Thr allele. The results from studies published on the association of FABP-2 Ala54Thr 
polymorphism with body mass index (BMI) are conflicting, but the conclusions from the meta 
analysis carried out by (Zhao et al., 2011) showed no evidence that the FABP-2 Ala54Thr 
polymorphism is significantly associated with BMI in overall populations. It is possible that 
carriers of the Thr allele in the T2DM patient confer some degree of susceptibility to obesity, 
associated with an influence of gene/environment interactions such as diet, exercise, body 
composition and life style modification (de Luis et al., 2006). 
In this study, the frequencies of the Ala allele of the PPAR-γ polymorphism in participants with 
and without diabetes were 1.3% and 5%, respectively. The frequency of the Ala allele appears to 
vary greatly by the genetic background of the populations (Huguenin et al., 2010). In general, 
the frequency of the Ala allele has been reported to be highest in Caucasians (Stumvoll et al., 
2002). Variations in the allelic frequency of the Pro12Ala polymorphism across different 
ethnicities and regions could be attributed to genetic variations and to different environmental 
and lifestyle exposures (Lindi et al., 2001). 
The present study also revealed that the Ala allele of the Pro12Ala polymorphism was 
associated with a significantly lower risk of T2DM in UAE population. Consistent with the current 
results, Altshuler et al., (2000) found a significant decrease in diabetes risk associated with the 
Ala allele in a Caucasian population. In Finnish subjects, the Ala12 variant of the PPAR-γ gene 
was associated with protection against T2DM. Meta-analyses (Ludovico et al., 2012) also 
showed a significant effect of the Ala allele on lower development of T2DM. 
The results of the current study did not find any major differences in glycaemia, LDL-c, HDL-c 
and TG between PPAR-γ genotype groups even though considerable differences in TC were 
present in diabetic group carriers of the Ala allele. Mori et al., (2001) reported that carriers of 
the Ala 12 allele had a higher cholesterol level compared to those that did not have the allele 
among diabetic subjects. A study done on an Italian population found that this polymorphism 
was not related with anthropometrical and biochemical parameters among non-glycaemic and 
diabetic subjects (Mancini et al., 1999). 
The substitution from proline to alanine at codon 12 has been shown to regulate transcriptional 
activity (Masugi et al., 2000). Because this polymorphism is next to the amino-terminus of the 
protein in the ligand-independent activation domain, its activity is induced by insulin through 
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phosphorylation. Alanine helps in the formation of helices, but proline prevents it. Thus, it is 
possible that a change in this amino acid affects the structure and consequently the function of 
the protein. The alanine isoform contributes to less efficient stimulation of PPAR-γ target genes 
and predisposes people to reduce levels of adipose tissue mass accumulation. This in turn may 
improve insulin sensitivity. It is well known that decreased insulin sensitivity plays an important 
role in the pathogenesis of T2DM. Although a lot of  data on individual gene variants that affect 
lipid and lipoprotein metabolism is present in literature, they are worthy for identifying 
individual profiles for T2DM risk and its altered protein is quite limited. This is due to the small 
effect that a single gene has, that can also vary depending on other factors such as lifestyle, 
environmental stimuli, and other genes. 
It was initially presumed that rs1801282 polymorphisms (Pro12 alelle) may influence the 
receptor activity, the ability to transactivate responsive promoters and so on to regulate the key 
target genes of PPAR-γ which could influence the lipid metabolism. But the specific biological 
mechanism needs to be further studied. On the other hand, FABP-2 is involved in the transport 
and   metabolism of saturated and unsaturated long chain fatty acids (FAs). The mis-sense 
Ala54Thr variation results in increased activity. Thus, subjects with the Thr54 allele may have 
increased intestinal absorption of cholesterol, and this is associated with the higher cholesterol 
and LDL cholesterol levels in those with Thr54 allele among diabetic patients. 
In conclusion, the results from the present study show a distinct association of the Ala54Thr 
polymorphism of FABP-2 gene with T2DM in several nationalities residing in the United Arab 
Emirates. This variant is a probable contributor to the risk of T2DM and problems related to it. 
The findings of this study appear to be in agreement with that of several other studies. One 
among such study done on the Guadeloupian population, concluded a statistically important 
association between the Ala54Thr polymorphism and T2DM as well as the physiological function 
of the FABP2 gene (Lepretre et al., 1999). Another study done on the Mexican-American 
population also confirmed the association of the Ala54Thr with diabetes and its related 
problems. A study on the Pima Indian population also came to the conclusion that the 
polymorphism in these genes was associated with increased fatty acid binding and increased fat 
oxidation, thus being linked with insulin resistance (Baier et al., 1995). 
Furthermore, this study showed that the Pro12Ala polymorphism had no significant effect on 
T2DM and did not pose as a risk factor for dyslipidemia. No association between Pro12Ala 
polymorphism and T2DM was found in the population sample of various nationalities residing in 
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the United Arab Emirates. The  findings of the present study are in agreement with the results of 
previous studies in which no direct influence of the PPAR-γ Pro12Ala polymorphism genetic 
variation in the development of T2DM was found (Tavares et al., 2004; Gallicchio et al., 2008; Lv 
et al., 2017).  
In conclusion, several limitations of this study should be considered. Firstly, more SNPs of FABP2 
and PPAR-gene should have been chosen to capture maximum genetic information. Secondly, 
there was a relatively small sample size in this study, other larger sample studies should be 
conducted in the future research.  
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